ASTRAZENECA PLC (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 00090 - Document - Document and Entity Information Network

*

*

 http://www.astrazeneca.com/role/DocumentDocumentAndEntityInformation
2 Ifrs Statement [Table] Table

*

*

 azn:IfrsStatementTable
3 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
4 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
5 Ordinary shares Member ifrs-full:OrdinarySharesMember
6 Preference shares Member ifrs-full:PreferenceSharesMember
7 Statement LineItems azn:IfrsStatementLineItems
8 Entity Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
9 Entity Central Index Key Concept (CIK Number) For Period dei:EntityCentralIndexKey
10 Document Type Concept (Submission Type) For Period dei:DocumentType
11 Document Period End Date Concept (Date) For Period dei:DocumentPeriodEndDate
12 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
13 Entity Filer Category Concept (Filer Category) For Period dei:EntityFilerCategory
14 Current Fiscal Year End Date Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
15 Entity Current Reporting Status Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
16 Entity Well-known Seasoned Issuer Concept (Yes/No) For Period dei:EntityWellKnownSeasonedIssuer
17 Entity Voluntary Filers Concept (Yes/No) For Period dei:EntityVoluntaryFilers
18 Entity Common Stock, Shares Outstanding Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
19 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
20 Entity Emerging Growth Company Concept (Yes/No) For Period dei:EntityEmergingGrowthCompany
21 Entity Shell Company Concept (Yes/No) For Period dei:EntityShellCompany
22 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
23 00100 - Statement - Consolidated Statement of Comprehensive Income Network

*

*

 http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncome
24 Implied Table Table

*

*

 implied:Table
25 Consolidated Statement of Comprehensive Income Abstract ifrs-full:StatementOfComprehensiveIncomeAbstract
26 Product Sales Concept (Monetary) For Period Credit ifrs-full:RevenueFromSaleOfGoods
27 Externalisation Revenue Concept (Monetary) For Period Credit azn:ExternalisationRevenue
28 Total Revenue Concept (Monetary) For Period Credit ifrs-full:Revenue
29 Cost of sales Concept (Monetary) For Period Debit ifrs-full:CostOfSales
30 Gross profit Concept (Monetary) For Period Credit ifrs-full:GrossProfit
31 Distribution costs Concept (Monetary) For Period Debit ifrs-full:DistributionCosts
32 Research and development expense Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
33 Selling, general and administrative costs Concept (Monetary) For Period Debit ifrs-full:SellingGeneralAndAdministrativeExpense
34 Other operating income & expense Concept (Monetary) For Period Credit ifrs-full:OtherOperatingIncomeExpense
35 Operating profit Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
36 Finance income Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
37 Finance expense Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
38 Share of after tax losses in associates and joint ventures Concept (Monetary) For Period Credit ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
39 Profit before tax Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
40 Taxation Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
41 Profit for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
42 Other comprehensive income: Abstract ifrs-full:OtherComprehensiveIncomeAbstract
43 Remeasurement of the defined benefit pension liability Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
44 Net losses on equity investments measured at fair value through other comprehensive income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments
45 Fair value movements related to own credit risk on bonds designated as fair value through profit or loss Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeBeforeTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability
46 Tax on items that will not be reclassified to profit or loss Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss
47 Total other comprehensive income that will not be reclassified to profit or loss, net of tax Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
48 Foreign exchange arising on consolidation Concept (Monetary) For Period Credit azn:GainsLossesOnExchangeDifferencesOnConsolidationBeforeTax
49 Foreign exchange arising on designating borrowings in net investment hedges Concept (Monetary) For Period Credit azn:GainsLossesOnExchangeDifferenceHedgesOfNetInvestmentsInForeignOperationsBeforeTax
50 Fair value movements on cash flow hedges Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
51 Fair value movements on cash flow hedges transferred to profit or loss Concept (Monetary) For Period Debit ifrs-full:ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax
52 Fair value movements on derivatives designated in net investment hedges Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnHedgesOfNetInvestmentsInForeignOperationsBeforeTax
53 Amortisation of loss on cash flow hedge Concept (Monetary) For Period Debit azn:AmortisationOfLossesOnCashFlowHedgesBeforeTax
54 Costs of hedging Concept (Monetary) For Period Debit azn:CostOfHedgingBeforeTax
55 Net available for sale (losses)/gains taken to equity Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeBeforeTaxAvailableforsaleFinancialAssets
56 Tax on items that may be reclassified subsequently to profit or loss Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss
57 Total other comprehensive income that will be reclassified to profit or loss, net of tax Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
58 Other comprehensive (loss) / income for the period, net of tax Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
59 Total comprehensive income for the period Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
60 Owners of the Parent Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToOwnersOfParent
61 Non-controlling interests Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToNoncontrollingInterests
62 Total comprehensive income attributable to: Abstract ifrs-full:ComprehensiveIncomeAttributableToAbstract
63 Owners of the Parent Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
64 Non-controlling interests Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
65 Total comprehensive income for the period Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
66 Basic earnings loss per (in dollars per share) Concept (Share) For Period ifrs-full:BasicEarningsLossPerShare
67 Diluted earnings loss per Share (in dollars per share) Concept (Share) For Period ifrs-full:DilutedEarningsLossPerShare
68 Weighted average number of Ordinary Shares in issue for basic earnings Concept (Shares) For Period ifrs-full:WeightedAverageShares
69 Diluted weighted average number of Ordinary Shares in issue (millions) Concept (Shares) For Period ifrs-full:AdjustedWeightedAverageShares
70 Dividends declared and paid in the period Concept (Monetary) For Period Debit ifrs-full:DividendsPaidOrdinaryShares
71 00105 - Statement - Consolidated Statement of Comprehensive Income (Parenthetical) Network

*

*

 http://www.astrazeneca.com/role/StatementConsolidatedStatementOfComprehensiveIncomeParenthetical
72 Implied Table Table

*

*

 implied:Table
73 Consolidated Statement of Comprehensive Income Abstract ifrs-full:StatementOfComprehensiveIncomeAbstract
74 Par value per ordinary share Concept (Share) As Of ifrs-full:ParValuePerShare
75 00200 - Statement - Consolidated Statement of Financial Position Network

*

*

 http://www.astrazeneca.com/role/StatementConsolidatedStatementOfFinancialPosition
76 Implied Table Table

*

*

 implied:Table
77 Statement of financial position [abstract] Abstract ifrs-full:StatementOfFinancialPositionAbstract
78 Assets. Abstract ifrs-full:AssetsAbstract
79 Non-current assets Abstract ifrs-full:NoncurrentAssetsAbstract
80 Property, plant and equipment Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
81 Goodwill Concept (Monetary) As Of Debit ifrs-full:Goodwill
82 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
83 Derivative financial instruments Concept (Monetary) As Of Debit ifrs-full:NoncurrentDerivativeFinancialAssets
84 Investments in associates and joint ventures Concept (Monetary) As Of Debit ifrs-full:InvestmentAccountedForUsingEquityMethod
85 Other investments Concept (Monetary) As Of Debit ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
86 Other receivables Concept (Monetary) As Of Debit ifrs-full:OtherNoncurrentReceivables
87 Deferred tax assets Concept (Monetary) As Of Debit ifrs-full:DeferredTaxAssets
88 Total non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssets
89 Current assets Abstract ifrs-full:CurrentAssetsAbstract
90 Inventories Concept (Monetary) As Of Debit ifrs-full:Inventories
91 Trade and other receivables Concept (Monetary) As Of Debit ifrs-full:TradeAndOtherCurrentReceivables
92 Other investments Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
93 Derivative financial instruments Concept (Monetary) As Of Debit ifrs-full:CurrentDerivativeFinancialAssets
94 Income tax receivable Concept (Monetary) As Of Debit ifrs-full:CurrentTaxAssets
95 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
96 Assets held for sale Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
97 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
98 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
99 Liabilities. Abstract ifrs-full:LiabilitiesAbstract
100 Current liabilities Abstract ifrs-full:CurrentLiabilitiesAbstract
101 Current debt Concept (Monetary) As Of Credit ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
102 Trade and other payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
103 Derivative financial instruments Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
104 Provisions Concept (Monetary) As Of Credit ifrs-full:CurrentProvisions
105 Income tax payable Concept (Monetary) As Of Credit ifrs-full:CurrentTaxLiabilities
106 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
107 Non-current liabilities Abstract ifrs-full:NoncurrentLiabilitiesAbstract
108 Interest-bearing loans and borrowings Concept (Monetary) As Of Credit ifrs-full:LongtermBorrowings
109 Derivative financial instruments Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
110 Deferred tax liabilities Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilities
111 Retirement benefit obligations Concept (Monetary) As Of Credit ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
112 Provisions Concept (Monetary) As Of Credit ifrs-full:NoncurrentProvisions
113 Other payables Concept (Monetary) As Of Credit ifrs-full:NoncurrentPayables
114 Total non-current liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentLiabilities
115 Total liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
116 Net assets Concept (Monetary) As Of Debit ifrs-full:NetAssetsLiabilities
117 Equity Abstract ifrs-full:EquityAbstract
118 Share capital Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
119 Share premium account Concept (Monetary) As Of Credit ifrs-full:SharePremium
120 Capital redemption reserve Concept (Monetary) As Of Credit ifrs-full:CapitalRedemptionReserve
121 Merger reserve Concept (Monetary) As Of Credit ifrs-full:MergerReserve
122 Other reserves Concept (Monetary) As Of Credit azn:OtherReservesOtherThanMergerAndCapitalRedemptionReserve
123 Retained earnings Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
124 Total equity attributable to owners of parent Concept (Monetary) As Of Credit ifrs-full:EquityAttributableToOwnersOfParent
125 Non-controlling interests Concept (Monetary) As Of Credit ifrs-full:NoncontrollingInterests
126 Total equity Concept (Monetary) As Of Credit ifrs-full:Equity
127 00300 - Statement - Consolidated Statement of Changes in Equity Network

*

*

 http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquity
128 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
129 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
130 Equity [member] Member ifrs-full:EquityMember
131 Share Capital Member ifrs-full:IssuedCapitalMember
132 Share Premium account Member ifrs-full:SharePremiumMember
133 Capital redemption reserve. Member ifrs-full:CapitalRedemptionReserveMember
134 Merger reserve. Member ifrs-full:MergerReserveMember
135 Other reserves Member ifrs-full:OtherReservesMember
136 Retained earnings. Member ifrs-full:RetainedEarningsMember
137 Total attributable to owners Member ifrs-full:EquityAttributableToOwnersOfParentMember
138 Non-controlling interests. Member ifrs-full:NoncontrollingInterestsMember
139 Consolidated Statement of Changes in Equity LineItems ifrs-full:StatementOfChangesInEquityLineItems
140 Equity at beginning of period Concept (Monetary) As Of Credit ifrs-full:Equity
141 Adoption of new accounting standard Concept (Monetary) As Of Credit azn:IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
142 Profit for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
143 Other comprehensive (loss) income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
144 Transfer to other reserves Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughTransferBetweenOtherReservesAndRetainedEarningsEquity
145 Dividends Concept (Monetary) For Period Debit azn:DividendsRecognisedAsDistributionsToOwnersOfParentNetOfForfeiture
146 Dividends paid by subsidiary to non-controlling interest Concept (Monetary) For Period Debit ifrs-full:DividendsRecognisedAsDistributionsToNoncontrollingInterests
147 Acerta Pharma put option (Note 25) Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughAppropriationOfRetainedEarningsOfOptionsEquity
148 Changes in non-controlling interest (Note 25) Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
149 Issue of Ordinary Shares Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
150 Share-based payments charge for the period Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
151 Settlement of share plan awards Concept (Monetary) For Period Credit azn:SettlementOfSharePlanAwardsEquity
152 Net movement Concept (Monetary) For Period Credit ifrs-full:ChangesInEquity
153 Equity at end of period Concept (Monetary) As Of Credit ifrs-full:Equity
154 00305 - Statement - Consolidated Statement of Changes in Equity (Parenthetical) Network

*

*

 http://www.astrazeneca.com/role/StatementConsolidatedStatementOfChangesInEquityParenthetical
155 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
156 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
157 Equity [member] Member ifrs-full:EquityMember
158 Total attributable to owners Member ifrs-full:EquityAttributableToOwnersOfParentMember
159 Consolidated Statement of Changes in Equity LineItems ifrs-full:StatementOfChangesInEquityLineItems
160 Other comprehensive (loss) income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
161 Costs of hedging Concept (Monetary) For Period Debit azn:CostOfHedgingBeforeTax
162 00400 - Statement - Consolidated Statement of Cash Flows Network

*

*

 http://www.astrazeneca.com/role/StatementConsolidatedStatementOfCashFlows
163 Implied Table Table

*

*

 implied:Table
164 Statement of cash flows [abstract] Abstract ifrs-full:StatementOfCashFlowsAbstract
165 Cash flows from operating activities Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
166 Profit before tax Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
167 Finance income and expense Concept (Monetary) For Period Credit ifrs-full:FinanceIncomeCost
168 Share of after tax losses in associates and joint ventures Concept (Monetary) For Period Credit ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
169 Depreciation, amortisation and impairment Concept (Monetary) For Period Debit ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
170 (Increase)/decrease in trade and other receivables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
171 Increase in inventories Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
172 (Decrease)/increase in trade and other payables and provisions Concept (Monetary) For Period Credit azn:AdjustmentsForIncreaseDecreaseInTradeOtherPayablesAndProvisions
173 Gains on disposal of intangible assets Concept (Monetary) For Period Debit azn:AdjustmentsForLossesGainsOnDisposalOfIntangibleAsset
174 Fair value movements on contingent consideration arising from business combinations Concept (Monetary) For Period Debit azn:ContingentConsiderationFairValueMovement
175 Non-cash and other movements Concept (Monetary) For Period Debit ifrs-full:OtherAdjustmentsForNoncashItems
176 Cash generated from operations Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperations
177 Interest paid Concept (Monetary) For Period Credit ifrs-full:InterestPaidClassifiedAsOperatingActivities
178 Tax paid Concept (Monetary) For Period Credit ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
179 Net cash (outflow)/inflow from operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
180 Cash flows from investing activities Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
181 Non-contingent payments on business combinations Concept (Monetary) For Period Credit ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
182 Movement in short-term investments and fixed deposits Concept (Monetary) For Period Debit ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities
183 Purchase of property, plant and equipment Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
184 Disposal of property, plant and equipment Concept (Monetary) For Period Debit ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
185 Purchase of intangible assets Concept (Monetary) For Period Credit ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
186 Disposal of intangible assets Concept (Monetary) For Period Debit ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
187 Purchase of non-current asset investments Concept (Monetary) For Period Credit ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities
188 Disposal of non-current asset investments Concept (Monetary) For Period Debit ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities
189 Payments to joint ventures Concept (Monetary) For Period Credit ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities
190 Payment of contingent consideration from business combinations Concept (Monetary) For Period Credit azn:ContingentConsiderationPaymentBusinessCombinationsClassifiedAsInvestingActivities
191 Interest received Concept (Monetary) For Period Debit ifrs-full:InterestReceivedClassifiedAsInvestingActivities
192 Payments made by subsidiaries to non-controlling interests Concept (Monetary) For Period Credit azn:PaymentsMadeToNonControllingInterestsBySubsidiariesClassifiedAsInvestingActivities
193 Net cash inflow/(outflow) from investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
194 Net cash inflow before financing activities Concept (Monetary) For Period Debit azn:CashFlowsFromUsedInOperatingAndInvestingActivities
195 Cash flows from financing activities Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
196 Proceeds from issue of share capital Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
197 Issue of loans Concept (Monetary) For Period Debit ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
198 Repayment of loans Concept (Monetary) For Period Credit ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
199 Dividends paid Concept (Monetary) For Period Credit ifrs-full:DividendsPaidClassifiedAsFinancingActivities
200 Hedge contracts relating to dividend payments Concept (Monetary) For Period Credit azn:HedgeContractsRelatingToDividendPaymentsReceiptsClassifiedAsFinancingActivities
201 Repayment of obligations under finance leases Concept (Monetary) For Period Credit ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities
202 Movement in short-term borrowings Concept (Monetary) For Period Debit ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities
203 Net cash outflow from financing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
204 Net increase/(decrease) in Cash and cash equivalents in the period Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
205 Cash and cash equivalents at the beginning of the period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
206 Exchange rate effects Concept (Monetary) For Period Debit ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
207 Cash and cash equivalents at the end of the period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
208 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
209 Overdrafts Concept (Monetary) As Of Credit ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
210 10001 - Disclosure - Group Accounting Policies Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPolicies
211 Implied Table Table

*

*

 implied:Table
212 Group Accounting Policies Abstract azn:DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract
213 Group Accounting Policies Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
214 10101 - Disclosure - Revenue Network

*

*

 http://www.astrazeneca.com/role/DisclosureRevenue
215 Implied Table Table

*

*

 implied:Table
216 Revenue Abstract ifrs-full:RevenueAbstract
217 Revenue Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRevenueExplanatory
218 10201 - Disclosure - Operating profit Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingProfit
219 Implied Table Table

*

*

 implied:Table
220 Operating profit Abstract ifrs-full:ProfitLossAbstract
221 Operating profit Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory
222 10301 - Disclosure - Finance income and expense Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinanceIncomeAndExpense
223 Implied Table Table

*

*

 implied:Table
224 Finance income and expense Abstract azn:FinanceIncomeExpenseAbstract
225 Finance income and expense Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
226 10401 - Disclosure - Taxation Network

*

*

 http://www.astrazeneca.com/role/DisclosureTaxation
227 Implied Table Table

*

*

 implied:Table
228 Taxation Abstract ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
229 Taxation Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIncomeTaxExplanatory
230 10501 - Disclosure - Earnings per $0.25 Ordinary Share Network

*

*

 http://www.astrazeneca.com/role/DisclosureEarningsPer025OrdinaryShare
231 Implied Table Table

*

*

 implied:Table
232 Earnings per $0.25 Ordinary Share Abstract ifrs-full:EarningsPerShareAbstract
233 Earnings per $0.25 Ordinary Share Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEarningsPerShareExplanatory
234 10601 - Disclosure - Segment information Network

*

*

 http://www.astrazeneca.com/role/DisclosureSegmentInformation
235 Implied Table Table

*

*

 implied:Table
236 Segment information Abstract ifrs-full:DisclosureOfOperatingSegmentsAbstract
237 Segment information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
238 10701 - Disclosure - Property, plant and equipment Network

*

*

 http://www.astrazeneca.com/role/DisclosurePropertyPlantAndEquipment
239 Implied Table Table

*

*

 implied:Table
240 Property, plant and equipment Abstract ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
241 Property, plant and equipment Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
242 10801 - Disclosure - Goodwill Network

*

*

 http://www.astrazeneca.com/role/DisclosureGoodwill
243 Implied Table Table

*

*

 implied:Table
244 Goodwill. Abstract ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillAbstract
245 Goodwill Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGoodwillExplanatory
246 10901 - Disclosure - Intangible assets Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssets
247 Implied Table Table

*

*

 implied:Table
248 Intangible assets Abstract ifrs-full:DisclosureOfIntangibleAssetsAbstract
249 Intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIntangibleAssetsExplanatory
250 11001 - Disclosure - Investments in associates and joint ventures Network

*

*

 http://www.astrazeneca.com/role/DisclosureInvestmentsInAssociatesAndJointVentures
251 Implied Table Table

*

*

 implied:Table
252 Investments in associates and joint ventures Abstract ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociatesAbstract
253 Investments in associates and joint ventures Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory
254 11101 - Disclosure - Other investments Network

*

*

 http://www.astrazeneca.com/role/DisclosureOtherInvestments
255 Implied Table Table

*

*

 implied:Table
256 Other investments Abstract azn:DisclosureOfOtherInvestmentsAbstract
257 Other investments Concept (Text Block (HTML)) For Period azn:DisclosureOfOtherInvestmentsTextBlock
258 11201 - Disclosure - Derivative financial instruments Network

*

*

 http://www.astrazeneca.com/role/DisclosureDerivativeFinancialInstruments
259 Implied Table Table

*

*

 implied:Table
260 Derivative financial instruments Abstract ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract
261 Derivative financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
262 11301 - Disclosure - Non-current other receivables Network

*

*

 http://www.astrazeneca.com/role/DisclosureNonCurrentOtherReceivables
263 Implied Table Table

*

*

 implied:Table
264 Non-current other receivables Abstract ifrs-full:NoncurrentReceivablesAbstract
265 Non-current other receivables Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory
266 11401 - Disclosure - Inventories Network

*

*

 http://www.astrazeneca.com/role/DisclosureInventories
267 Implied Table Table

*

*

 implied:Table
268 Inventories Abstract ifrs-full:ClassesOfInventoriesAbstract
269 Inventories Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInventoriesExplanatory
270 11501 - Disclosure - Current trade and other receivables Network

*

*

 http://www.astrazeneca.com/role/DisclosureCurrentTradeAndOtherReceivables
271 Implied Table Table

*

*

 implied:Table
272 Current trade and other receivables Abstract ifrs-full:TradeAndOtherCurrentReceivablesAbstract
273 Current trade and other receivables Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory
274 11601 - Disclosure - Cash and cash equivalents Network

*

*

 http://www.astrazeneca.com/role/DisclosureCashAndCashEquivalents
275 Implied Table Table

*

*

 implied:Table
276 Cash and cash equivalents. Abstract ifrs-full:CashAndCashEquivalentsAbstract
277 Cash and cash equivalents Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
278 11701 - Disclosure - Assets held for sale Network

*

*

 http://www.astrazeneca.com/role/DisclosureAssetsHeldForSale
279 Implied Table Table

*

*

 implied:Table
280 Assets held for sale Abstract ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract
281 Assets held for sale Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory
282 11801 - Disclosure - Interest-bearing loans and borrowings Network

*

*

 http://www.astrazeneca.com/role/DisclosureInterestBearingLoansAndBorrowings
283 Implied Table Table

*

*

 implied:Table
284 Interest-bearing loans and borrowings Abstract ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsAbstract
285 Interest-bearing loans and borrowings Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBorrowingsExplanatory
286 11901 - Disclosure - Trade and other payables Network

*

*

 http://www.astrazeneca.com/role/DisclosureTradeAndOtherPayables
287 Implied Table Table

*

*

 implied:Table
288 Trade and other payables Abstract ifrs-full:TradeAndOtherPayablesAbstract
289 Trade and other payables Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
290 12001 - Disclosure - Provisions Network

*

*

 http://www.astrazeneca.com/role/DisclosureProvisions
291 Implied Table Table

*

*

 implied:Table
292 Provisions. Abstract ifrs-full:ProvisionsAbstract
293 Provisions Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfProvisionsExplanatory
294 12101 - Disclosure - Post-retirement benefits Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefits
295 Implied Table Table

*

*

 implied:Table
296 Post-retirement benefits Abstract ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
297 Post-retirement benefits Concept (Text Block (HTML)) For Period azn:DisclosureOfPostEmploymentBenefitsTextBlock
298 12201 - Disclosure - Reserves Network

*

*

 http://www.astrazeneca.com/role/DisclosureReserves
299 Implied Table Table

*

*

 implied:Table
300 Reserves Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
301 Reserves Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory
302 12301 - Disclosure - Share capital of the Company Network

*

*

 http://www.astrazeneca.com/role/DisclosureShareCapitalOfCompany
303 Implied Table Table

*

*

 implied:Table
304 Share capital of the Company Abstract ifrs-full:DisclosureOfClassesOfShareCapitalAbstract
305 Share capital of the Company Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIssuedCapitalExplanatory
306 12401 - Disclosure - Dividends to shareholders Network

*

*

 http://www.astrazeneca.com/role/DisclosureDividendsToShareholders
307 Implied Table Table

*

*

 implied:Table
308 Dividends to shareholders Abstract azn:DividendsToShareholdersAbstract
309 Dividends to shareholders Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDividendsExplanatory
310 12501 - Disclosure - Non-controlling interests Network

*

*

 http://www.astrazeneca.com/role/DisclosureNonControllingInterests
311 Implied Table Table

*

*

 implied:Table
312 Non-controlling interests. Abstract ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
313 Non-controlling interests Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory
314 12601 - Disclosure - Acquisitions of business operations Network

*

*

 http://www.astrazeneca.com/role/DisclosureAcquisitionsOfBusinessOperations
315 Implied Table Table

*

*

 implied:Table
316 Disclosure of detailed information about business combination [abstract] Abstract ifrs-full:DisclosureOfBusinessCombinationsAbstract
317 Acquisitions of business operations Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBusinessCombinationsExplanatory
318 12701 - Disclosure - Financial risk management objectives and policies Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPolicies
319 Implied Table Table

*

*

 implied:Table
320 Disclosure Of financial risk management objectives and policies Abstract azn:DisclosureOfFinancialRiskManagementAbstract
321 Financial risk management objectives and policies Concept (Text Block (HTML)) For Period azn:DisclosureOfFinancialRiskManagementTextBlock
322 12801 - Disclosure - Employee costs and share plans for employees Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployees
323 Implied Table Table

*

*

 implied:Table
324 Employee costs and share plans for employees Abstract azn:EmployeeCostsAndSharePlansForEmployeesAbstract
325 Employee costs and share plans for employees Concept (Text Block (HTML)) For Period azn:DisclosureOfEmployeeCostsAndShareBasedPaymentArrangementsTextBlock
326 12901 - Disclosure - Commitments and contingent liabilities Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilities
327 Implied Table Table

*

*

 implied:Table
328 Legal Proceedings and Contingent Liabilities Abstract azn:IfrsCommitmentsAndContingenciesDisclosureAbstract
329 Commitments and contingent liabilities Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
330 13001 - Disclosure - Operating leases Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingLeases
331 Implied Table Table

*

*

 implied:Table
332 Operating leases Abstract ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract
333 Operating leases Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfLeasesExplanatory
334 13101 - Disclosure - Statutory and other information Network

*

*

 http://www.astrazeneca.com/role/DisclosureStatutoryAndOtherInformation
335 Implied Table Table

*

*

 implied:Table
336 Statutory and other information Abstract ifrs-full:AdditionalInformationAbstract
337 Statutory and other information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAdditionalInformationExplanatory
338 13201 - Disclosure - Subsequent events Network

*

*

 http://www.astrazeneca.com/role/DisclosureSubsequentEvents
339 Implied Table Table

*

*

 implied:Table
340 Subsequent events Abstract ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract
341 Subsequent events Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
342 20002 - Disclosure - Group Accounting Policies (Policies) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesPolicies
343 Implied Table Table

*

*

 implied:Table
344 Group Accounting Policies Abstract azn:DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract
345 Basis of accounting and preparation of financial information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
346 Basis for preparation of Financial Statements on a going concern basis Concept (Text Block (HTML)) For Period azn:BasisForPreparationOfFinancialStatementsOnGoingConcernBasisPolicyTextBlock
347 Estimates and judgements Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
348 Revenue Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
349 Cost of sales Concept (Text Block (HTML)) For Period azn:DescriptionOfAccountingPolicyForCostOfSalesTextBlock
350 Research and development Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
351 Business combinations and goodwill Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory
352 Joint arrangements and associates Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory
353 Employee benefits Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
354 Taxation Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
355 Share-based payments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
356 Property, plant and equipment Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
357 Borrowing costs Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForBorrowingCostsExplanatory
358 Leases Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
359 Subsidiaries Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory
360 Inventories Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories
361 Assets held for sale Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory
362 Trade and other receivables Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory
363 Trade and other payables Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory
364 Financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
365 Cash and cash equivalents Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
366 Fixed deposits Concept (Text Block (HTML)) For Period azn:FixedDepositsPolicyTextBlock
367 Other investments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory
368 Bank and other borrowings Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory
369 Derivatives Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory
370 Foreign currencies Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
371 Litigation and environmental liabilities Concept (Text Block (HTML)) For Period azn:LitigationAndEnvironmentalLiabilitiesPolicyTextBlock
372 Impairment Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory
373 International accounting transition Concept (Text Block (HTML)) For Period azn:InternationalAccountingTransitionPolicyTextBlock
374 Financial risk Concept (Text Block (HTML)) For Period azn:FinancialRiskPolicyPolicyTextBlock
375 Liquidity risk Concept (Text Block (HTML)) For Period azn:LiquidityRiskPolicyPolicyTextBlock
376 Interest rate risk Concept (Text Block (HTML)) For Period azn:InterestRateRiskPolicyPolicyTextBlock
377 Foreign currency risk Concept (Text Block (HTML)) For Period azn:ForeignCurrencyRiskPolicyPolicyTextBlock
378 Credit risk Concept (Text Block (HTML)) For Period azn:CreditRiskPolicyPolicyTextBlock
379 Applicable accounting standards and interpretations issued but not yet adopted Concept (Text Block (HTML)) For Period azn:ApplicableAccountingStandardsAndInterpretationsIssuedButNotYetAdoptedPolicyTextBlock
380 30003 - Disclosure - Group Accounting Policies (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesTables
381 Disclosure of initial application of standards or interpretations [table] Table

*

*

 ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable
382 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
383 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
384 Financial assets Member ifrs-full:FinancialAssetsMember
385 Financial liabilities Member ifrs-full:FinancialLiabilitiesMember
386 Application of new accounting standards LineItems ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems
387 Schedule of adjustments due to initial application of standards Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
388 30103 - Disclosure - Revenue (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureRevenueTables
389 Disclosure of disaggregation of revenue from contracts with customers [table] Table

*

*

 ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable
390 IFRS Income Statement Location [Axis] Axis azn:IfrsIncomeStatementLocationAxis
391 IFRS Income Statement Location [Domain] Member azn:IfrsIncomeStatementLocationDomain
392 Externalisation Revenue Member azn:ExternalisationRevenueMember
393 Disclosure of disaggregation of revenue from contracts with customers [line items] LineItems ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
394 Schedule of product sales Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
395 30203 - Disclosure - Operating profit (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingProfitTables
396 Implied Table Table

*

*

 implied:Table
397 Operating profit Abstract ifrs-full:ProfitLossAbstract
398 Schedule of other operating income and expense Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory
399 Schedule of restructuring costs Concept (Text Block (HTML)) For Period azn:IfrsScheduleOfRestructuringAndRelatedCostsTextBlock
400 Schedule of net gains and losses on financial instruments included within operating profit Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
401 30303 - Disclosure - Finance income and expense (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinanceIncomeAndExpenseTables
402 Implied Table Table

*

*

 implied:Table
403 Finance income and expense Abstract azn:FinanceIncomeExpenseAbstract
404 Schedule of net finance expense Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinanceCostExplanatory
405 Schedule of net gains and losses on financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory
406 30403 - Disclosure - Taxation (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTaxationTables
407 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
408 IFRS Statement Scenario [Axis] Axis azn:IfrsStatementScenarioAxis
409 IFRS Scenario Unspecified [Domain] Member azn:IfrsScenarioUnspecifiedDomain
410 Before the offset of balances within countries Member azn:BalancesBeforeOffsetOfBalancesWithinCountriesMember
411 After the offset of balances within countries Member azn:BalancesAfterOffsetOfBalancesWithinCountriesMember
412 Taxation LineItems azn:IncomeTaxDisclosureLineItems
413 Schedule of taxation, comprehensive income Concept (Text Block (HTML)) For Period azn:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
414 Schedule of tax reconciliation to UK statutory rate Concept (Text Block (HTML)) For Period azn:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
415 Schedule of deferred tax movements Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
416 Schedule of net deferred tax balance Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDeferredTaxesExplanatory
417 30503 - Disclosure - Earnings per $0.25 Ordinary Share (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEarningsPer025OrdinaryShareTables
418 Implied Table Table

*

*

 implied:Table
419 Earnings per $0.25 Ordinary Share Abstract ifrs-full:EarningsPerShareAbstract
420 Schedule of Earnings per Ordinary Share Concept (Text Block (HTML)) For Period ifrs-full:EarningsPerShareExplanatory
421 30603 - Disclosure - Segment information (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureSegmentInformationTables
422 Implied Table Table

*

*

 implied:Table
423 Segment information Abstract ifrs-full:DisclosureOfOperatingSegmentsAbstract
424 Tabular disclosure of information by geographic area Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGeographicalAreasExplanatory
425 Tabular disclosure of assets by geographic area Concept (Text Block (HTML)) For Period azn:DisclosureOfAssetsByGeographicAreaTableTextBlock
426 Tabular disclosure of product sales Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfProductsAndServicesExplanatory
427 30703 - Disclosure - Property, plant and equipment (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePropertyPlantAndEquipmentTables
428 Implied Table Table

*

*

 implied:Table
429 Property, plant and equipment Abstract ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
430 Schedule of property plant and equipment Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
431 Schedule of net book value of land and buildings Concept (Text Block (HTML)) For Period azn:ScheduleOfNetBookValueOfLandAndBuildingTableTextBlock
432 30803 - Disclosure - Goodwill (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGoodwillTables
433 Implied Table Table

*

*

 implied:Table
434 Goodwill. Abstract ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillAbstract
435 Schedule of changes in Goodwill Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory
436 30903 - Disclosure - Intangible assets (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssetsTables
437 Implied Table Table

*

*

 implied:Table
438 Intangible assets Abstract ifrs-full:DisclosureOfIntangibleAssetsAbstract
439 Schedule of reconciliation of changes in intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
440 Summary of amortisation charges Concept (Text Block (HTML)) For Period azn:DisclosureOfAmortisationChargesIntangibleAssetsOtherThanGoodwillTableTextBlock
441 Summary of impairment charges Concept (Text Block (HTML)) For Period azn:DisclosureOfImpairmentChargesIntangibleAssetsOtherThanGoodwillTableTextBlock
442 Summary of significant intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIntangibleAssetsMaterialToEntityExplanatory
443 31003 - Disclosure - Investments in associates and joint ventures (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInvestmentsInAssociatesAndJointVenturesTables
444 Implied Table Table

*

*

 implied:Table
445 Investments in associates and joint ventures Abstract ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociatesAbstract
446 Schedule of investments in associates and joint ventures Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
447 Schedule of summarised financial information for the associate and joint venture entities Concept (Text Block (HTML)) For Period azn:DisclosureOfSummarisedFinancialInformationForAssociateAndJointVentureEntities
448 31103 - Disclosure - Other investments (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOtherInvestmentsTables
449 Implied Table Table

*

*

 implied:Table
450 Other investments Abstract azn:DisclosureOfOtherInvestmentsAbstract
451 Schedule of other investments Concept (Text Block (HTML)) For Period azn:ScheduleOfOtherInvestmentsTableTextBlock
452 Schedule of analysis equity securities and bonds available for sale Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFairValueMeasurementExplanatory
453 Schedule of fair value movements in level 3 investments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFairValueMeasurementOfEquityExplanatory
454 31203 - Disclosure - Derivative financial instruments (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureDerivativeFinancialInstrumentsTables
455 Implied Table Table

*

*

 implied:Table
456 Derivative financial instruments Abstract ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsAbstract
457 Schedule of derivative financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsExplanatory
458 Schedule of interest rates on derivative financial instruments Concept (Text Block (HTML)) For Period azn:DisclosureOfInterestRatesOnDerivativeFinancialInstrumentsTableTextBlock
459 31403 - Disclosure - Inventories (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInventoriesTables
460 Implied Table Table

*

*

 implied:Table
461 Inventories Abstract ifrs-full:ClassesOfInventoriesAbstract
462 Schedule of inventory Concept (Text Block (HTML)) For Period azn:IfrsScheduleOfInventoryCurrentTableTextBlock
463 31503 - Disclosure - Current trade and other receivables (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCurrentTradeAndOtherReceivablesTables
464 Implied Table Table

*

*

 implied:Table
465 Current trade and other receivables Abstract ifrs-full:TradeAndOtherCurrentReceivablesAbstract
466 Schedule of trade, other current receivables and prepayments Concept (Text Block (HTML)) For Period azn:DisclosureOfCurrentTradeAndOtherReceivablesAndPrepaymentsTableTextBlock
467 31603 - Disclosure - Cash and cash equivalents (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCashAndCashEquivalentsTables
468 Implied Table Table

*

*

 implied:Table
469 Cash and cash equivalents. Abstract ifrs-full:CashAndCashEquivalentsAbstract
470 Summary of cash and cash equivalents Concept (Text Block (HTML)) For Period azn:DisclosureOfCashAndCashEquivalentsTableTextBlock
471 Summary of non-cash and other movements within operating activities Concept (Text Block (HTML)) For Period azn:DisclosureOfNoncashAndOtherMovementsInOperatingActivitiesTableTextBlock
472 31803 - Disclosure - Interest-bearing loans and borrowings (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInterestBearingLoansAndBorrowingsTables
473 Implied Table Table

*

*

 implied:Table
474 Interest-bearing loans and borrowings Abstract ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsAbstract
475 Schedule of interest bearing loans and borrowings Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
476 Schedule of reconciliation of interest bearing loans and borrowings Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory
477 Schedule of comparison of carrying values and fair values of interest-bearing loans and borrowings Concept (Text Block (HTML)) For Period azn:DisclosureOfComparisonOfCarryingValuesAndFairValuesOfInterestBearingLoansAndBorrowingsTableTextBlock
478 Schedule of interest rates used to discount future cash flows for fair value adjustments Concept (Text Block (HTML)) For Period azn:DisclosureOfInterestRatesUsedToDiscountFutureCashFlowsForFairValueAdjustments
479 31903 - Disclosure - Trade and other payables (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTradeAndOtherPayablesTables
480 Implied Table Table

*

*

 implied:Table
481 Trade and other payables Abstract ifrs-full:TradeAndOtherPayablesAbstract
482 Schedule of Trade and other payables Concept (Text Block (HTML)) For Period azn:DisclosureOfTradeAndOtherPayablesTableTextBlock
483 Schedule of Contingent consideration Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfContingentLiabilitiesInBusinessCombinationExplanatory
484 Schedule of maximum development and sales milestones payable under outstanding contingent consideration Concept (Text Block (HTML)) For Period azn:DisclosureOfContingentLiabilitiesInBusinessCombinationOfDevelopmentAndSalesMilestonesPayableUnderOutstandingContingentConsiderationTableTextBlock
485 32003 - Disclosure - Provisions (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureProvisionsTables
486 Implied Table Table

*

*

 implied:Table
487 Provisions. Abstract ifrs-full:ProvisionsAbstract
488 Schedule of other provision Concept (Text Block (HTML)) For Period azn:DisclosureOfProvisionsTableTextBlock
489 Schedule of maturity period Concept (Text Block (HTML)) For Period azn:DisclosureOfMaturityTableOfProvisionsTableTextBlock
490 32103 - Disclosure - Post-retirement benefits (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsTables
491 Implied Table Table

*

*

 implied:Table
492 Post-retirement benefits Abstract ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
493 Schedule of financial assumptions for major defined benefit schemes Concept (Text Block (HTML)) For Period azn:ScheduleOfFinancialAssumptionsUsedForDefinedBenefitPlansTableTextBlock
494 Schedule of demographic assumptions for major defined benefit schemes Concept (Text Block (HTML)) For Period azn:ScheduleOfDemographicAssumptionsUsedForDefinedBenefitPlansTableTextBlock
495 Schedule of risks associated with the Company's defined benefit pensions Concept (Text Block (HTML)) For Period azn:DisclosureOfRisksAssociatedWithDefinedBenefitPensionsTableTextBlock
496 Schedule of fair values of scheme assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory
497 Schedule of post-retirement scheme deficit recognised in Consolidated Statement of Financial Position, scheme assets and scheme obligations Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory
498 Schedule of amounts charged to Consolidated Statement of Comprehensive Income, in respect of defined benefit schemes Concept (Text Block (HTML)) For Period azn:ScheduleOfNetDefinedBenefitCostsAndOtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansTableTextBlock
499 Schedule of rate sensitivities of significant actuarial assumptions Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory
500 32203 - Disclosure - Reserves (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureReservesTables
501 Implied Table Table

*

*

 implied:Table
502 Reserves Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
503 Reconciliation of reserves Concept (Text Block (HTML)) For Period azn:ReconciliationOfReservesTableTextBlock
504 32303 - Disclosure - Share capital of the Company (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureShareCapitalOfCompanyTables
505 Implied Table Table

*

*

 implied:Table
506 Share capital of the Company Abstract ifrs-full:DisclosureOfClassesOfShareCapitalAbstract
507 Summary of classes of share capital Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
508 Summary of movement of ordinary shares Concept (Text Block (HTML)) For Period azn:SummaryOfMovementOfOrdinarySharesTableTextBlock
509 32403 - Disclosure - Dividends to shareholders (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureDividendsToShareholdersTables
510 Implied Table Table

*

*

 implied:Table
511 Dividends to shareholders Abstract azn:DividendsToShareholdersAbstract
512 Summary of dividends to shareholders Concept (Text Block (HTML)) For Period azn:SummaryOfDividendsToShareholdersTableTextBlock
513 Reconciliation of dividends paid Concept (Text Block (HTML)) For Period azn:ReconciliationOfDividendsPaidTableTextBlock
514 32503 - Disclosure - Non-controlling interests (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureNonControllingInterestsTables
515 Implied Table Table

*

*

 implied:Table
516 Non-controlling interests. Abstract ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
517 Summarised financial information for non-controlling interests Concept (Text Block (HTML)) For Period azn:SummarisedFinancialInformationNoncontrollingInterestsTableTextBlock
518 32603 - Disclosure - Acquisitions of business operations (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureAcquisitionsOfBusinessOperationsTables
519 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
520 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
521 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
522 Acerta Pharma Acquisition Member azn:AcertaPharmaAcquisitionMember
523 Disclosure of detailed information about business combination LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
524 Summary of fair values assigned to business combination Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory
525 32703 - Disclosure - Financial risk management objectives and policies (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesTables
526 Disclosure of provision matrix [table] Table

*

*

 ifrs-full:DisclosureOfProvisionMatrixTable
527 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
528 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
529 Credit risk assets Member azn:CreditRiskAssetsMember
530 Trade receivables Member ifrs-full:TradeReceivablesMember
531 Financial risk LineItems ifrs-full:DisclosureOfProvisionMatrixLineItems
532 Schedule of liquidity risk Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfLiquidityRiskExplanatory
533 Schedule of market risk Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfMarketRiskExplanatory
534 Schedule of foreign currency risk Concept (Text Block (HTML)) For Period azn:DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock
535 Schedule of credit risk Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCreditRiskExplanatory
536 32803 - Disclosure - Employee costs and share plans for employees (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesTables
537 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
538 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
539 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
540 AstraZeneca 2014 Performance Share Plan Member azn:Astrazeneca2014PerformanceSharePlanMember
541 AstraZeneca Investment Plan Member azn:AstrazenecaInvestmentPlanMember
542 AstraZeneca Global Restricted Stock Plan Member azn:AstrazenecaGlobalRestrictedStockPlanMember
543 AstraZeneca Restricted Share Plan Member azn:AstrazenecaRestrictedSharePlanMember
544 Astrazeneca Extended Incentive Plan Member azn:AstrazenecaExtendedIncentivePlanMember
545 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
546 Schedules of employee numbers Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory
547 Schedule of employee costs Concept (Text Block (HTML)) For Period azn:DisclosureOfEmployeeCostsTableTextBlock
548 Schedule of shares awarded Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory
549 32903 - Disclosure - Commitments and contingent liabilities (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables
550 Implied Table Table

*

*

 implied:Table
551 Legal Proceedings and Contingent Liabilities Abstract azn:IfrsCommitmentsAndContingenciesDisclosureAbstract
552 Schedule of commitments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsExplanatory
553 Schedule of potential development and revenue-related payments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfContingentLiabilitiesExplanatory
554 33003 - Disclosure - Operating leases (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingLeasesTables
555 Implied Table Table

*

*

 implied:Table
556 Operating leases Abstract ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract
557 Schedule of total rentals under operating leases charged to profit Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory
558 Schedule of future minimum lease payments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory
559 33103 - Disclosure - Statutory and other information (Tables) Network

*

*

 http://www.astrazeneca.com/role/DisclosureStatutoryAndOtherInformationTables
560 Implied Table Table

*

*

 implied:Table
561 Statutory and other information Abstract ifrs-full:AdditionalInformationAbstract
562 Schedule of auditor's remuneration Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAuditorsRemunerationExplanatory
563 Schedule of key management personnel compensation Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
564 40001 - Disclosure - Group Accounting Policies (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesDetails
565 Summary Of Significant Accounting Policies [Table] Table

*

*

 azn:SummaryOfSignificantAccountingPoliciesTable
566 Maturity [axis] Axis ifrs-full:MaturityAxis
567 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
568 Years 3 and 4 Member ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember
569 Years 2 and 3 Member ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember
570 Years 1 and 2 Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
571 Due within one year Member ifrs-full:NotLaterThanOneYearMember
572 Methods of generation [axis] Axis ifrs-full:MethodsOfGenerationAxis
573 Methods of generation [member] Member ifrs-full:MethodsOfGenerationMember
574 Internally generated Member ifrs-full:InternallyGeneratedMember
575 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
576 Intangible assets other than goodwill [member] Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
577 Capitalised development expenditure Member ifrs-full:CapitalisedDevelopmentExpenditureMember
578 Range [axis] Axis ifrs-full:RangeAxis
579 Ranges [member] Member ifrs-full:RangesMember
580 Minimum Member ifrs-full:BottomOfRangeMember
581 Maximum Member ifrs-full:TopOfRangeMember
582 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
583 Property, plant and equipment [member] Member ifrs-full:PropertyPlantAndEquipmentMember
584 Buildings Member ifrs-full:BuildingsMember
585 Plant and equipment Member azn:PlantsAndEquipmentsMember
586 Group Accounting Policies LineItems azn:SummaryOfSignificantAccountingPoliciesLineItems
587 Financial resources Concept (Monetary) As Of Debit azn:FinancialResourcesThatIncludeCashUndrawnCommittedBankFacilitiesExcludingCurrentOutstandingDebt
588 Cash balances Concept (Monetary) As Of Debit ifrs-full:BalancesWithBanks
589 Undrawn committed bank facilities Concept (Monetary) As Of Credit ifrs-full:UndrawnBorrowingFacilities
590 Interest-bearing loans and borrowings Concept (Monetary) As Of Credit ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
591 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
592 Period of time return accruals are based on Concept (xbrli:durationItemType) For Period azn:PeriodOfTimeToCalculateReturnAccruals
593 Sales recorded when the Company is the principal in a profit share agreement (as a percentage) Concept (Percent) For Period azn:SalesRecordedWhenCompanyIsPrincipalPercentage
594 Asset lives, property, plant and equipment Concept (xbrli:durationItemType) For Period azn:UsefulLivesPropertyPlantAndEquipment
595 Cumulative translation reserve Concept (Monetary) As Of Credit ifrs-full:ReserveOfExchangeDifferencesOnTranslation
596 Available-for-sale assets profit/loss through other comprehensive income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets
597 40002 - Disclosure - Group Accounting Policies - IFRS 9 Assets (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesIfrs9AssetsDetails
598 Disclosure of financial assets at date of initial application of IFRS 9 [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9Table
599 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
600 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
601 IFRS 9 Member ifrs-full:InAccordanceWithIFRS9Member
602 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
603 Financial assets Member ifrs-full:FinancialAssetsMember
604 Non Current Financial Assets [Member] Member azn:NonCurrentFinancialAssetsMember
605 Equity securities Member ifrs-full:EquityInvestmentsMember
606 Non-current Derivatives Member azn:NonCurrentDerivativesMember
607 Derivatives Member ifrs-full:DerivativesMember
608 Non-current other receivables Member azn:NonCurrentOtherReceivablesMember
609 Current Financial Assets [Member] Member azn:CurrentFinancialAssetsMember
610 Trade receivables Member ifrs-full:TradeReceivablesMember
611 Trade receivables - not subject to factoring Member azn:TradeReceivablesNotSubjectToFactoringMember
612 Trade receivables - subject to factoring Member azn:TradeReceivablesSubjectToFactoringMember
613 Other receivables Member azn:OtherReceivablesMember
614 Other investments Member azn:InvestmentsOtherMember
615 Equity securities and bonds Member azn:EquitySecuritiesAndBondsMember
616 Fixed deposits Member azn:FixedDepositsMember
617 Cash, Cash Equivalents [Member] Member azn:CashCashEquivalentsMember
618 Cash at bank and in hand Member azn:CashAtBankAndInHandMember
619 Short-term deposits excluding money market funds Member azn:ShortTermDepositsExcludingMoneyMarketFundsMember
620 Money market funds Member azn:IfrsMoneyMarketFundsMember
621 Initial application of IFRS 9 LineItems ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9LineItems
622 Original Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsCarryingAmountImmediatelyBeforeInitialApplicationOfIFRS9
623 New Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9
624 40003 - Disclosure - Group Accounting Policies - IFRS 9 Liabilities (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesIfrs9LiabilitiesDetails
625 Disclosure of financial assets at date of initial application of IFRS 9 [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9Table
626 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
627 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
628 IFRS 9 Member ifrs-full:InAccordanceWithIFRS9Member
629 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
630 Financial liabilities Member ifrs-full:FinancialLiabilitiesMember
631 Current Financial Liabilities [Member] Member azn:CurrentFinancialLiabilitiesMember
632 Derivatives Member ifrs-full:DerivativesMember
633 Non Current Financial Liabilities [Member] Member azn:NonCurrentFinancialLiabilitiesMember
634 Non-current Derivatives Member azn:NonCurrentDerivativesMember
635 Initial application of IFRS 9 LineItems ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9LineItems
636 Financial liabilities, carrying amount immediately before initial application of IFRS 9 Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesCarryingAmountImmediatelyBeforeInitialApplicationOfIFRS9
637 Financial liabilities, carrying amount immediately after initial application of IFRS 9 Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9
638 40004 - Disclosure - Group Accounting Policies - IFRS 15 (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesIfrs15Details
639 Disclosure of initial application of standards or interpretations [table] Table

*

*

 ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable
640 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
641 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
642 IFRS 15 Member ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member
643 Application of new accounting standards LineItems ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems
644 Contract liabilities Concept (Monetary) As Of Credit ifrs-full:ContractLiabilities
645 Contract assets Concept (Monetary) As Of Debit ifrs-full:ContractAssets
646 Tax expense (income), continuing operations Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
647 Retained earnings Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
648 Externalisation Revenue Concept (Monetary) For Period Credit azn:ExternalisationRevenue
649 40005 - Disclosure - Group Accounting Policies - IFRS 9 Impact (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesIfrs9ImpactDetails
650 Disclosure of financial assets at date of initial application of IFRS 9 [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9Table
651 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
652 Financial assets Member ifrs-full:FinancialAssetsMember
653 Non Current Financial Assets [Member] Member azn:NonCurrentFinancialAssetsMember
654 Equity securities Member ifrs-full:EquityInvestmentsMember
655 Disclosure of financial assets at date of initial application of IFRS 9 [line items] LineItems ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9LineItems
656 Fixed income securities available for sale Concept (Monetary) As Of Debit ifrs-full:CurrentFinancialAssetsAvailableforsale
657 Equity securities available for sale Concept (Monetary) As Of Debit ifrs-full:NoncurrentFinancialAssetsAvailableforsale
658 40006 - Disclosure - Group Accounting Policies - IFRS 16 (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGroupAccountingPoliciesIfrs16Details
659 Disclosure of initial application of standards or interpretations [table] Table

*

*

 ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable
660 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
661 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
662 IFRS 16 Member azn:InAccordanceWithIfrs16Member
663 Application of new accounting standards LineItems ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems
664 Right-of-use assets Concept (Monetary) As Of Debit ifrs-full:RightofuseAssets
665 Lease liabilities Concept (Monetary) As Of Credit ifrs-full:LeaseLiabilities
666 40101 - Disclosure - Revenue (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureRevenueDetails
667 Disclosure of disaggregation of revenue from contracts with customers [table] Table

*

*

 ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable
668 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
669 Products and services [member] Member ifrs-full:ProductsAndServicesMember
670 Oncology Member azn:OncologyProductsMember
671 Tagrisso Member azn:TagrissoMember
672 Faslodex Member azn:FaslodexMember
673 Zoladex Member azn:ZoladexMember
674 Lynparza Member azn:LynparzaMember
675 Imfinzi Member azn:ImfinziMember
676 Iressa Member azn:IressaMember
677 Arimidex Member azn:ArimidexMember
678 Casodex Member azn:CasodexMember
679 Calquence Member azn:CalquenceMember
680 Oncology, Others Member azn:OtherOncologyProductsMember
681 CVRM Member azn:CardiovascularAndMetabolicDiseasesProductsMember
682 Crestor Member azn:CrestorMember
683 Farxiga Member azn:FarxigaMember
684 Brilinta Member azn:BrilintaMember
685 Seloken/Toprol-XL Member azn:SelokenToprolXlMember
686 Bydureon Member azn:BydureonMember
687 Onglyza Member azn:OnglyzaMember
688 Atacand Member azn:AtacandMember
689 Byetta Member azn:ByettaMember
690 Symlin Member azn:SymlinMember
691 Plendil Member azn:PlendilMember
692 CVDM, Others Member azn:OtherCardiovascularAndMetabolicDiseasesProductsMember
693 Respiratory Member azn:RespiratoryProductsMember
694 Symbicort Member azn:SymbicortMember
695 Pulmicort Member azn:PulmicortMember
696 Fasenra Member azn:FasenraMember
697 Daliresp/Daxas Member azn:DalirespDaxasMember
698 Tudorza/Eklira Member azn:TudorzaEkliraMember
699 Duaklir Member azn:DuaklirMember
700 Bevespi Member azn:BevespiMember
701 Respiratory, Others Member azn:OtherRespiratoryProductsMember
702 Other Member azn:OtherProductsMember
703 Nexium Member azn:NexiumMember
704 Synagis Member azn:SynagisMember
705 Seroquel XR/IR Member azn:SeroquelXrIrMember
706 Losec/Prilosec Member azn:LosecPrilosecMember
707 FluMist/Fluenz Member azn:FlumistFluenzMember
708 Movantik/Moventig Member azn:MovantikMoventigMember
709 Other, Others Member azn:OtherProductsOthersMember
710 Brodalumab Member azn:BrodalumabMember
711 Lynparza and Selumetinb Member azn:LynparzaAndSelumetinbMember
712 Anaesthetics Medicines Member azn:AnaestheticsMedicinesPortfolioMember
713 MEDI8897 Member azn:Medi8897Member
714 Externalisation Revenue Member azn:ExternalisationRevenueMember
715 Royal Revenue Member azn:RoyalRevenueMember
716 Milestone Revenue Member azn:MilestoneRevenueMember
717 Major customers [axis] Axis ifrs-full:MajorCustomersAxis
718 Customers [member] Member ifrs-full:MajorCustomersMember
719 Aspen Member azn:AspenGlobalIncorporatedMember
720 CMS Member azn:ChinaMedicalSystemHoldingsLtdMember
721 Aralez Member azn:AralezPharmaceuticalsInc.Member
722 Valeant and Leo Member azn:ValeantAndLeoMember
723 Sanofi Member azn:SanofiPasteurIncMember
724 MSD Member azn:MsdMember
725 TerSera Member azn:TerseraTherapeuticsLlcMember
726 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
727 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
728 Emerging Markets Member azn:EmergingMarketsMember
729 US Member azn:IfrsCountryUsMember
730 Europe Member azn:IfrsEuropeMember
731 Rest of World Member azn:WorldExcludingEmergingMarketsUnitedStatesAndEuropeMember
732 IFRS Income Statement Location [Axis] Axis azn:IfrsIncomeStatementLocationAxis
733 IFRS Income Statement Location [Domain] Member azn:IfrsIncomeStatementLocationDomain
734 Externalisation Revenue Member azn:ExternalisationRevenueMember
735 Royal Revenue Member azn:RoyalRevenueMember
736 Milestone Revenue Member azn:MilestoneRevenueMember
737 Revenues LineItems ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
738 Revenue Concept (Monetary) For Period Credit ifrs-full:RevenueFromContractsWithCustomers
739 Rebate, returns and chargebacks (as a percent) Concept (Percent) For Period azn:RebateReturnsAndChargebacksAdjustmentPercentage
740 40102 - Disclosure - Revenue - Externalisation Revenue (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureRevenueExternalisationRevenueDetails
741 Disclosure of disaggregation of revenue from contracts with customers [table] Table

*

*

 ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable
742 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
743 Products and services [member] Member ifrs-full:ProductsAndServicesMember
744 Lynparza and Selumetinb Member azn:LynparzaAndSelumetinbMember
745 Crestor Member azn:CrestorMember
746 Zoladex Member azn:ZoladexMember
747 Anaesthetics Medicines Member azn:AnaestheticsMedicinesPortfolioMember
748 Brodalumab Member azn:BrodalumabMember
749 MEDI8897 Member azn:Medi8897Member
750 Plendil Member azn:PlendilMember
751 Toprol-XL Member azn:ToprolxlMember
752 Tralokinumab Member azn:TralokinumabMember
753 Externalisation Revenue Member azn:ExternalisationRevenueMember
754 Upfront Revenue Member azn:UpfrontRevenueMember
755 Milestone Revenue Member azn:MilestoneRevenueMember
756 Royal Revenue Member azn:RoyalRevenueMember
757 Other Externalisation Revenue Member azn:OtherExternalisationRevenueMember
758 Major customers [axis] Axis ifrs-full:MajorCustomersAxis
759 Customers [member] Member ifrs-full:MajorCustomersMember
760 MSD Member azn:MsdMember
761 Almirall Member azn:AlmirallMember
762 TerSera Member azn:TerseraTherapeuticsLlcMember
763 Aspen Member azn:AspenGlobalIncorporatedMember
764 Valeant and Leo Member azn:ValeantAndLeoMember
765 Sanofi Member azn:SanofiPasteurIncMember
766 CMS Member azn:ChinaMedicalSystemHoldingsLtdMember
767 Aralez Member azn:AralezPharmaceuticalsInc.Member
768 LEO Pharma Member azn:LeoPharmaMember
769 IFRS Income Statement Location [Axis] Axis azn:IfrsIncomeStatementLocationAxis
770 IFRS Income Statement Location [Domain] Member azn:IfrsIncomeStatementLocationDomain
771 Externalisation Revenue Member azn:ExternalisationRevenueMember
772 Upfront Revenue Member azn:UpfrontRevenueMember
773 Milestone Revenue Member azn:MilestoneRevenueMember
774 Royal Revenue Member azn:RoyalRevenueMember
775 Other Externalisation Revenue Member azn:OtherExternalisationRevenueMember
776 Geographical [Axis] Axis srt:StatementGeographicalAxis
777 Geographical [Domain] Member srt:SegmentGeographicalDomain
778 Japan Member azn:IfrsCountryJpMember
779 Revenues LineItems ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
780 Revenue Concept (Monetary) For Period Credit ifrs-full:RevenueFromContractsWithCustomers
781 Contract liabilities Concept (Monetary) As Of Credit ifrs-full:ContractLiabilities
782 40201 - Disclosure - Operating profit - Other operating income and expense (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingProfitOtherOperatingIncomeAndExpenseDetails
783 Disclosure Of Profit Loss, Operating Activities [Table] Table

*

*

 azn:DisclosureOfProfitLossOperatingActivitiesTable
784 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
785 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
786 Most markets outside the US Member azn:MostMarketsOutsideUnitedStatesMember
787 Rest of the world Member azn:RestOfWorldExcludingUkSwedenAndUsMember
788 Europe Member azn:IfrsEuropeMember
789 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
790 Products and services [member] Member ifrs-full:ProductsAndServicesMember
791 Small molecule antibiotics Member azn:SmallMoleculeAntibioticsMember
792 Rhinocort Member azn:RhinocortMember
793 MEDI2070 Member azn:MEDI2070Member
794 Imdur Member azn:ImdurMember
795 Nexium Member azn:NexiumMember
796 Atacand Member azn:AtacandMember
797 Anaesthetics Medicines Member azn:AnaestheticsMedicinesPortfolioMember
798 Alvesco, Omnaris and Zetonna Member azn:AlvescoOmnarisAndZetonnaMember
799 Seroquel XR/IR Member azn:SeroquelXrIrMember
800 Seloken/Toprol-XL Member azn:SelokenToprolXlMember
801 Zomig Member azn:ZomigMember
802 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
803 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
804 Business combinations [member] Member ifrs-full:BusinessCombinationsMember
805 BMS's share of Global Diabetes Alliance Member azn:BmssShareOfGlobalDiabetesAllianceMember
806 Global Anaesthetics portfolio Member azn:GlobalAnaestheticsPortfolioMember
807 Acerta Pharma Member azn:AcertaPharmaMember
808 Operating profit, other operating income and expense LineItems azn:DisclosureOfProfitLossFromOperatingActivitiesLineItems
809 Changes in fair value of contingent consideration credit (charge) Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
810 Legal proceedings provision Concept (Monetary) For Period Debit azn:IfrsLossContingencyLossInPeriod
811 Royalties income Concept (Monetary) For Period Credit azn:OtherOperatingIncomeRelatedToRoyalties
812 Royalties amortisation Concept (Monetary) For Period Debit ifrs-full:RoyaltyExpense
813 Gains on disposal of intangible assets Concept (Monetary) For Period Credit azn:GainOnDispositionOfIntangibleAssets
814 Gains on disposal of short-term investments Concept (Monetary) For Period Credit ifrs-full:GainsOnDisposalsOfInvestments
815 Net (losses)/gains on disposal of other non-current assets Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets
816 Impairment of property, plant and equipment Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
817 Legal settlements Concept (Monetary) For Period Credit azn:IfrsGainLossRelatedToLitigationSettlement
818 Other income Concept (Monetary) For Period Credit ifrs-full:MiscellaneousOtherOperatingIncome
819 Other expense Concept (Monetary) For Period Debit ifrs-full:MiscellaneousOtherOperatingExpense
820 Other operating income and expense Concept (Monetary) For Period Credit ifrs-full:OtherOperatingIncomeExpense
821 40202 - Disclosure - Operating profit - Restructuring costs (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingProfitRestructuringCostsDetails
822 Restructuring Costs [Table] Table

*

*

 azn:RestructuringCostsTable
823 IFRS Income Statement Location [Axis] Axis azn:IfrsIncomeStatementLocationAxis
824 IFRS Income Statement Location [Domain] Member azn:IfrsIncomeStatementLocationDomain
825 Cost of sales Member azn:IfrsCostOfSalesMember
826 Research and development expense Member azn:IfrsResearchAndDevelopmentExpenseMember
827 Selling, general and administrative costs Member azn:IfrsSellingGeneralAndAdministrativeExpensesMember
828 Other operating income and expense Member azn:IfrsOtherOperatingIncomeExpenseMember
829 IFRS Restructuring Cost And Reserve [Axis] Axis azn:IfrsRestructuringCostAndReserveAxis
830 IFRS Type of Restructuring [Domain] Member azn:IfrsTypeOfRestructuringDomain
831 Severance costs Member azn:IfrsEmployeeSeveranceMember
832 Accelerated depreciation and impairment Member azn:AcceleratedDepreciationAndImpairmentMember
833 Other restructuring Member azn:IfrsOtherRestructuringMember
834 Restructuring programmes LineItems azn:RestructuringCostsLineItems
835 Total charge Concept (Monetary) For Period Debit ifrs-full:ExpenseOfRestructuringActivities
836 40203 - Disclosure - Operating profit - Financial instruments (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingProfitFinancialInstrumentsDetails
837 Implied Table Table

*

*

 implied:Table
838 Operating profit Abstract ifrs-full:ProfitLossAbstract
839 Losses on forward foreign exchange contracts Concept (Monetary) For Period Credit ifrs-full:TradingIncomeExpenseOnForeignExchangeContracts
840 Gains/(losses) on receivables and payables Concept (Monetary) For Period Credit azn:GainsLossesOnReceivablesAndPayables
841 Gains on disposal of short-term investments Concept (Monetary) For Period Credit ifrs-full:GainsOnDisposalsOfInvestments
842 Gains on other available for sale investments Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnAvailableforsaleFinancialAssets
843 Total Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss
844 40301 - Disclosure - Finance income and expense - Net finance expense (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinanceIncomeAndExpenseNetFinanceExpenseDetails
845 Implied Table Table

*

*

 implied:Table
846 Finance income and expense Abstract azn:FinanceIncomeExpenseAbstract
847 Finance income Abstract azn:FinanceIncomeAbstract
848 Returns on fixed deposits and equity securities Concept (Monetary) For Period Credit azn:FinanceIncomeReturnsOnFixedDepositsAndEquitySecurities
849 Returns on short-term deposits Concept (Monetary) For Period Credit ifrs-full:InterestIncomeOnDeposits
850 Fair value gains on debt and interest rate swaps Concept (Monetary) For Period Credit ifrs-full:GainsOnChangeInFairValueOfDerivatives
851 Net exchange gains Concept (Monetary) For Period Credit ifrs-full:NetForeignExchangeGain
852 Discount unwind on other long-term assets Concept (Monetary) For Period Credit azn:FinanceIncomeDiscountUnwindOnOtherLongTermAssets
853 Interest on tax receivables Concept (Monetary) For Period Credit ifrs-full:InterestIncomeOnLoansAndReceivables
854 Total Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
855 Finance expense Abstract azn:FinanceExpenseAbstract
856 Interest on debt and commercial paper Concept (Monetary) For Period Debit ifrs-full:InterestExpenseOnDebtInstrumentsIssued
857 Interest on overdrafts, finance leases and other financing costs Concept (Monetary) For Period Debit ifrs-full:InterestExpenseOnBankLoansAndOverdrafts
858 Net interest on post-employment defined benefit plan net liabilities (Note 21) Concept (Monetary) For Period Debit azn:DefinedBenefitPlansInterestExpenseIncomeNet
859 Net exchange losses Concept (Monetary) For Period Debit ifrs-full:NetForeignExchangeLoss
860 Discount unwind on contingent consideration arising from business combinations (Note 19) Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateContingentLiabilitiesRecognisedInBusinessCombination
861 Discount unwind on other long-term liabilities Concept (Monetary) For Period Debit azn:FinanceExpenseDiscountUnwindOnOtherLongTermLiabilities
862 Fair value losses on debt and interest rate swaps Concept (Monetary) For Period Debit ifrs-full:LossesOnChangeInFairValueOfDerivatives
863 Interest on tax payables Concept (Monetary) For Period Debit azn:InterestOnTaxPayable
864 Total Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
865 Net finance expense Concept (Monetary) For Period Credit ifrs-full:FinanceIncomeCost
866 40302 - Disclosure - Finance income and expense - Financial instruments (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinanceIncomeAndExpenseFinancialInstrumentsDetails
867 Disclosure of detailed information about financial instruments [table] Table

*

*

 ifrs-full:DisclosureOfFinancialInstrumentsTable
868 Categories of financial assets [axis] Axis ifrs-full:CategoriesOfFinancialAssetsAxis
869 Financial assets, category [member] Member ifrs-full:FinancialAssetsCategoryMember
870 Instruments designated at fair value through profit and loss Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember
871 Types of hedges [axis] Axis ifrs-full:TypesOfHedgesAxis
872 Hedges [member] Member ifrs-full:TypesOfHedgesMember
873 Instruments in a fair value hedge relationship Member ifrs-full:FairValueHedgesMember
874 Instruments designated in cash flow hedge Member ifrs-full:CashFlowHedgesMember
875 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
876 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
877 Interest rate fair value hedging instruments Member azn:InterestRateFairValueHedgingInstrumentsMember
878 Derivatives Member ifrs-full:DerivativesMember
879 Interest rate swaps Member ifrs-full:InterestRateSwapContractMember
880 Loans Member ifrs-full:LoanCommitmentsMember
881 Net gains and losses on financial instruments LineItems ifrs-full:DisclosureOfFinancialInstrumentsLineItems
882 Interest and fair value adjustments in respect of debt designated at fair value through profit or loss, net of derivatives Concept (Monetary) For Period Credit azn:ChangesInInterestAndFairValueOfDebtDesignatedAtFairValueThroughProfitOrLossNetOfDerivatives
883 Interest and changes in carrying values of debt designated as hedged items in fair value hedges, net of derivatives Concept (Monetary) For Period Credit azn:ChangesInInterestAndCarryingAmountOfDebtDesignatedAsHedgedItemsNetOfDerivatives
884 Interest and fair value changes on fixed and short-term deposits, equity securities, other derivatives and tax balances Concept (Monetary) For Period Credit azn:ChangesInInterestAndFairValueOfFixedAndShortTermDepositsEquitySecuritiesAndOtherDerivatives
885 Interest on debt, overdrafts, finance leases and commercial paper held at amortised cost Concept (Monetary) For Period Credit azn:InterestOnDebtOverdraftsFinanceLeasesAndCommercialPaperHeldAtAmortisedCost
886 Losses on change in fair value of derivatives Concept (Monetary) For Period Debit ifrs-full:LossesOnChangeInFairValueOfDerivatives
887 Gain on change in fair value of related hedged items Concept (Monetary) For Period Credit ifrs-full:GainLossOnChangeInFairValueOfHedgedItemUsedAsBasisForRecognisingHedgeIneffectiveness
888 Gains on change in fair value of derivatives Concept (Monetary) For Period Credit ifrs-full:GainLossOnChangeInFairValueOfHedgingInstrumentUsedAsBasisForRecognisingHedgeIneffectiveness
889 Ineffectiveness on net investment hedge taken to profit Concept (Monetary) For Period Credit ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
890 40401 - Disclosure - Taxation - Comprehensive income (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTaxationComprehensiveIncomeDetails
891 Implied Table Table

*

*

 implied:Table
892 Taxation Abstract ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
893 Current tax expense Abstract ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract
894 Current year Concept (Monetary) For Period Debit ifrs-full:CurrentTaxExpenseIncome
895 Adjustment to prior years Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
896 Total Concept (Monetary) For Period Debit ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
897 Deferred tax expense Abstract ifrs-full:DeferredTaxExpenseIncomeAbstract
898 Origination and reversal of temporary differences Concept (Monetary) For Period Debit ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
899 Adjustment to prior years Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDeferredTaxOfPriorPeriods
900 Total Concept (Monetary) For Period ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
901 Taxation recognised in the profit for the period Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
902 Current and deferred tax Abstract ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeAbstract
903 Items that will not be reclassified to profit or loss: Abstract ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossAbstract
904 Remeasurement of the defined benefit liability Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
905 Share-based payments Concept (Monetary) For Period Debit azn:IncomeTaxRelatingToShareBasedPaymentsOfOtherComprehensiveIncome
906 Net losses on equity investments measured at fair value through other comprehensive income Concept (Monetary) For Period Debit azn:IncomeTaxRelatingToGainsLossesOnEquityInvestmentsMeasuredAtFairValueIncludedInOtherComprehensiveIncome
907 Deferred tax impact of reduction in US tax rate and other tax rates Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInAccumulatedDeferredTaxRecognisedInOtherComprehensiveIncomeDueToChangeInTaxRate
908 Total Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss
909 Items that may be reclassified subsequently to profit or loss: Abstract ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossAbstract
910 Foreign exchange arising on consolidation Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
911 Foreign exchange arising on designating borrowings in net investment hedges Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToHedgesOfNetInvestmentsInForeignOperationsOfOtherComprehensiveIncome
912 Net available for sale (gains)/losses recognised in other comprehensive income Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome
913 Other Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToOtherIndividuallyImmaterialComponentsOfOtherComprehensiveIncome
914 Deferred tax impact of reduction in US tax rate Concept (Monetary) For Period Debit azn:IncreaseDecreaseInAccumulatedDeferredTaxRecognisedInOtherComprehensiveIncomeDueToChangeInTaxRateThatWillBeReclassifiedToProfitOrLoss
915 Total Concept (Monetary) For Period Debit ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss
916 Taxation related to components of other comprehensive income Concept (Monetary) For Period Debit azn:TotalIncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
917 40402 - Disclosure - Taxation - Reconciliation (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTaxationReconciliationDetails
918 Income Tax Disclosure [Table] Table

*

*

 azn:IncomeTaxDisclosureTable
919 IFRS Statement Scenario [Axis] Axis azn:IfrsStatementScenarioAxis
920 IFRS Scenario Unspecified [Domain] Member azn:IfrsScenarioUnspecifiedDomain
921 Forecast Member azn:IfrsScenarioForecastMember
922 UK Statutory Corporation Tax Rate after reduction Member azn:DomesticStatutoryCorporationTaxRateAfterReductionMember
923 Agreements between tax authorities in respect of transfer pricing arrangements Member azn:AgreementsBetweenTaxAuthoritiesInRespectOfTransferPricingArrangementsMember
924 Expiry of relevant statute of limitations Member azn:ExpiryOfRelevantStatuteOfLimitationsMember
925 Provision build for transfer pricing contingencies Member azn:ProvisionBuildForTransferPricingContingenciesMember
926 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
927 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
928 US Member country:US
929 DUTCH AND SWEDEN Member azn:NetherlandsAndSwedenMember
930 DUTCH Member country:NL
931 SWEDEN Member country:SE
932 Taxation LineItems azn:IncomeTaxDisclosureLineItems
933 Reported tax rate (as a percentage) Concept (Percent) For Period ifrs-full:AverageEffectiveTaxRate
934 Deferred tax credit relating to reduction in other tax rates Concept (Monetary) For Period Debit ifrs-full:TaxEffectFromChangeInTaxRate
935 Credit adjustment to tax rate due to expiry of statute of limitations and conclusion of tax authority review Concept (Monetary) For Period Credit azn:TaxRateEffectOfVariousItems
936 Tax rate adjustment, term Concept (xbrli:durationItemType) For Period azn:ChangeInTaxRateTransferPricingArrangementsTerm
937 Reported tax rate excluding effects of adjustment (as a percentage) Concept (Percent) For Period azn:EffectiveTaxRateBeforeAdjustment
938 Cash tax paid Concept (Monetary) For Period Credit ifrs-full:IncomeTaxesPaidRefund
939 Cash tax paid as a percentage of profit before tax (as a percentage) Concept (Percent) For Period azn:CashTaxesPaidPercentageOfProfitLossBeforeTax
940 Prior period current tax adjustment Concept (Monetary) For Period Credit ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
941 Deferred tax for unremitted earnings of Group companies overseas Concept (Monetary) As Of Debit azn:IfrsDeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
942 Temporary differences associated with investments in subsidiaries and branches, deferred tax liabilities have not been recognised Concept (Monetary) As Of ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures
943 Tax rate (as a percentage) Concept (Percent) For Period ifrs-full:ApplicableTaxRate
944 Tax credit related to transfer pricing arrangements Concept (Monetary) For Period Credit azn:TaxCreditRelatedToTransferPricing
945 Tax credit related to statute of limitations Concept (Monetary) For Period Credit azn:TaxCreditRelatedToStatuteOfLimitations
946 Tax credit Concept (Monetary) For Period Credit azn:TaxCreditFromChangeInTaxRate
947 Tax charge Concept (Monetary) For Period Debit azn:TaxChargeFromChangeInTaxRate
948 Profit before tax Concept (Monetary) For Period Credit ifrs-full:AccountingProfit
949 Notional taxation charge at UK corporation tax rate of 19% (2017: 19.25%; 2016: 20%) Concept (Monetary) For Period Debit ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
950 Differences in effective overseas tax rates Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfForeignTaxRates
951 Unrecognised deferred tax asset Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfTaxLosses
952 Items not deductible for tax purposes Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
953 Items not chargeable for tax purposes Concept (Monetary) For Period Credit ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
954 Other items Concept (Monetary) For Period Debit ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
955 Adjustments in respect of prior periods Concept (Monetary) For Period Debit azn:TaxEffectOfAdjustmentsForCurrentTaxOfPriorPeriods
956 Taxation recognised in the profit for the period Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
957 UK Statutory Corporation Tax rate Concept (Percent) For Period azn:DomesticStatutoryCorporationTaxRate
958 40403 - Disclosure - Taxation - Movements in deferred tax balance (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTaxationMovementsInDeferredTaxBalanceDetails
959 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
960 Temporary difference, unused tax losses and unused tax credits [axis] Axis ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
961 Temporary difference, unused tax losses and unused tax credits [member] Member ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
962 Intangibles, property, plant & equipment Member azn:IntangiblesAssetsPropertyPlantAndEquipmentMember
963 Pension and post-retirement benefits Member azn:PensionAndPostRetirementBenefitsMember
964 Intercompany inventory transfers Member azn:IntercompanyInventoryTransfersMember
965 Untaxed reserves Member azn:UntaxedReservesMember
966 Losses and tax credits carried forward Member azn:LossesAndTaxCreditsCarriedForwardMember
967 Accrued expenses and other Member azn:AccruedExpensesAndOtherLiabilitiesMember
968 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
969 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
970 Acerta Pharma Member azn:AcertaPharmaMember
971 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
972 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
973 United Kingdom Member country:GB
974 Range [axis] Axis ifrs-full:RangeAxis
975 Ranges [member] Member ifrs-full:RangesMember
976 Minimum Member ifrs-full:BottomOfRangeMember
977 Maximum Member ifrs-full:TopOfRangeMember
978 Taxation LineItems ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
979 Balance at the beginning of the period Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilityAsset
980 Net adjustment to the opening balance of retained earnings Concept (Monetary) For Period Debit azn:NetAdjustmentForDeferredTaxesToBeginningBalanceOfRetainedEarnings
981 Taxation expense Concept (Monetary) For Period ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
982 Other comprehensive income Concept (Monetary) For Period ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
983 Equity Concept (Monetary) For Period ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
984 Additions through business combinations Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
985 Exchange Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset
986 Other movements Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
987 Balance at the end of the period Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilityAsset
988 Unused tax losses and unused tax credits, expiry term Concept (xbrli:durationItemType) For Period azn:ExpiryTermOfUnusedTaxLossesAndUnusedTaxCredits
989 Net deferred tax asset Concept (Monetary) As Of Debit ifrs-full:NetDeferredTaxAssets
990 40404 - Disclosure - Taxation - Net deferred tax balance (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTaxationNetDeferredTaxBalanceDetails
991 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
992 Temporary difference, unused tax losses and unused tax credits [axis] Axis ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
993 Temporary difference, unused tax losses and unused tax credits [member] Member ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
994 Intangibles, property, plant & equipment Member azn:IntangiblesAssetsPropertyPlantAndEquipmentMember
995 Pension and post-retirement benefits Member azn:PensionAndPostRetirementBenefitsMember
996 Intercompany inventory transfers Member azn:IntercompanyInventoryTransfersMember
997 Untaxed reserves Member azn:UntaxedReservesMember
998 Losses and tax credits carried forward Member azn:LossesAndTaxCreditsCarriedForwardMember
999 Accrued expenses and other Member azn:AccruedExpensesAndOtherLiabilitiesMember
1000 IFRS Statement Scenario [Axis] Axis azn:IfrsStatementScenarioAxis
1001 IFRS Scenario Unspecified [Domain] Member azn:IfrsScenarioUnspecifiedDomain
1002 Before the offset of balances within countries Member azn:BalancesBeforeOffsetOfBalancesWithinCountriesMember
1003 After the offset of balances within countries Member azn:BalancesAfterOffsetOfBalancesWithinCountriesMember
1004 Range [axis] Axis ifrs-full:RangeAxis
1005 Ranges [member] Member ifrs-full:RangesMember
1006 Minimum Member ifrs-full:BottomOfRangeMember
1007 Maximum Member ifrs-full:TopOfRangeMember
1008 Taxation LineItems ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
1009 Deferred tax assets Concept (Monetary) As Of Debit ifrs-full:NetDeferredTaxAssets
1010 Deferred tax liabilities Concept (Monetary) As Of Credit ifrs-full:NetDeferredTaxLiabilities
1011 Net deferred tax balance Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilityAsset
1012 Deductible temporary differences for which no deferred tax asset is recognised Concept (Monetary) As Of ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
1013 Unrecognised deferred tax assets expiration period (in years) Concept (xbrli:durationItemType) For Period azn:PeriodOfTimeUnrecognisedDeferredTaxesWillExpire
1014 40501 - Disclosure - Earnings per $0.25 Ordinary Share (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEarningsPer025OrdinaryShareDetails
1015 Implied Table Table

*

*

 implied:Table
1016 Earnings per $0.25 Ordinary Share Abstract ifrs-full:EarningsPerShareAbstract
1017 Profit for the year attributable to equity holders ($m) Concept (Monetary) For Period Credit ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
1018 Basic earnings per Ordinary Share (in dollars per share) Concept (Share) For Period ifrs-full:BasicEarningsLossPerShare
1019 Diluted earnings per Ordinary Share (in dollars per share) Concept (Share) For Period ifrs-full:DilutedEarningsLossPerShare
1020 Weighted average number of Ordinary Shares in issue for basic earnings (millions) Concept (Shares) For Period ifrs-full:WeightedAverageShares
1021 Dilutive impact of share options outstanding (millions) Concept (Shares) For Period ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
1022 Diluted weighted average number of Ordinary Shares in issue (millions) Concept (Shares) For Period ifrs-full:AdjustedWeightedAverageShares
1023 40601 - Disclosure - Segment information - geographical areas (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureSegmentInformationGeographicalAreasDetails
1024 Disclosure of geographical areas [table] Table

*

*

 ifrs-full:DisclosureOfGeographicalAreasTable
1025 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1026 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1027 UK Member azn:IfrsCountryGbMember
1028 External Member azn:ExternalUkMember
1029 Europe Member azn:IfrsEuropeMember
1030 France Member azn:IfrsCountryFrMember
1031 Germany Member azn:IfrsCountryDeMember
1032 Italy Member azn:IfrsCountryItMember
1033 Spain Member azn:IfrsCountryEsMember
1034 Sweden Member azn:IfrsCountrySeMember
1035 Others Member azn:OtherContinentalEuropeExcludingBelgiumFranceGermanyItalySpainAndSwedenMember
1036 The Americas Member azn:IfrsAmericasMember
1037 Canada Member azn:IfrsCountryCaMember
1038 US Member azn:IfrsCountryUsMember
1039 Others Member azn:OtherAmericasExcludingUsAndCanadaMember
1040 Asia, Africa And Australasia Member azn:AsiaAfricaAndAustralasiaMember
1041 Australia Member azn:IfrsCountryAuMember
1042 China Member azn:IfrsCountryCnMember
1043 Japan Member azn:IfrsCountryJpMember
1044 Others Member azn:OtherAsiaAfricaAndAustralasiaExcludingAustraliaChinaAndJapanMember
1045 Segment consolidation items [axis] Axis ifrs-full:SegmentConsolidationItemsAxis
1046 Entity's total for segment consolidation items [member] Member ifrs-full:EntitysTotalForSegmentConsolidationItemsMember
1047 Operating segments Member ifrs-full:OperatingSegmentsMember
1048 Disclosure of geographical location LineItems ifrs-full:DisclosureOfGeographicalAreasLineItems
1049 Total Revenue Concept (Monetary) For Period Credit ifrs-full:Revenue
1050 40602 - Disclosure - Segment information - Intra-Group pricing (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureSegmentInformationIntraGroupPricingDetails
1051 Disclosure of geographical areas [table] Table

*

*

 ifrs-full:DisclosureOfGeographicalAreasTable
1052 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1053 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1054 UK Member azn:IfrsCountryGbMember
1055 Europe Member azn:IfrsEuropeMember
1056 The Americas Member azn:IfrsAmericasMember
1057 Asia, Africa And Australasia Member azn:AsiaAfricaAndAustralasiaMember
1058 Disclosure of geographical location LineItems ifrs-full:DisclosureOfGeographicalAreasLineItems
1059 Operating (loss)/profit Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
1060 (Loss)/profit before tax Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
1061 Non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
1062 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
1063 Assets acquired Concept (Monetary) As Of Debit azn:PurchaseOfPropertyPlantAndEquipmentGoodwillAndIntangibleAssets
1064 Net operating assets Concept (Monetary) As Of Debit azn:NetOperatingAssets
1065 40603 - Disclosure - Segment information - Property, plant and equipment (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureSegmentInformationPropertyPlantAndEquipmentDetails
1066 Disclosure of geographical areas [table] Table

*

*

 ifrs-full:DisclosureOfGeographicalAreasTable
1067 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1068 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1069 UK Member azn:IfrsCountryGbMember
1070 Sweden Member azn:IfrsCountrySeMember
1071 US Member azn:IfrsCountryUsMember
1072 Rest of the world Member azn:RestOfWorldExcludingUkSwedenAndUsMember
1073 Disclosure of geographical location LineItems ifrs-full:DisclosureOfGeographicalAreasLineItems
1074 Property, plant and equipment. Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
1075 40604 - Disclosure - Segment information - Product Sales (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureSegmentInformationProductSalesDetails
1076 Disclosure of geographical areas [table] Table

*

*

 ifrs-full:DisclosureOfGeographicalAreasTable
1077 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1078 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1079 UK Member azn:IfrsCountryGbMember
1080 Europe Member azn:IfrsEuropeMember
1081 The Americas Member azn:IfrsAmericasMember
1082 Asia, Africa And Australasia Member azn:AsiaAfricaAndAustralasiaMember
1083 Major customers [axis] Axis ifrs-full:MajorCustomersAxis
1084 Customers [member] Member ifrs-full:MajorCustomersMember
1085 Customer one, 2018 Member azn:MajorCustomer2018OneMember
1086 Customer one, 2015 Member azn:MajorCustomer2015OneMember
1087 Disclosure of geographical location LineItems ifrs-full:DisclosureOfGeographicalAreasLineItems
1088 Product Sales Concept (Monetary) For Period Credit ifrs-full:RevenueFromSaleOfGoods
1089 Number of transactions with wholesaler Concept (Integer) As Of azn:NumberOfWholesaler
1090 40701 - Disclosure - Property, plant and equipment (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePropertyPlantAndEquipmentDetails
1091 Disclosure of detailed information about property, plant and equipment [table] Table

*

*

 ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable
1092 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
1093 Property, plant and equipment [member] Member ifrs-full:PropertyPlantAndEquipmentMember
1094 Land and buildings Member ifrs-full:LandAndBuildingsMember
1095 Freeholds Member azn:LandAndBuildingsFreeholdsMember
1096 Leaseholds Member azn:LandAndBuildingsLeaseholdsMember
1097 Plant and equipment Member azn:PlantsAndEquipmentsMember
1098 Information technology assets under finance leases Member azn:InformationTechnologyAssetsUnderFinanceLeasesMember
1099 Assets in course of construction Member ifrs-full:ConstructionInProgressMember
1100 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
1101 Carrying amount [member] Member ifrs-full:CarryingAmountMember
1102 Cost Member ifrs-full:GrossCarryingAmountMember
1103 Depreciation Member ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember
1104 Property, plant and equipment LineItems ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems
1105 Balance at the beginning period Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
1106 Capital expenditure Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
1107 Charge for year Concept (Monetary) For Period ifrs-full:DepreciationPropertyPlantAndEquipment
1108 Impairment Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
1109 Transfer of assets into use Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment
1110 Disposals and other movements Concept (Monetary) For Period Credit ifrs-full:DisposalsPropertyPlantAndEquipment
1111 Disposals and other movements Concept (Monetary) For Period Credit azn:DisposalsAndOtherMovementsPropertyPlantAndEquipment
1112 Exchange adjustments Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
1113 Balance at the end period Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
1114 Transfers between classes Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment
1115 40801 - Disclosure - Goodwill (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureGoodwillDetails
1116 Disclosure of reconciliation of changes in goodwill [table] Table

*

*

 ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillTable
1117 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
1118 Carrying amount [member] Member ifrs-full:CarryingAmountMember
1119 Cost Member ifrs-full:GrossCarryingAmountMember
1120 Depreciation Member ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember
1121 Disclosure of reconciliation of changes in goodwill LineItems ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillLineItems
1122 Beginning balance Concept (Monetary) As Of Debit ifrs-full:Goodwill
1123 Additions through business combinations (Note 25) Concept (Monetary) As Of Debit ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
1124 Exchange and other adjustments Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill
1125 Ending balance Concept (Monetary) As Of Debit ifrs-full:Goodwill
1126 Group projections of pre-tax cash flows period Concept (xbrli:durationItemType) For Period azn:DiscountedRiskProjectionsOfPreTaxCashFlowsTerm
1127 Post-tax weighted average cost of capital Concept (Percent) As Of azn:PostTaxWeightedAverageCostOfCapital
1128 Discount rate on cash flow projections Concept (Percent) As Of ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
1129 Goodwill impairment Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill
1130 40901 - Disclosure - Intangible assets - Reconciliation of changes in intangible assets (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssetsReconciliationOfChangesInIntangibleAssetsDetails
1131 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
1132 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
1133 Carrying amount [member] Member ifrs-full:CarryingAmountMember
1134 Cost Member ifrs-full:GrossCarryingAmountMember
1135 Amortisation and impairment losses Member ifrs-full:AccumulatedDepreciationAndAmortisationMember
1136 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
1137 Intangible assets other than goodwill [member] Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
1138 Product, marketing and distribution rights Member azn:ProductMarketingAndDistributionRightsMember
1139 Other intangibles Member ifrs-full:OtherIntangibleAssetsMember
1140 Software development costs Member azn:SoftwareDevelopmentCostsMember
1141 Disclosure of reconciliation of changes in intangible assets LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
1142 Beginning balance Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
1143 Additions through business combinations (Note 25) Concept (Monetary) For Period Debit ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
1144 Additions - separately acquired Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
1145 Transferred to assets held for sales (Note 17) Concept (Monetary) For Period Credit ifrs-full:DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsOtherThanGoodwill
1146 Amortisation for year Concept (Monetary) For Period ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
1147 Impairment Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
1148 Disposals Concept (Monetary) For Period Credit ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
1149 Exchange and other adjustments Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
1150 Ending balance Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
1151 40902 - Disclosure - Intangible assets - Summary of amortisation charges (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssetsSummaryOfAmortisationChargesDetails
1152 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
1153 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
1154 Intangible assets other than goodwill [member] Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
1155 Product, marketing and distribution rights Member azn:ProductMarketingAndDistributionRightsMember
1156 Other intangibles Member ifrs-full:OtherIntangibleAssetsMember
1157 Software development costs Member azn:SoftwareDevelopmentCostsMember
1158 Disclosure of reconciliation of changes in intangible assets LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
1159 Cost of sales Concept (Monetary) For Period Debit azn:AmortisationIntangibleAssetsOtherThanGoodwillIncludedInCostOfSales
1160 Research and development expense Concept (Monetary) For Period Debit azn:AmortisationIntangibleAssetsOtherThanGoodwillIncludedInResearchAndDevelopmentExpense
1161 Selling, general and administrative costs Concept (Monetary) For Period Debit azn:AmortisationIntangibleAssetsOtherThanGoodwillIncludedInSellingGeneralAndAdministrativeCosts
1162 Other operating income and expense Concept (Monetary) For Period Debit azn:AmortisationIntangibleAssetsOtherThanGoodwillIncludedInOtherOperatingIncomeAndExpense
1163 Total Concept (Monetary) For Period ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
1164 40903 - Disclosure - Intangible assets - Summary of impairment charges (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssetsSummaryOfImpairmentChargesDetails
1165 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
1166 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
1167 Intangible assets other than goodwill [member] Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
1168 Product, marketing and distribution rights Member azn:ProductMarketingAndDistributionRightsMember
1169 Other intangibles Member ifrs-full:OtherIntangibleAssetsMember
1170 Software development costs Member azn:SoftwareDevelopmentCostsMember
1171 Disclosure of reconciliation of changes in intangible assets LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
1172 Research and development expense Concept (Monetary) For Period Debit azn:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillIncludedInResearchAndDevelopmentExpense
1173 Selling, general and administrative costs Concept (Monetary) For Period Debit azn:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillIncludedInSellingGeneralAndAdministrativeCosts
1174 Total Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
1175 40904 - Disclosure - Intangible assets - Termination of R&D activities (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssetsTerminationOfRDActivitiesDetails
1176 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
1177 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
1178 Intangible assets other than goodwill [member] Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
1179 Launched products Member azn:LaunchedProductsMember
1180 Products in development Member ifrs-full:IntangibleAssetsUnderDevelopmentMember
1181 Other intangibles Member ifrs-full:OtherIntangibleAssetsMember
1182 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
1183 Products and services [member] Member ifrs-full:ProductsAndServicesMember
1184 Eklira Member azn:EkliraMember
1185 Movantik Member azn:MovantikMember
1186 MEDI0680 Member azn:Medi0680Member
1187 Byetta Member azn:ByettaMember
1188 FluMist Member azn:FlumistMember
1189 Tralokinumab Member azn:TralokinumabMember
1190 Ardea Member azn:ArdeaMember
1191 Disclosure of reconciliation of changes in intangible assets LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
1192 Post-tax weighted average cost of capital Concept (Percent) As Of azn:PostTaxWeightedAverageCostOfCapital
1193 Weighted average pre-tax discount rate Concept (Percent) As Of ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
1194 Impairment Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
1195 Carrying value Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
1196 Change in probability of a generic entry into the market Concept (Percent) As Of azn:ChangeInProbabilityOfGenericEntryIntoMarket
1197 Increase in impairment charge due to changes in assumptions of valuation model Concept (Monetary) For Period Debit azn:ChangeInImpairmentChargeDueToChangesInValuationModel
1198 Group's valuation model Concept (Integer) As Of azn:PercentageOfReasonablyPossibleDecreaseInAssumption
1199 Reversal of impairment Concept (Monetary) For Period Credit ifrs-full:ReversalOfImpairmentLoss
1200 40905 - Disclosure - Intangible assets - Significant intangible assets (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureIntangibleAssetsSignificantIntangibleAssetsDetails
1201 Disclosure of intangible assets material to entity [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsMaterialToEntityTable
1202 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
1203 Intangible assets other than goodwill [member] Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
1204 Product, marketing and distribution rights Member azn:ProductMarketingAndDistributionRightsMember
1205 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
1206 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
1207 Acerta Pharma Member azn:AcertaPharmaMember
1208 ZS Pharma Member azn:ZsPharmaMember
1209 MedImmune Member azn:MedimmuneMember
1210 BMS Member azn:BmsSShareOfGlobalDiabetesAllianceMember
1211 Ardea biosciences Member azn:ArdeaBiosciencesMember
1212 Almirall and Actavis Member azn:AlmirallAndActavisMember
1213 Pearl Therapeutics Member azn:PearlTherapeuticsMember
1214 Omthera Member azn:OmtheraPharmaceuticalsMember
1215 FibroGen Member azn:FibrogenMember
1216 Joint ventures [axis] Axis ifrs-full:JointVenturesAxis
1217 Entity's total for joint ventures [member] Member ifrs-full:EntitysTotalForJointVenturesMember
1218 Merck Member azn:MerckMember
1219 Intangible assets material to entity [axis] Axis ifrs-full:IntangibleAssetsMaterialToEntityAxis
1220 Intangible assets material to entity [member] Member ifrs-full:IntangibleAssetsMaterialToEntityMember
1221 RSV franchise Member azn:RsvFranchiseMember
1222 Farxiga/Forxiga Member azn:FarxigaForxigaMember
1223 Bydureon Member azn:BydureonMember
1224 Onglyza Member azn:OnglyzaMember
1225 Other diabetes Member azn:OtherDiabetesMember
1226 Roxadustat Member azn:RoxadustatMember
1227 Range [axis] Axis ifrs-full:RangeAxis
1228 Ranges [member] Member ifrs-full:RangesMember
1229 Minimum Member ifrs-full:BottomOfRangeMember
1230 Maximum Member ifrs-full:TopOfRangeMember
1231 Disclosure of intangible assets materials LineItems ifrs-full:DisclosureOfIntangibleAssetsMaterialToEntityLineItems
1232 Intangible assets material to entity Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsMaterialToEntity
1233 Remaining amortisation period of intangible assets material to entity Concept (Decimal) As Of ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity
1234 41001 - Disclosure - Investments in associates and joint ventures - Rollforward (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInvestmentsInAssociatesAndJointVenturesRollforwardDetails
1235 Implied Table Table

*

*

 implied:Table
1236 Investments in associates and joint ventures Abstract ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociatesAbstract
1237 At 1 January Concept (Monetary) As Of Debit ifrs-full:InvestmentAccountedForUsingEquityMethod
1238 Additions Concept (Monetary) For Period Debit azn:AdditionsToInvestmentsInAssociatesAndJointVentures
1239 Share of after tax losses in associates and joint ventures Concept (Monetary) For Period Credit ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
1240 Unrecognised Profit on Transactions with Joint Ventures Concept (Monetary) For Period Credit azn:UnrecognisedProfitOnTransactionsWithJointVentures
1241 Exchange adjustments Concept (Monetary) For Period Credit azn:ExchangeAdjustmentsToInvestmentsInAssociatesAndJointVentures
1242 At 31 December Concept (Monetary) As Of Debit ifrs-full:InvestmentAccountedForUsingEquityMethod
1243 41002 - Disclosure - Investments in associates and joint ventures - Narration (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInvestmentsInAssociatesAndJointVenturesNarrationDetails
1244 Disclosure of joint ventures [table] Table

*

*

 ifrs-full:DisclosureOfJointVenturesTable
1245 Legal Entity [Axis] Axis dei:LegalEntityAxis
1246 Entity [Domain] Member dei:EntityDomain
1247 Archigen Biotech Limited Member azn:ArchigenBiotechLimitedMember
1248 Joint ventures [axis] Axis ifrs-full:JointVenturesAxis
1249 Entity's total for joint ventures [member] Member ifrs-full:EntitysTotalForJointVenturesMember
1250 Viela Bio Member azn:VielaBioIncMember
1251 China, Dizhe (Jiangsu) Pharmaceutical Co. Limited Member azn:ChinaDizheJiangsuPharmaceuticalCo.LimitedMember
1252 Chinese Future Industry Investment Fund Member azn:ChineseFutureIndustryInvestmentFundMember
1253 Centus Biotherapeutics Limited Member azn:CentusBiotherapeuticsLimitedMember
1254 Archigen Biotech Limited Member azn:ArchigenBiotechLimitedMember
1255 Subsidiaries [axis] Axis ifrs-full:SignificantInvestmentsInSubsidiariesAxis
1256 Entity's total for subsidiaries [member] Member ifrs-full:EntitysTotalForSubsidiariesMember
1257 Entasis Member azn:EntasisTherapeuticsLtdAndEntasisTherapeuticsIncMember
1258 Archigen Biotech Limited Member azn:ArchigenBiotechLimitedMember
1259 Less than 100% Subsidiaries and Joint Ventures LineItems ifrs-full:DisclosureOfJointVenturesLineItems
1260 Funds raised from third party investors Concept (Monetary) As Of Credit azn:FundsRaisedFromThirdPartyInvestors
1261 Number of third party investors Concept (Integer) As Of azn:NumberOfThirdPartyInvestors
1262 Voting interest as a percentage Concept (Percent) For Period ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
1263 Investments in associate Concept (Monetary) As Of Debit ifrs-full:InvestmentsInAssociates
1264 Gain or loss recognised on deconsolidation Concept (Monetary) For Period Credit ifrs-full:GainsLossesRecognisedWhenControlInSubsidiaryIsLost
1265 Gain from IPO Concept (Monetary) For Period Credit azn:GainLossFromIpoOfInvestmentInSubsidary
1266 Number of board members representing AstraZeneca Concept (Integer) As Of azn:NumberOfBoardMembersCompanyHas
1267 Number of board members Concept (Integer) As Of azn:NumberOfBoardMembers
1268 Contribution to joint venture Concept (Monetary) As Of Debit ifrs-full:InvestmentsInJointVentures
1269 Ownership interest in joint venture as a percentage Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestInJointVenture
1270 Number of potential medicines in pre-clinical development Concept (Integer) For Period azn:NumberOfPotentialMedicinesInPreClinicalDevelopment
1271 Consideration Concept (Monetary) For Period Debit ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
1272 Gain on sale Concept (Monetary) For Period Credit azn:GainLossOnSaleOfIntangibleAssets
1273 Total liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
1274 Net liabilities Concept (Monetary) As Of Debit ifrs-full:NetAssetsLiabilities
1275 Net liabilities attributable to AstraZeneca Concept (Monetary) As Of Credit ifrs-full:EquityAttributableToOwnersOfParent
1276 Provision for trade and other payables Concept (Monetary) As Of Credit azn:ProvisionForTradeAndOtherPayables
1277 41003 - Disclosure - Investments in associates and joint ventures - Financial information (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInvestmentsInAssociatesAndJointVenturesFinancialInformationDetails
1278 Disclosure of associate and joint ventures [table] Table

*

*

 azn:DisclosureOfAssociateAndJointVenturesTable
1279 Classes of assets [axis] Axis ifrs-full:ClassesOfAssetsAxis
1280 Assets [member] Member ifrs-full:ClassesOfAssetsMember
1281 Associate and joint ventures Member ifrs-full:InvestmentsAccountedForUsingEquityMethodMember
1282 Disclosure of associate and joint ventures LineItems azn:DisclosureOfAssociateAndJointVenturesLineItems
1283 Non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssets
1284 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
1285 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
1286 Net assets Concept (Monetary) As Of Debit ifrs-full:NetAssetsLiabilities
1287 Amount attributable to AstraZeneca Concept (Monetary) As Of Credit ifrs-full:EquityAttributableToOwnersOfParent
1288 Exchange adjustments Concept (Monetary) As Of Credit azn:ExchangeAdjustments
1289 Total investments in subsidiaries, joint ventures and associates Concept (Monetary) As Of Debit ifrs-full:InvestmentAccountedForUsingEquityMethod
1290 41101 - Disclosure - Other investments (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOtherInvestmentsDetails
1291 Disclosure of financial assets [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsTable
1292 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
1293 Financial assets Member ifrs-full:FinancialAssetsMember
1294 Equity securities Member ifrs-full:EquityInvestmentsMember
1295 Fixed income securities Member azn:IfrsFixedIncomeInvestmentsMember
1296 Categories of financial assets [axis] Axis ifrs-full:CategoriesOfFinancialAssetsAxis
1297 Financial assets, category [member] Member ifrs-full:FinancialAssetsCategoryMember
1298 Available-for-sale Member ifrs-full:FinancialAssetsAvailableforsaleCategoryMember
1299 IFRS Income Statement Location [Axis] Axis azn:IfrsIncomeStatementLocationAxis
1300 IFRS Income Statement Location [Domain] Member azn:IfrsIncomeStatementLocationDomain
1301 Other operating income and expense Member azn:IfrsOtherOperatingIncomeExpenseMember
1302 Other investments LineItems ifrs-full:DisclosureOfFinancialAssetsLineItems
1303 Equity securities at fair value through other comprehensive income Concept (Monetary) As Of Debit ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome
1304 Equity securities available for sale Concept (Monetary) As Of Debit ifrs-full:NoncurrentFinancialAssetsAvailableforsale
1305 Other investments - non-current Concept (Monetary) As Of Debit ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
1306 Fixed income securities at fair value through profit and loss Concept (Monetary) As Of Debit ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss
1307 Fixed income securities available for sale Concept (Monetary) As Of Debit ifrs-full:CurrentFinancialAssetsAvailableforsale
1308 Fixed deposits Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
1309 Other investments - current Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
1310 Impairment charges Concept (Monetary) For Period Debit ifrs-full:ImpairmentLossOnFinancialAssets
1311 41102 - Disclosure - Other investments - Fair value hierarchy (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOtherInvestmentsFairValueHierarchyDetails
1312 Disclosure of financial assets [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsTable
1313 Levels of fair value hierarchy [axis] Axis ifrs-full:LevelsOfFairValueHierarchyAxis
1314 All levels of fair value hierarchy [member] Member ifrs-full:AllLevelsOfFairValueHierarchyMember
1315 Level 1 Member ifrs-full:Level1OfFairValueHierarchyMember
1316 Level 3 Member ifrs-full:Level3OfFairValueHierarchyMember
1317 Other investments LineItems ifrs-full:DisclosureOfFinancialAssetsLineItems
1318 FVPL Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
1319 FVOCI Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
1320 AFS Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAvailableforsale
1321 41103 - Disclosure - Other investments - Level 3 investments (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOtherInvestmentsLevel3InvestmentsDetails
1322 Disclosure of fair value measurement of assets [table] Table

*

*

 ifrs-full:DisclosureOfFairValueMeasurementOfAssetsTable
1323 Classes of assets [axis] Axis ifrs-full:ClassesOfAssetsAxis
1324 Assets [member] Member ifrs-full:ClassesOfAssetsMember
1325 Other investments Member ifrs-full:OtherEquitySecuritiesMember
1326 Other investments LineItems ifrs-full:DisclosureOfFinancialAssetsLineItems
1327 Assets at beginning of period Concept (Monetary) As Of Debit ifrs-full:Assets
1328 Additions Concept (Monetary) For Period Debit ifrs-full:PurchasesFairValueMeasurementAssets
1329 Revaluations Concept (Monetary) For Period Debit azn:RevaluationsFairValueMeasurementAssets
1330 Transfers out Concept (Monetary) For Period Credit ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets
1331 Disposals Concept (Monetary) For Period Credit ifrs-full:SalesFairValueMeasurementAssets
1332 Impairments and exchange adjustments Concept (Monetary) For Period Credit azn:ImpairmentsAndExchangeAdjustmentsFairValueMeasurementAssets
1333 Assets at end of period Concept (Monetary) As Of Debit ifrs-full:Assets
1334 41201 - Disclosure - Derivative financial instruments - Assets and liabilities (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureDerivativeFinancialInstrumentsAssetsAndLiabilitiesDetails
1335 Disclosure of detailed information about hedging instruments [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutHedgingInstrumentsTable
1336 Types of hedges [axis] Axis ifrs-full:TypesOfHedgesAxis
1337 Hedges [member] Member ifrs-full:TypesOfHedgesMember
1338 Instruments in a fair value hedge relationship Member ifrs-full:FairValueHedgesMember
1339 Instruments designated in cash flow hedge Member ifrs-full:CashFlowHedgesMember
1340 Investments in foreign operations Member ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember
1341 Net investment hedge Member azn:NetInvestmentHedgeMember
1342 Categories of financial assets [axis] Axis ifrs-full:CategoriesOfFinancialAssetsAxis
1343 Financial assets, category [member] Member ifrs-full:FinancialAssetsCategoryMember
1344 Instruments designated at fair value through profit and loss Member ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember
1345 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
1346 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
1347 Derivatives Member ifrs-full:DerivativesMember
1348 Interest rate swaps Member ifrs-full:InterestRateSwapContractMember
1349 Cross currency swaps Member ifrs-full:CurrencySwapContractMember
1350 Other derivatives Member azn:OtherDerivativesMember
1351 Currency [Axis] Axis srt:CurrencyAxis
1352 All Currencies [Domain] Member currency:AllCurrenciesDomain
1353 Japanese yen Member currency:JPY
1354 Chinese Renminbi Member currency:CNY
1355 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
1356 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
1357 1.95% Callable bond Member azn:CallableBond1.95PercentMember
1358 Fixed rate euro callable bonds Member azn:FixedRateEuroCallableBondsMember
1359 0.25% Callable bond Member azn:CallableBond0.25PercentMember
1360 0.75% Callable bond Member azn:CallableBond0.75PercentMember
1361 1.25% Callable bond Member azn:CallableBond1.25PercentMember
1362 0.875% Non-callable bond Member azn:NonCallableBond0.875PercentMember
1363 Disclosure of detailed information about hedges LineItems ifrs-full:DisclosureOfHedgeAccountingLineItems
1364 Non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentDerivativeFinancialAssets
1365 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentDerivativeFinancialAssets
1366 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
1367 Non-current liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
1368 Total Concept (Monetary) As Of Debit azn:DerivativeFinancialAssetsLiabilitiesNet
1369 Borrowings covered by hedges Concept (Monetary) As Of Credit azn:BorrowingsCoveredByHedges
1370 Borrowings Concept (Monetary) As Of Credit ifrs-full:Borrowings
1371 Interest rate on borrowings Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
1372 Fair value Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAtFairValue
1373 Fair value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
1374 Notional amount Concept (Monetary) As Of ifrs-full:NotionalAmount
1375 Exchange rate Concept (Decimal) As Of ifrs-full:ClosingForeignExchangeRate
1376 Amount matured Concept (Monetary) For Period Credit azn:MaturityOfDerivative
1377 Basis spread on variable interest rate Concept (Percent) For Period azn:IfrsDebtInstrumentBasisSpreadOnVariableRate
1378 Ineffectiveness on net investment hedge taken to profit Concept (Monetary) For Period Credit ifrs-full:GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss
1379 41202 - Disclosure - Derivative financial instruments - Interest rates (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureDerivativeFinancialInstrumentsInterestRatesDetails
1380 Disclosure of financial instruments by type of interest rate [table] Table

*

*

 ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable
1381 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
1382 Financial assets Member ifrs-full:FinancialAssetsMember
1383 Derivatives Member ifrs-full:DerivativesMember
1384 Range [axis] Axis ifrs-full:RangeAxis
1385 Ranges [member] Member ifrs-full:RangesMember
1386 Minimum Member ifrs-full:BottomOfRangeMember
1387 Maximum Member ifrs-full:TopOfRangeMember
1388 Disclosure of financial instruments by interest rate LineItems ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems
1389 Discount rate on cash flow projections Concept (Percent) As Of ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
1390 41301 - Disclosure - Non-current other receivables (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureNonCurrentOtherReceivablesDetails
1391 Disclosure of other noncurrent receivables [table] Table

*

*

 azn:DisclosureOfOtherNoncurrentReceivablesTable
1392 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
1393 Counterparties [member] Member ifrs-full:CounterpartiesMember
1394 Shionogi Member azn:ShionogiMember
1395 Moderna therapeutics Member azn:ModernaTherapeuticsMember
1396 Disclosure of other non-current receivables LineItems azn:DisclosureOfOtherNoncurrentReceivablesLineItems
1397 Non current other receivables Concept (Monetary) As Of Debit ifrs-full:OtherNoncurrentReceivables
1398 Non current prepayment Concept (Monetary) As Of Debit ifrs-full:NoncurrentPrepayments
1399 Current prepayment Concept (Monetary) As Of Debit ifrs-full:CurrentPrepayments
1400 Amount of non current receivables from disposal of business Concept (Monetary) As Of Debit azn:DisposalOfBusinessNonCurrentReceivables
1401 41401 - Disclosure - Inventories (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInventoriesDetails
1402 Implied Table Table

*

*

 implied:Table
1403 Inventories Abstract ifrs-full:ClassesOfInventoriesAbstract
1404 Raw materials and consumables Concept (Monetary) As Of Debit ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies
1405 Inventories in process Concept (Monetary) As Of Debit ifrs-full:WorkInProgress
1406 Finished goods and goods for resale Concept (Monetary) As Of Debit ifrs-full:FinishedGoods
1407 Inventories Concept (Monetary) As Of Debit ifrs-full:Inventories
1408 Cost Of Inventories Recognised As Expense Concept (Monetary) For Period Debit ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
1409 Inventory write-offs Concept (Monetary) For Period ifrs-full:InventoryWritedown2011
1410 41501 - Disclosure - Current trade and other receivables (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCurrentTradeAndOtherReceivablesDetails
1411 Disclosure of trade and other current receivables [table] Table

*

*

 azn:DisclosureOfTradeAndOtherCurrentReceivablesTable
1412 Maturity [axis] Axis ifrs-full:MaturityAxis
1413 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1414 Due within one year Member ifrs-full:NotLaterThanOneYearMember
1415 Due after more than one year Member ifrs-full:LaterThanOneYearMember
1416 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
1417 Financial assets Member ifrs-full:FinancialAssetsMember
1418 Trade receivables - subject to factoring Member azn:TradeReceivablesSubjectToFactoringMember
1419 Current trade and other receivables LineItems azn:DisclosureOfTradeAndOtherReceivablesLineItems
1420 Trade receivables Concept (Monetary) As Of Debit azn:CurrentTradeReceivableGross
1421 Less: Amounts provided for doubtful debts (Note 26) Concept (Monetary) As Of Credit azn:ProvisionsForDoubtfulDebtsRelatedToTradeAndOtherReceivables
1422 Net current trade and other receivables Concept (Monetary) As Of Debit ifrs-full:CurrentTradeReceivables
1423 Other receivables Concept (Monetary) As Of Debit ifrs-full:OtherCurrentReceivables
1424 Prepayments and accrued income Concept (Monetary) As Of Debit ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome
1425 Total trade and other current receivables Concept (Monetary) As Of Debit ifrs-full:TradeAndOtherCurrentReceivables
1426 Contract assets Concept (Monetary) As Of Debit ifrs-full:ContractAssets
1427 41601 - Disclosure - Cash and cash equivalents (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCashAndCashEquivalentsDetails
1428 Disclosure of financial assets at date of initial application of IFRS 9 [table] Table

*

*

 ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9Table
1429 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
1430 Financial assets Member ifrs-full:FinancialAssetsMember
1431 Money market funds Member azn:IfrsMoneyMarketFundsMember
1432 Cash and cash Equivalents LineItems ifrs-full:DisclosureOfFinancialAssetsAtDateOfInitialApplicationOfIFRS9LineItems
1433 Cash at bank and in hand Concept (Monetary) As Of Debit ifrs-full:Cash
1434 Short-term deposits Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
1435 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
1436 Unsecured bank overdrafts Concept (Monetary) As Of Credit ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
1437 Cash and cash equivalents in the cash flow statement Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
1438 cash and cash equivalents Insurance solvency, capital and security requirements Concept (Monetary) For Period Debit azn:AshAndCashEquivalentsForInsuranceSolvencyCapitalAndSecurity
1439 41602 - Disclosure - Cash and cash equivalents - Non-cash and other movements, within operating activities (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCashAndCashEquivalentsNonCashAndOtherMovementsWithinOperatingActivitiesDetails
1440 Implied Table Table

*

*

 implied:Table
1441 Cash and cash equivalents. Abstract ifrs-full:CashAndCashEquivalentsAbstract
1442 Gains on disposal of short-term investments Concept (Monetary) For Period Credit ifrs-full:GainsOnDisposalsOfInvestments
1443 Net gains/(losses) on disposal on non-current assets Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets
1444 Changes on fair value of put option (Acerta Pharma) Concept (Monetary) For Period Credit ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives
1445 Share-based payments charge for period Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
1446 Settlement of share plan awards Concept (Monetary) For Period Debit azn:AdjustmentsForSettlementOfSharePlanAwards
1447 Pension contributions Concept (Monetary) For Period Debit azn:AdjustmentsForPensionContributions
1448 Pension charges recorded in operating profit Concept (Monetary) For Period Debit azn:AdjustmentsForPensionCharges
1449 Foreign exchange and other Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
1450 Total operating activities non-cash and other movements Concept (Monetary) For Period Debit ifrs-full:OtherAdjustmentsForNoncashItems
1451 41701 - Disclosure - Assets held for sale (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureAssetsHeldForSaleDetails
1452 Implied Table Table

*

*

 implied:Table
1453 Assets held for sale Abstract ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract
1454 Assets held for sale Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
1455 41801 - Disclosure - Interest-bearing loans and borrowings (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInterestBearingLoansAndBorrowingsDetails
1456 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
1457 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
1458 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
1459 Overdrafts Member azn:BankOverdraftMember
1460 Bank collateral Member azn:BankCollateralMember
1461 Finance leases Member ifrs-full:LeaseLiabilitiesMember
1462 5.9% Callable bond Member azn:CallableBond5.9PercentMember
1463 Floating rate notes due 2018 Member azn:FloatingRateLoanDue2018Member
1464 1.75% Callable bond Member azn:CallableBond1.75PercentMember
1465 1.95% Callable bond Member azn:CallableBond1.95PercentMember
1466 Commercial paper Member azn:OtherLoansCommercialPaperMember
1467 0.875% Non-callable bond Member azn:NonCallableBond0.875PercentMember
1468 0.25% Callable bond Member azn:CallableBond0.25PercentMember
1469 Floating rate loan due 2022 Member azn:FloatingRateLoanDue2022Member
1470 Callable Bond 2.375 Percent Due on 2020 Member azn:CallableBond2.375PercentDueOn2020Member
1471 Callable Bond 2.375 Percent Due on 2022 Member azn:CallableBond2.375PercentDueOn2022Member
1472 7% Guaranteed debentures Member azn:GuaranteedDebentures7PercentMember
1473 Floating rate notes due 2023 Member azn:FloatingRateNotesDue2023Member
1474 3.5% Callable bond Member azn:CallableBond3.5PercentMember
1475 0.75% Callable bond Member azn:CallableBond0.75PercentMember
1476 3.375% Callable bond Member azn:CallableBond3.375PercentMember
1477 3.125% Callable bond Member azn:CallableBond3.125PercentMember
1478 1.25% Callable bond Member azn:CallableBond1.25PercentMember
1479 4% Callable bond due in 2029 Member azn:CallableBond4PercentDue2029Member
1480 5.75% Non-callable bond Member azn:NonCallableBond5.75PercentMember
1481 6.45% Callable bond Member azn:CallableBond6.45PercentMember
1482 4% Callable bond due in 2042 Member azn:CallableBond4PercentMember
1483 4.375% Callable bond due in 2045 Member azn:CallableBond4.375PercentMember
1484 4..3.75% Callable bond due in 2048 Member azn:CallableBond4.375PercentDue2048Member
1485 Other loans Member azn:OtherLoansMember
1486 Interest bearing loans and borrowings LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
1487 Current debt Concept (Monetary) As Of Credit ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
1488 Non-current liabilities Concept (Monetary) As Of Credit ifrs-full:LongtermBorrowings
1489 Interest rate on borrowings Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
1490 41802 - Disclosure - Interest-bearing loans and borrowings - Rollforward (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInterestBearingLoansAndBorrowingsRollforwardDetails
1491 Disclosure of reconciliation of liabilities arising from financing activities [table] Table

*

*

 ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable
1492 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
1493 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
1494 Current loans and borrowings Member azn:CurrentLoansAndBorrowingsMember
1495 Non-current loans and borrowings Member azn:NoncurrentLoansAndBorrowingsMember
1496 Reconciliation of liabilities LineItems ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems
1497 Liabilities arising from financing activities at beginning of period Concept (Monetary) As Of Credit ifrs-full:LiabilitiesArisingFromFinancingActivities
1498 Issue of loans Concept (Monetary) For Period Credit azn:IncreaseThroughNewBorrowingsLiabilitiesArisingFromFinancingActivities
1499 Repayment of loans Concept (Monetary) For Period Debit azn:DecreaseThroughRepaymentOfBorrowingsLiabilitiesArisingFromFinancingActivities
1500 Movement in short term borrowings Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughChangesInShortTermBorrowingsLiabilitiesArisingFromFinancingActivities
1501 Total changes in liabilities arising on financing activities Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
1502 Movement in overdrafts Concept (Monetary) For Period Credit azn:IncreaseDecreaseInBankOverdraftsClassifiedAsFinancingActivities
1503 Transfers Concept (Monetary) For Period Credit azn:IncreaseDecreaseInTransfersClassifiedAsFinancingActivities
1504 Exchange and other movements Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
1505 Liabilities arising from financing activities at end of period Concept (Monetary) As Of Credit ifrs-full:LiabilitiesArisingFromFinancingActivities
1506 41803 - Disclosure - Interest-bearing loans and borrowings - Category of carrying values and fair values (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInterestBearingLoansAndBorrowingsCategoryOfCarryingValuesAndFairValuesDetails
1507 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
1508 Categories of financial liabilities [axis] Axis ifrs-full:CategoriesOfFinancialLiabilitiesAxis
1509 Financial liabilities, category [member] Member ifrs-full:FinancialLiabilitiesCategoryMember
1510 Instruments at fair value through profit or loss Member ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember
1511 Amortised cost Member ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember
1512 Types of hedges [axis] Axis ifrs-full:TypesOfHedgesAxis
1513 Hedges [member] Member ifrs-full:TypesOfHedgesMember
1514 Instruments in a fair value hedge relationship Member ifrs-full:FairValueHedgesMember
1515 Instruments designated in cash flow hedge Member ifrs-full:CashFlowHedgesMember
1516 Investments in foreign operations Member ifrs-full:HedgesOfNetInvestmentInForeignOperationsMember
1517 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
1518 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
1519 Overdrafts Member azn:BankOverdraftMember
1520 Finance leases Member ifrs-full:LeaseLiabilitiesMember
1521 Loans Member ifrs-full:LoanCommitmentsMember
1522 0.875% Non-callable bond Member azn:NonCallableBond0.875PercentMember
1523 1.75% Callable bond Member azn:CallableBond1.75PercentMember
1524 0.25% Callable bond Member azn:CallableBond0.25PercentMember
1525 7% Guaranteed debentures Member azn:GuaranteedDebentures7PercentMember
1526 0.75% Callable bond Member azn:CallableBond0.75PercentMember
1527 1.25% Callable bond Member azn:CallableBond1.25PercentMember
1528 1.95% Callable bond Member azn:CallableBond1.95PercentMember
1529 5.75% Non-callable bond Member azn:NonCallableBond5.75PercentMember
1530 Maturity [axis] Axis ifrs-full:MaturityAxis
1531 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1532 Due within one year Member ifrs-full:NotLaterThanOneYearMember
1533 Due after more than one year Member ifrs-full:LaterThanOneYearMember
1534 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
1535 Financial liabilities Member ifrs-full:FinancialLiabilitiesMember
1536 Interest rate swaps Member ifrs-full:InterestRateSwapContractMember
1537 Category of carrying values and fair values LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
1538 Total carrying value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilities
1539 Fair value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
1540 Borrowings covered by hedges Concept (Monetary) As Of Credit azn:BorrowingsCoveredByHedges
1541 Borrowings Concept (Monetary) As Of Credit ifrs-full:Borrowings
1542 Interest rate on borrowings Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
1543 Loss on fair value hedge adjustment Concept (Monetary) As Of Credit ifrs-full:AccumulatedFairValueHedgeAdjustmentOnHedgedItemIncludedInCarryingAmountLiabilities
1544 Loss on fair value of bonds due to decrease credit risk Concept (Monetary) For Period Debit azn:DecreaseInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability
1545 Gain on fair value of bonds due to increase credit risk Concept (Monetary) For Period Credit azn:IncreaseInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability
1546 41804 - Disclosure - Interest-bearing loans and borrowings - Interest rates used to discount future cash flows (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureInterestBearingLoansAndBorrowingsInterestRatesUsedToDiscountFutureCashFlowsDetails
1547 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
1548 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
1549 Financial liabilities Member ifrs-full:FinancialLiabilitiesMember
1550 Borrowings Member ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember
1551 Range [axis] Axis ifrs-full:RangeAxis
1552 Ranges [member] Member ifrs-full:RangesMember
1553 Minimum Member ifrs-full:BottomOfRangeMember
1554 Maximum Member ifrs-full:TopOfRangeMember
1555 Interest rates used to discount future cash flows LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
1556 Weighted average pre-tax discount rate Concept (Percent) As Of ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
1557 41901 - Disclosure - Trade and other payables (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTradeAndOtherPayablesDetails
1558 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
1559 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
1560 Products and services [member] Member ifrs-full:ProductsAndServicesMember
1561 Contract Revenue Member azn:ContractRevenueMember
1562 Other Revenue Member azn:OtherRevenueMember
1563 Externalisation Revenue Member azn:ExternalisationRevenueMember
1564 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
1565 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
1566 Acerta Pharma Member azn:AcertaPharmaMember
1567 Disclosure of detailed information about business combination [line items] LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
1568 Current liabilities Abstract ifrs-full:CurrentLiabilitiesAbstract
1569 Trade payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
1570 Value added and payroll taxes and social security Concept (Monetary) As Of Credit ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
1571 Rebates, chargebacks, returns and other revenue accruals Concept (Monetary) As Of Credit azn:RebatesAndChargebacksCurrent
1572 Clinical trial accruals Concept (Monetary) As Of Credit azn:ClinicalTrialAccruals
1573 Other accruals Concept (Monetary) As Of Credit ifrs-full:AccrualsClassifiedAsCurrent
1574 Externalisation revenue contract liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentContractLiabilities
1575 Contingent consideration Concept (Monetary) As Of Credit azn:ContingentConsiderationCurrent
1576 Other payables Concept (Monetary) As Of Credit ifrs-full:OtherCurrentPayables
1577 Total Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
1578 Contract liabilities within rebates, chargebacks, returns and other accruals Concept (Monetary) As Of Credit azn:ContractLiabilitiesWithinRebatesChargebacksReturnsAndOtherAccruals
1579 Contract liabilities Concept (Monetary) As Of Credit ifrs-full:ContractLiabilities
1580 Non-current liabilities Abstract ifrs-full:NoncurrentPayablesAbstract
1581 Accruals Concept (Monetary) As Of Credit ifrs-full:AccrualsClassifiedAsNoncurrent
1582 Externalisation revenue contract liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentContractLiabilities
1583 Contingent consideration Concept (Monetary) As Of Credit azn:ContingentConsiderationNoncurrent
1584 Other payables Concept (Monetary) As Of Credit ifrs-full:OtherNoncurrentPayables
1585 Total Concept (Monetary) As Of Credit ifrs-full:NoncurrentPayables
1586 Trade payables Abstract ifrs-full:TradeAndOtherCurrentPayablesAbstract
1587 Trade payables, supply chain financing programme Concept (Monetary) As Of Credit azn:TradePayablesFinancingProgramme
1588 41902 - Disclosure - Trade and other payables - Contingent consideration (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTradeAndOtherPayablesContingentConsiderationDetails
1589 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
1590 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
1591 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
1592 BMS's share of Global Diabetes Alliance Member azn:BmssShareOfGlobalDiabetesAllianceMember
1593 Disclosure of detailed information about business combination LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
1594 Reconciliation of changes in contingent liabilities in business combination Abstract ifrs-full:ReconciliationOfChangesInContingentLiabilitiesRecognisedInBusinessCombinationAbstract
1595 Contingent liabilities recognised in business combination at beginning of period Concept (Monetary) As Of Credit ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
1596 Settlements Concept (Monetary) For Period Debit ifrs-full:SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
1597 Revaluations Concept (Monetary) For Period Debit azn:RevaluedLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
1598 Discount unwind (Note 3) Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughChangeInDiscountRateContingentLiabilitiesRecognisedInBusinessCombination
1599 Foreign exchange Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughForeignExchangeContingentLiabilitiesRecognisedInBusinessCombination
1600 Contingent liabilities recognised in business combination at end of period Concept (Monetary) As Of Credit ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
1601 Revaluations of contingent consideration Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInContingentConsiderationAssetLiability
1602 Increase/decrease in contingent consideration balance with increase/decrease in sales of 10% compared with current estimates Concept (Monetary) As Of Debit azn:PotentialIncreaseDecreaseInContingentConsiderationBalanceDueToChangeInEstimates
1603 The increase/decrease in sales estimates Concept (Percent) For Period azn:IncreaseDecreaseInSalesEstimates
1604 41903 - Disclosure - Trade and other payables - Development and sales milestones payable (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureTradeAndOtherPayablesDevelopmentAndSalesMilestonesPayableDetails
1605 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
1606 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
1607 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
1608 Spirogen Member azn:SpirogenMember
1609 Amplimmune Member azn:AmplimmuneMember
1610 Omthera Member azn:OmtheraPharmaceuticalsMember
1611 Pearl Therapeutics Member azn:PearlTherapeuticsMember
1612 BMS's share of Global Diabetes Alliance Member azn:BmssShareOfGlobalDiabetesAllianceMember
1613 Almirall Member azn:AlmirallMember
1614 Definiens Group Member azn:DefiniensMember
1615 Range [axis] Axis ifrs-full:RangeAxis
1616 Ranges [member] Member ifrs-full:RangesMember
1617 Maximum Member ifrs-full:TopOfRangeMember
1618 Disclosure of detailed information about business combination LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
1619 Maximum future milestones Concept (Monetary) As Of Credit ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
1620 42001 - Disclosure - Provisions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureProvisionsDetails
1621 Disclosure of other provisions [table] Table

*

*

 ifrs-full:DisclosureOfOtherProvisionsTable
1622 Classes of other provisions [axis] Axis ifrs-full:ClassesOfProvisionsAxis
1623 Other provisions [member] Member ifrs-full:OtherProvisionsMember
1624 Severance Member ifrs-full:RestructuringProvisionMember
1625 Environmental Member ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember
1626 Employee benefits Member azn:EmployeeBenefitsMember
1627 Legal Member ifrs-full:LegalProceedingsProvisionMember
1628 Other provisions. Member ifrs-full:MiscellaneousOtherProvisionsMember
1629 Maturity [axis] Axis ifrs-full:MaturityAxis
1630 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1631 Due within one year Member ifrs-full:NotLaterThanOneYearMember
1632 Due after more than one year Member ifrs-full:LaterThanOneYearMember
1633 Other Provisions LineItems ifrs-full:DisclosureOfOtherProvisionsLineItems
1634 At January 1 Concept (Monetary) As Of Credit ifrs-full:OtherProvisions
1635 Charge for year Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
1636 Cash paid Concept (Monetary) For Period Debit ifrs-full:ProvisionUsedOtherProvisions
1637 Reversals Concept (Monetary) For Period Debit ifrs-full:UnusedProvisionReversedOtherProvisions
1638 Exchange and other movements Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
1639 At 31 December Concept (Monetary) As Of Credit ifrs-full:OtherProvisions
1640 Current provision Concept (Monetary) As Of Credit ifrs-full:CurrentProvisions
1641 Non current provision Concept (Monetary) As Of Credit ifrs-full:NoncurrentProvisions
1642 Total Concept (Monetary) As Of Credit ifrs-full:OtherProvisions
1643 Number of payments Concept (Decimal) For Period azn:NumberOfPayments
1644 42101 - Disclosure - Post-retirement benefits - Pensions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsPensionsDetails
1645 Disclosure of defined benefit plans [table] Table

*

*

 ifrs-full:DisclosureOfDefinedBenefitPlansTable
1646 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1647 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1648 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1649 Pension schemes within UK, the US and Sweden Member azn:DomesticDefinedBenefitPensionPlansAndForeignDefinedBenefitPensionPlansUnitedStatesAndSwedenMember
1650 UK defined benefit pension Member azn:DomesticDefinedBenefitPensionPlansMember
1651 US and Sweden defined benefit pension Member azn:ForeignDefinedBenefitPensionPlansUnitedStatesAndSwedenMember
1652 US defined benefit pension Member azn:ForeignDefinedBenefitPensionPlansUnitedStatesMember
1653 Sweden defined benefit pension Member azn:ForeignDefinedBenefitPensionPlansSwedenMember
1654 Three main country defined benefit plans Member azn:DomesticDefinedBenefitPlansAndForeignDefinedBenefitPlansUnitedStatesAndSwedenMember
1655 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1656 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1657 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1658 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1659 Geographical [Axis] Axis srt:StatementGeographicalAxis
1660 Geographical [Domain] Member srt:SegmentGeographicalDomain
1661 UK, US and Sweden Member azn:UnitedKingdomUnitedStatesAndSwedenMember
1662 US and Sweden Member azn:UnitedStatesAndSwedenMember
1663 US Member country:US
1664 SWEDEN Member country:SE
1665 Maturity [axis] Axis ifrs-full:MaturityAxis
1666 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
1667 Due within one year Member ifrs-full:NotLaterThanOneYearMember
1668 IFRS Statement Scenario [Axis] Axis azn:IfrsStatementScenarioAxis
1669 IFRS Scenario Unspecified [Domain] Member azn:IfrsScenarioUnspecifiedDomain
1670 Forecast Member azn:IfrsScenarioForecastMember
1671 Post-retirement benefits LineItems ifrs-full:DisclosureOfDefinedBenefitPlansLineItems
1672 Number of employees Concept (Decimal) As Of ifrs-full:NumberOfEmployees
1673 Defined benefit obligations as a percentage of total Concept (Percent) As Of azn:DefinedBenefitPlansDefinedBenefitObligationConcentrationPercentageOfTotalDefinedBenefitObligations
1674 Contribution Concept (Monetary) For Period Debit ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
1675 Further contribution Concept (Monetary) For Period Credit ifrs-full:EstimateOfContributionsExpectedToBePaidToPlan
1676 Letter of credit for additional deficit recovery contribution payment Concept (Monetary) For Period Credit azn:DefinedBenefitPlansLetterOfCreditForAdditionalDeficitRecoveryContributionPayment
1677 Number of equal installments Concept (Integer) As Of azn:NumberOfInstallment
1678 Inflation assumption (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
1679 Salary increases assumption (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
1680 Pension increases assumption (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
1681 Investment returns assumption (as a percent) Concept (Percent) As Of azn:ActuarialAssumptionOfExpectedRateOfInvestmentReturns
1682 Plan liabilities Concept (Monetary) As Of Credit ifrs-full:DefinedBenefitObligationAtPresentValue
1683 Market value of plan assets Concept (Monetary) As Of Debit ifrs-full:PlanAssetsAtFairValue
1684 Refund adjustments required in respect of governing documentation Concept (Monetary) For Period Credit azn:SurplusInPlanAdjustmentRefund
1685 GMP equalisation past service cost Concept (Monetary) For Period Debit azn:PastServiceCostGuaranteedMinimumPensionsEqualisation
1686 Number of main defined benefit pension obligation countries Concept (Integer) For Period azn:DefinedBenefitPlansNumberOfMainDefinedBenefitObligationCountries
1687 42102 - Disclosure - Post-retirement benefits - Post-retirement benefits other than pensions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsPostRetirementBenefitsOtherThanPensionsDetails
1688 Disclosure of defined benefit plans [table] Table

*

*

 ifrs-full:DisclosureOfDefinedBenefitPlansTable
1689 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1690 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1691 Post-retirement defined benefits other than pensions Member azn:DefinedBenefitOtherPostRetirementPlansMember
1692 Post-retirement benefits LineItems ifrs-full:DisclosureOfDefinedBenefitPlansLineItems
1693 Retired employees and covered dependants that currently benefit Concept (Decimal) For Period ifrs-full:NumberOfParticipantsOfRetirementBenefitPlanReceivingBenefits
1694 Current employees that will be eligible on their retirement Concept (Decimal) For Period ifrs-full:NumberOfOtherParticipantsOfRetirementBenefitPlan
1695 Cost of post-retirement benefits Concept (Monetary) For Period Debit ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
1696 Market value of plan assets Concept (Monetary) As Of Debit ifrs-full:PlanAssetsAtFairValue
1697 Plan liabilities Concept (Monetary) As Of Credit ifrs-full:DefinedBenefitObligationAtPresentValue
1698 42103 - Disclosure - Post-retirement benefits - Assumptions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsAssumptionsDetails
1699 Disclosure of defined benefit plans [table] Table

*

*

 ifrs-full:DisclosureOfDefinedBenefitPlansTable
1700 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1701 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1702 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1703 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1704 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1705 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1706 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1707 Geographical [Axis] Axis srt:StatementGeographicalAxis
1708 Geographical [Domain] Member srt:SegmentGeographicalDomain
1709 US and Sweden Member azn:UnitedStatesAndSwedenMember
1710 US Member country:US
1711 SWEDEN Member country:SE
1712 Actuarial assumptions [axis] Axis ifrs-full:ActuarialAssumptionsAxis
1713 Actuarial assumptions [member] Member ifrs-full:ActuarialAssumptionsMember
1714 Life expectancy assumptions at age 65 for male members retiring in 2017 (2016) Member azn:ActuarialAssumptionOfExpectedLifeExpectancyOfMalePlanParticipantsAtAgeSixtyFiveRetiringInCurrentPeriodMember
1715 Life expectancy assumptions at age 65 for male members expected to retire in 2037 (2036) Member azn:ActuarialAssumptionOfExpectedLifeExpectancyOfMalePlanParticipantsAtAgeSixtyFiveRetiringTwentyYearsAfterCurrentPeriodMember
1716 Post-retirement benefits LineItems ifrs-full:DisclosureOfDefinedBenefitPlansLineItems
1717 Inflation assumption (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflation
1718 Rate of increase in salaries (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
1719 Rate of increase in pensions in payment (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
1720 Discount rate - defined benefit obligation (as a percent) Concept (Percent) As Of ifrs-full:ActuarialAssumptionOfDiscountRates
1721 Discount rate - interest cost Concept (Percent) As Of azn:ActuarialAssumptionOfDiscountRatesForInterestCost
1722 Discount rate - service cost Concept (Percent) As Of azn:ActuarialAssumptionOfDiscountRatesForServiceCost
1723 Member who will transfer out (as a percentage) Concept (Percent) For Period azn:DefinedBenefitPlansTransferOutAssumption
1724 Reduction in liabilities due to transfers Concept (Monetary) For Period Debit azn:DefinedBenefitPlansReductionInLiabilitiesDueToTransfers
1725 Weighted average duration of the post-retirement scheme obligations Concept (xbrli:durationItemType) For Period azn:DefinedBenefitPlansWeightedAverageDurationOfDefinedBenefitObligation
1726 Retirement age used in life expectancy assumption Concept (xbrli:durationItemType) For Period azn:ActuarialValuationBenchmarkRetirementAgeOfParticipantInDefinedBenefitPlanOnValuationDateUsedInExpectedLifeExpectancyAssumption
1727 Life expectancy assumption Concept (xbrli:durationItemType) For Period azn:ActuarialAssumptionOfExpectedLifeExpectancyOfParticipantInDefinedBenefitPlan
1728 Long-term improvement rate of Mortality Projections Model Concept (Percent) For Period azn:MortalityProjectionsModelPercentageOfLongTermImprovement
1729 42104 - Disclosure - Post-retirement benefits - Risks (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsRisksDetails
1730 Disclosure of defined benefit plans [table] Table

*

*

 ifrs-full:DisclosureOfDefinedBenefitPlansTable
1731 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1732 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1733 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1734 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1735 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1736 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1737 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
1738 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
1739 Derivatives: Longevity swap Member azn:DerivativesLongevitySwapMember
1740 Post-retirement benefits LineItems ifrs-full:DisclosureOfDefinedBenefitPlansLineItems
1741 Defined benefit obligations as a percentage of total Concept (Percent) As Of azn:DefinedBenefitPlansDefinedBenefitObligationConcentrationPercentageOfTotalDefinedBenefitObligations
1742 Percentage of Pension Fund in growth assets Concept (Percent) As Of azn:DefinedBenefitPlanPlanAssetAllocationsGrowthAssets
1743 Currency risk of plan assets hedged (as a percent) Concept (Percent) As Of azn:PercentageOfPlanAssetsHedgedByCurrencyDerivatives
1744 Interest rate risk of plan assets hedged (as a percent) Concept (Percent) For Period azn:PercentageOfPlanAssetsHedgedByInterestRateDerivatives
1745 Expected interest rate risk of plan assets hedged (as a percent) Concept (Percent) For Period azn:ExpectedPercentageOfPlanAssetsHedgedByInterestRateDerivatives
1746 Annual inflation increase cap (as a percent) Concept (Percent) For Period azn:IncreaseInDefinedBenefitLiabilityPriceInflationCap
1747 Inflation risk of plan assets hedged (as a percent) Concept (Percent) As Of azn:PercentageOfPlanAssetsHedgedByInflationRateDerivatives
1748 Expected inflation risk of plan assets hedged (as a percent) Concept (Percent) For Period azn:ExpectedPercentageOfPlanAssetsHedgedByInflationRateDerivatives
1749 Period under hedge Concept (xbrli:durationItemType) For Period azn:DerivativeHedgedPeriod
1750 Number of current pensioners Concept (Decimal) For Period ifrs-full:NumberOfParticipantsOfRetirementBenefitPlanReceivingBenefits
1751 Defined benefit obligation covered by hedge Concept (Monetary) As Of Credit azn:DerivativeAmountOfHedgedDefinedBenefitObligation
1752 Period of increase in life expectancy to receive cash under hedge Concept (xbrli:durationItemType) For Period azn:DerivativeCashReceivableOnHedgeReferencePeriodOfIncreaseInLifeExpectancy
1753 Increase in pension fund assets from hedged increase in life expectancy Concept (Monetary) For Period Debit azn:HedgedItemIncreaseInPlanAssetsDueToIncreaseInLongevity
1754 42105 - Disclosure - Post-retirement benefits - Scheme assets and obligations (Detail) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsSchemeAssetsAndObligationsDetail
1755 Disclosure of fair value of plan assets [table] Table

*

*

 ifrs-full:DisclosureOfFairValueOfPlanAssetsTable
1756 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1757 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1758 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1759 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1760 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1761 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1762 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1763 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
1764 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
1765 Government bonds Member ifrs-full:LoansToGovernmentMember
1766 Corporate bonds Member ifrs-full:CorporateLoansMember
1767 Derivatives Member ifrs-full:DerivativesMember
1768 Investment funds: Listed Equities Member azn:InvestmentFundsListedEquitiesMember
1769 Investment funds:Global Macro Hedge Member azn:InvestmentFundsGlobalMacroHedgeMember
1770 Investment funds:Diversified growth/Multi Strategy Member azn:InvestmentFundsDiversifiedGrowthOrMultiStrategyMember
1771 Investment funds:Multi-asset credit Member azn:InvestmentFundsMultiAssetCreditMember
1772 Net defined benefit liability (asset) [axis] Axis ifrs-full:NetDefinedBenefitLiabilityAssetAxis
1773 Net defined benefit liability (asset) [member] Member ifrs-full:NetDefinedBenefitLiabilityAssetMember
1774 Scheme obligations Member ifrs-full:PresentValueOfDefinedBenefitObligationMember
1775 Active membership Member azn:PresentValueOfDefinedBenefitObligationActivePlanParticipantsMember
1776 Deferred membership Member azn:PresentValueOfDefinedBenefitObligationDeferredPlanParticipantsMember
1777 Pensioners Member azn:PresentValueOfDefinedBenefitObligationPensionersMember
1778 Ifrs Investment Type [Axis] Axis azn:IfrsInvestmentTypeAxis
1779 Ifrs Investments [Domain] Member azn:IfrsInvestmentsDomain
1780 Quoted Member azn:QuotedInvestmentMember
1781 Unquoted Member azn:UnquotedInvestmentMember
1782 Scheme assets LineItems ifrs-full:DisclosureOfFairValueOfPlanAssetsLineItems
1783 Debt Concept (Monetary) As Of Debit ifrs-full:DebtInstrumentsAmountContributedToFairValueOfPlanAssets
1784 Derivatives: Concept (Monetary) As Of Debit ifrs-full:DerivativesAmountContributedToFairValueOfPlanAssets
1785 Investment funds: Concept (Monetary) As Of Debit ifrs-full:InvestmentFundsAmountContributedToFairValueOfPlanAssets
1786 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets
1787 Others Concept (Monetary) As Of Debit ifrs-full:OtherAssetsAmountContributedToFairValueOfPlanAssets
1788 Scheme deficit Abstract ifrs-full:SurplusDeficitInPlanAbstract
1789 Total fair value of scheme assets Concept (Monetary) As Of Debit ifrs-full:PlanAssetsAtFairValue
1790 Total value of scheme obligations Concept (Monetary) As Of Credit ifrs-full:DefinedBenefitObligationAtPresentValue
1791 Deficit in the scheme as recognised in the Consolidated Statement of Financial Position Concept (Monetary) As Of Debit ifrs-full:SurplusDeficitInPlan
1792 42106 - Disclosure - Post-retirement benefits - Change in fair value of scheme assets (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsChangeInFairValueOfSchemeAssetsDetails
1793 Disclosure of net defined benefit liability (asset) [table] Table

*

*

 ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable
1794 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1795 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1796 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1797 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1798 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1799 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1800 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1801 Net defined benefit liability (asset) [axis] Axis ifrs-full:NetDefinedBenefitLiabilityAssetAxis
1802 Net defined benefit liability (asset) [member] Member ifrs-full:NetDefinedBenefitLiabilityAssetMember
1803 Scheme assets Member ifrs-full:PlanAssetsMember
1804 Fair value of scheme assets LineItems ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
1805 Movement Abstract ifrs-full:ChangesInNetDefinedBenefitLiabilityAssetAbstract
1806 Beginning of year Concept (Monetary) As Of Credit ifrs-full:LiabilityAssetOfDefinedBenefitPlans
1807 Interest income on scheme assets Concept (Monetary) For Period Credit ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
1808 Expenses Concept (Monetary) For Period Credit azn:AdministrativeExpenseEffectOnNetDefinedBenefitLiabilityAsset
1809 Actuarial gains (losses) Concept (Monetary) For Period Debit azn:ActuarialGainsLossesNetDefinedBenefitLiabilityAsset
1810 Exchange and other adjustments Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
1811 Employer contributions Concept (Monetary) For Period Debit ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
1812 Participant contributions Concept (Monetary) For Period Debit ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
1813 Benefits paid Concept (Monetary) For Period Debit ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
1814 End of year Concept (Monetary) As Of Credit ifrs-full:LiabilityAssetOfDefinedBenefitPlans
1815 Actual return on the plan assets Concept (Monetary) For Period Debit ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
1816 42107 - Disclosure - Post-retirement benefits - Movement in and components of scheme obligations (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsMovementInAndComponentsOfSchemeObligationsDetails
1817 Disclosure of net defined benefit liability (asset) [table] Table

*

*

 ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable
1818 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1819 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1820 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1821 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1822 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1823 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1824 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1825 Net defined benefit liability (asset) [axis] Axis ifrs-full:NetDefinedBenefitLiabilityAssetAxis
1826 Net defined benefit liability (asset) [member] Member ifrs-full:NetDefinedBenefitLiabilityAssetMember
1827 Scheme obligations Member ifrs-full:PresentValueOfDefinedBenefitObligationMember
1828 Funded - pension schemes Member azn:PresentValueOfDefinedBenefitObligationFundedPensionMember
1829 Funded - post-retirement healthcare Member azn:PresentValueOfDefinedBenefitObligationFundedPostRetirementHealthcareMember
1830 Unfunded - pension schemes Member azn:PresentValueOfDefinedBenefitObligationUnfundedPensionMember
1831 Unfunded - post-retirement healthcare Member azn:PresentValueOfDefinedBenefitObligationUnfundedPostRetirementHealthcareMember
1832 Post-retirement scheme obligations LineItems ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
1833 Movement Abstract ifrs-full:ChangesInNetDefinedBenefitLiabilityAssetAbstract
1834 Beginning of year Concept (Monetary) As Of Credit ifrs-full:DefinedBenefitObligationAtPresentValue
1835 Current service cost Concept (Monetary) For Period Credit ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
1836 Past service credit/(cost) Concept (Monetary) For Period Credit ifrs-full:PastServiceCostNetDefinedBenefitLiabilityAsset
1837 Participant contributions Concept (Monetary) For Period Debit ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
1838 Benefits paid Concept (Monetary) For Period Debit ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
1839 Interest expense on post-retirement scheme obligations Concept (Monetary) For Period Credit ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
1840 Actuarial (losses) gains on defined benefit obligation Concept (Monetary) For Period Debit azn:ActuarialGainsLossesNetDefinedBenefitLiabilityAsset
1841 Exchange and other adjustments Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
1842 End of year Concept (Monetary) As Of Credit ifrs-full:DefinedBenefitObligationAtPresentValue
1843 Obligations of plans Concept (Monetary) As Of Credit ifrs-full:DefinedBenefitObligationAtPresentValue
1844 42108 - Disclosure - Post-retirement benefits - Amounts charged to comprehensive income (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsAmountsChargedToComprehensiveIncomeDetails
1845 Disclosure of defined benefit plans [table] Table

*

*

 ifrs-full:DisclosureOfDefinedBenefitPlansTable
1846 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1847 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1848 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1849 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1850 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1851 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1852 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1853 Post-retirement benefits LineItems ifrs-full:DisclosureOfDefinedBenefitPlansLineItems
1854 Current service cost Concept (Monetary) For Period Debit azn:DefinedBenefitPlansServiceCost
1855 Past service credit/(cost) Concept (Monetary) For Period Debit azn:DefinedBenefitPlansPastServiceCostCredit
1856 Expenses Concept (Monetary) For Period Debit azn:DefinedBenefitPlansAdministrativeExpense
1857 Total charge to operating profit Concept (Monetary) For Period Debit azn:DefinedBenefitPlansPostEmploymentBenefitExpenseBeforeInterestExpenseIncome
1858 Interest income on scheme assets Concept (Monetary) For Period Credit azn:DefinedBenefitPlansInterestIncome
1859 Interest expense on post-retirement scheme obligations Concept (Monetary) For Period Debit azn:DefinedBenefitPlansInterestExpense
1860 Net interest on post-employment defined benefit plan liabilities Concept (Monetary) For Period Debit azn:DefinedBenefitPlansInterestExpenseIncomeNet
1861 Charge before taxation Concept (Monetary) For Period Debit ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
1862 Other comprehensive income Abstract ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossBeforeTaxAbstract
1863 Difference between the actual return and the expected return on the post-retirement scheme assets Concept (Monetary) For Period Credit azn:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansDifferenceBetweenActualAndExpectedReturnOnPlanAssets
1864 Experience gains/(losses) arising on the post-retirement scheme obligations Concept (Monetary) For Period Credit azn:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansExperienceAdjustments
1865 Changes in financial assumptions underlying the present value of the post-retirement scheme obligations Concept (Monetary) For Period Credit azn:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansChangesInFinancialAssumptions
1866 Changes in demographic assumptions Concept (Monetary) For Period Credit azn:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansChangesInDemographicAssumptions
1867 Remeasurement of the defined benefit liability Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
1868 GMP equalisation past service cost Concept (Monetary) For Period Debit azn:PastServiceCostGuaranteedMinimumPensionsEqualisation
1869 Group costs in respect of defined contribution schemes Concept (Monetary) For Period Debit ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
1870 42109 - Disclosure - Post-retirement benefits - Effect of change in significant actuarial assumptions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosurePostRetirementBenefitsEffectOfChangeInSignificantActuarialAssumptionsDetails
1871 Disclosure of sensitivity analysis for actuarial assumptions [table] Table

*

*

 ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable
1872 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
1873 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
1874 Pension schemes Member ifrs-full:DefinedBenefitPlansOtherThanMultiemployerPlansStatePlansAndPlansThatShareRisksBetweenEntitiesUnderCommonControlMember
1875 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
1876 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
1877 UK defined benefit plans Member ifrs-full:CountryOfDomicileMember
1878 Rest of Group defined benefit plans Member ifrs-full:ForeignCountriesMember
1879 Geographical [Axis] Axis srt:StatementGeographicalAxis
1880 Geographical [Domain] Member srt:SegmentGeographicalDomain
1881 UK, US and Sweden Member azn:UnitedKingdomUnitedStatesAndSwedenMember
1882 US and Sweden Member azn:UnitedStatesAndSwedenMember
1883 US Member country:US
1884 SWEDEN Member country:SE
1885 Actuarial assumptions [axis] Axis ifrs-full:ActuarialAssumptionsAxis
1886 Actuarial assumptions [member] Member ifrs-full:ActuarialAssumptionsMember
1887 Discount rate Member ifrs-full:ActuarialAssumptionOfDiscountRatesMember
1888 Inflation rate Member ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember
1889 Rate of increase in salaries Member ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember
1890 Mortality rate Member ifrs-full:ActuarialAssumptionOfMortalityRatesMember
1891 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
1892 Financial assets Member ifrs-full:FinancialAssetsMember
1893 Longevity swap Member azn:DefinedBenefitPlanParticipantLongevitySwapContractMember
1894 Effect of a change in the significant actuarial assumptions used to determine the retirement benefits obligations LineItems ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems
1895 Number of main defined benefit pension obligation countries Concept (Integer) For Period azn:DefinedBenefitPlansNumberOfMainDefinedBenefitObligationCountries
1896 Actuarial assumption increase (as a percent) Concept (Percent) As Of ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
1897 Actuarial assumption increase Concept (xbrli:durationItemType) For Period azn:PeriodOfReasonablyPossibleIncreaseInActuarialAssumption
1898 Effect of increase in actuarial assumption on defined benefit pension obligation Concept (Monetary) As Of Credit ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
1899 Effect of increase in actuarial assumption on defined benefit pension obligation, covered by longevity swap Concept (Monetary) For Period Debit azn:HedgedItemIncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
1900 Actuarial assumption decrease (as a percent) Concept (Percent) As Of ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
1901 Actuarial assumption decrease Concept (xbrli:durationItemType) For Period azn:PeriodOfReasonablyPossibleDecreaseInActuarialAssumption
1902 Effect of decrease in actuarial assumption on defined benefit pension obligation Concept (Monetary) As Of Credit ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
1903 Effect of decrease in actuarial assumption on defined benefit pension obligation, covered by longevity swap Concept (Monetary) As Of Debit azn:HedgedItemIncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
1904 42201 - Disclosure - Reserves (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureReservesDetails
1905 Disclosure of reserves within equity [table] Table

*

*

 ifrs-full:DisclosureOfReservesWithinEquityTable
1906 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
1907 Equity [member] Member ifrs-full:EquityMember
1908 Retained earnings. Member ifrs-full:RetainedEarningsMember
1909 Disclosure of reserves within equity [line items] LineItems ifrs-full:DisclosureOfReservesWithinEquityLineItems
1910 Goodwill written off Concept (Monetary) For Period Credit ifrs-full:GoodwillDerecognisedWithoutHavingPreviouslyBeenIncludedInDisposalGroupClassifiedAsHeldForSale
1911 Number of shares deducted from retained earnings Concept (Shares) For Period ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
1912 Amount of shares deducted from retained earnings Concept (Monetary) For Period Credit azn:IncreaseDecreaseInNumberOfSharesOutstandingAmount
1913 42202 - Disclosure - Reserves - Reconciliation (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureReservesReconciliationDetails
1914 Disclosure of reserves within equity [table] Table

*

*

 ifrs-full:DisclosureOfReservesWithinEquityTable
1915 Types of hedges [axis] Axis ifrs-full:TypesOfHedgesAxis
1916 Hedges [member] Member ifrs-full:TypesOfHedgesMember
1917 Instruments designated in cash flow hedge Member ifrs-full:CashFlowHedgesMember
1918 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
1919 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
1920 Derivatives Member ifrs-full:DerivativesMember
1921 Cross currency swaps Member ifrs-full:CurrencySwapContractMember
1922 Matured cross currency swaps Member azn:MaturedCrossCurrencySwapsMember
1923 Currency [Axis] Axis srt:CurrencyAxis
1924 All Currencies [Domain] Member currency:AllCurrenciesDomain
1925 Japanese yen Member currency:JPY
1926 Chinese Renminbi Member currency:CNY
1927 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
1928 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
1929 5.75% Non-callable bond Member azn:NonCallableBond5.75PercentMember
1930 0.875% Non-callable bond Member azn:NonCallableBond0.875PercentMember
1931 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
1932 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
1933 Acerta Pharma Member azn:AcertaPharmaMember
1934 BMS's share of Global Diabetes Alliance Member azn:BmssShareOfGlobalDiabetesAllianceMember
1935 Almirall Member azn:AlmirallMember
1936 Definiens Group Member azn:DefiniensMember
1937 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
1938 Equity [member] Member ifrs-full:EquityMember
1939 Other reserves Member ifrs-full:OtherReservesMember
1940 Foreign currency translation reserve Member ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember
1941 Retained earnings. Member ifrs-full:RetainedEarningsMember
1942 Disclosure of reserves within equity [line items] LineItems ifrs-full:DisclosureOfReservesWithinEquityLineItems
1943 Cumulative translation differences included within retained earnings, beginning balance Concept (Monetary) As Of Credit ifrs-full:ReserveOfExchangeDifferencesOnTranslation
1944 Foreign exchange arising on consolidation Concept (Monetary) For Period Credit azn:GainsLossesOnExchangeDifferencesOnConsolidationBeforeTax
1945 Exchange adjustments on goodwill (recorded against other reserves) Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill
1946 Foreign exchange arising on designating borrowings in net investment hedges Concept (Monetary) For Period Credit azn:GainsLossesOnExchangeDifferenceHedgesOfNetInvestmentsInForeignOperationsBeforeTax
1947 Fair value movements on derivatives designated in net investment hedges Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnHedgesOfNetInvestmentsInForeignOperationsBeforeTax
1948 Net exchange movement in retained earnings Concept (Monetary) For Period Credit azn:NetMovementOfExchangeDifferencesOnTranslation
1949 Cumulative translation differences included within retained earnings, ending balance Concept (Monetary) As Of Credit ifrs-full:ReserveOfExchangeDifferencesOnTranslation
1950 Foreign exchange arising on net investment hedges Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughForeignExchangeArisingOnHedges
1951 Borrowings Concept (Monetary) As Of Credit ifrs-full:Borrowings
1952 Interest rate on borrowings Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
1953 Borrowings covered by hedges Concept (Monetary) As Of Credit azn:BorrowingsCoveredByHedges
1954 Foreign exchange change arising on contingent consideration liabilities Concept (Monetary) For Period Credit azn:IncreaseDecreaseThroughForeignExchangeContingentLiabilitiesRecognisedInBusinessCombination
1955 Amount matured Concept (Monetary) For Period Credit azn:MaturityOfDerivative
1956 Derivative financial instruments Concept (Monetary) As Of Debit ifrs-full:CurrentDerivativeFinancialAssets
1957 Reserve of cash flow hedges Concept (Monetary) As Of Credit ifrs-full:ReserveOfCashFlowHedges
1958 Reserves from cancellation of share premium account Concept (Monetary) As Of Credit azn:ReservesFromCancellationOfSharePremiumAccount
1959 Reserve from redenomination of share capital Concept (Monetary) As Of Credit azn:ReserveFromRedenominationOfShareCapital
1960 Gain on cost of hedging Concept (Monetary) For Period Credit azn:GainOnCostOfHedging
1961 Loss on cost of hedging Concept (Monetary) For Period Debit azn:LossOnCostsOfHedging
1962 42301 - Disclosure - Share capital of the Company (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureShareCapitalOfCompanyDetails
1963 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
1964 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
1965 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
1966 Ordinary shares Member ifrs-full:OrdinarySharesMember
1967 Preference shares Member ifrs-full:PreferenceSharesMember
1968 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
1969 Par value per share Concept (Share) As Of ifrs-full:ParValuePerShare
1970 Issued capital Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
1971 Days of written noticed required Concept (xbrli:durationItemType) For Period azn:NumberOfDaysOfWrittenNoticeRequired
1972 Number of shares outstanding at beginning of period Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
1973 Issues of shares (share schemes) Concept (Shares) For Period ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
1974 Number of shares outstanding at end of period Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
1975 Number of shares in the Company held by subsidiaries Concept (Shares) As Of ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates
1976 Shares repurchased Concept (Monetary) For Period Debit ifrs-full:PurchaseOfTreasuryShares
1977 42401 - Disclosure - Dividends to shareholders (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureDividendsToShareholdersDetails
1978 Implied Table Table

*

*

 implied:Table
1979 Dividends to shareholders Abstract azn:DividendsToShareholdersAbstract
1980 Final Concept (Monetary) For Period Debit ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYears
1981 Interim Concept (Monetary) For Period Debit ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear
1982 Total Concept (Monetary) For Period Debit ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent
1983 Final Concept (Share) For Period azn:DividendsRecognizedAsDistributionsToOwnersOfParentRelatingToPriorYearsPerShare
1984 Interim Concept (Share) For Period azn:DividendsRecognizedAsDistributionsToOwnersOfParentRelatingToCurrentYearPerShare
1985 Total Concept (Share) For Period azn:DividendsRecognizedAsDistributionsToOwnersOfParentPerShare
1986 Period of time unclaimed dividends were forfeited Concept (xbrli:durationItemType) For Period azn:PeriodOfTimeDividendsWereForfeited
1987 Unclaimed dividends forfeited and adjusted for in retained earnings Concept (Monetary) For Period Credit azn:AmountOfUnclaimedDividendsForfeitedAndAdjustedForInRetainedEarnings
1988 42402 - Disclosure - Dividends to shareholders - Dividends Paid (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureDividendsToShareholdersDividendsPaidDetails
1989 Implied Table Table

*

*

 implied:Table
1990 Dividends to shareholders Abstract azn:DividendsToShareholdersAbstract
1991 Dividends charged to equity Concept (Monetary) For Period Debit ifrs-full:DividendsRecognisedAsDistributionsToOwnersOfParent
1992 Exchange losses/(gain) on payment of dividend Concept (Monetary) For Period Credit azn:DividendPaymentExchangeGainLosses
1993 Hedge contracts relating to dividend payments Concept (Monetary) For Period Credit azn:HedgeContractsRelatingToDividendPaymentsReceiptsClassifiedAsFinancingActivities
1994 Dividends paid (per share) Concept (Share) For Period ifrs-full:DividendsPaidOrdinarySharesPerShare
1995 42501 - Disclosure - Non-controlling (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureNonControllingDetails
1996 Disclosure of subsidiaries [table] Table

*

*

 ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesTable
1997 Subsidiaries [axis] Axis ifrs-full:SignificantInvestmentsInSubsidiariesAxis
1998 Entity's total for subsidiaries [member] Member ifrs-full:EntitysTotalForSubsidiariesMember
1999 Acerta Pharma Member azn:AcertaPharmaBvMember
2000 Disclosure of subsidiaries [line items] LineItems ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
2001 Equity Concept (Monetary) As Of Credit ifrs-full:Equity
2002 Total comprehensive losses Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
2003 Total Revenue Concept (Monetary) For Period Credit ifrs-full:Revenue
2004 (Loss)/profit after tax Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
2005 Other comprehensive income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
2006 Total comprehensive income for the period Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
2007 Non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssets
2008 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
2009 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
2010 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
2011 Total liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
2012 Net assets Concept (Monetary) As Of Debit ifrs-full:NetAssetsLiabilities
2013 Net cash inflow/(outflow) from operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
2014 Net cash (outflow)/inflow from investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
2015 Increase/(decrease) in cash and cash equivalents in the year Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
2016 42601 - Disclosure - Acquisitions of business operations - 2016 acquisitions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureAcquisitionsOfBusinessOperations2016AcquisitionsDetails
2017 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
2018 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
2019 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
2020 Acerta Pharma Acquisition Member azn:AcertaPharmaAcquisitionMember
2021 Disclosure of detailed information about business combination [line items] LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
2022 Number of employees Concept (Decimal) As Of ifrs-full:NumberOfEmployees
2023 Percentage of voting equity interests acquired Concept (Percent) As Of ifrs-full:PercentageOfVotingEquityInterestsAcquired
2024 Percentage of voting equity interests left to acquire Concept (Percent) As Of azn:PercentageOfRemainingVotingEquityInterestsToAcquire
2025 Consideration transferred, acquisition-date fair value Concept (Monetary) As Of Credit ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
2026 Upfront payment Concept (Monetary) As Of Credit ifrs-full:CashTransferred
2027 Further payment Concept (Monetary) As Of Credit ifrs-full:LiabilitiesIncurred
2028 Value of remaining non-controlling interests Concept (Monetary) As Of Credit azn:ValueOfRemainingNoncontrollingInterest
2029 Revenue since acquisition date Concept (Monetary) For Period Credit ifrs-full:RevenueOfAcquiree
2030 Loss after tax since acquisition date Concept (Monetary) For Period Credit ifrs-full:ProfitLossOfAcquiree
2031 Profit after tax if acquisition occurred at beginning of period Concept (Monetary) For Period Credit ifrs-full:ProfitLossOfCombinedEntity
2032 42602 - Disclosure - Acquisitions of business operations - Fair values assigned 2016 acquisitions (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureAcquisitionsOfBusinessOperationsFairValuesAssigned2016AcquisitionsDetails
2033 Disclosure of detailed information about business combination [table] Table

*

*

 ifrs-full:DisclosureOfBusinessCombinationsTable
2034 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
2035 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
2036 Acerta Pharma Acquisition Member azn:AcertaPharmaAcquisitionMember
2037 Disclosure of detailed information about business combination [line items] LineItems ifrs-full:DisclosureOfBusinessCombinationsLineItems
2038 Intangible assets (Note 9) Concept (Monetary) As Of Debit ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
2039 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate
2040 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate
2041 Deferred tax liabilities Concept (Monetary) As Of Credit ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
2042 Total net assets acquired Concept (Monetary) As Of Debit ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
2043 Non-controlling interests Concept (Monetary) As Of Credit ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate
2044 Goodwill (Note 8) Concept (Monetary) As Of Debit ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
2045 Fair value of total consideration Concept (Monetary) As Of Credit ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
2046 Less: consideration Concept (Monetary) As Of Credit ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate
2047 Total upfront consideration Concept (Monetary) As Of Credit ifrs-full:CashTransferred
2048 Less: cash and cash equivalents acquired Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
2049 Net cash outflow Concept (Monetary) For Period Credit ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
2050 42701 - Disclosure - Financial risk management objectives and policies - Capital management (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesCapitalManagementDetails
2051 Implied Table Table

*

*

 implied:Table
2052 Disclosure Of financial risk management objectives and policies Abstract azn:DisclosureOfFinancialRiskManagementAbstract
2053 Net debt position Concept (Monetary) As Of Credit azn:NetDebtPosition
2054 42702 - Disclosure - Financial risk management objectives and policies - Liquidity risk (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesLiquidityRiskDetails
2055 Disclosure of maturity analysis for financial liabilities [table] Table

*

*

 azn:DisclosureOfMaturityAnalysisForFinancialLiabilitiesTable
2056 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
2057 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
2058 Euro medium term note programme Member azn:EuroMediumTermNoteProgrammeMember
2059 SEC registered programme Member azn:SecRegisteredProgrammeMember
2060 Maturity [axis] Axis ifrs-full:MaturityAxis
2061 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
2062 Due within one year Member ifrs-full:NotLaterThanOneYearMember
2063 Years 1 and 2 Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
2064 Years 2 and 3 Member ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember
2065 Years 3 and 4 Member ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember
2066 Years 4 and 5 Member ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember
2067 Later than five years Member ifrs-full:LaterThanFiveYearsMember
2068 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
2069 Financial liabilities Member ifrs-full:FinancialLiabilitiesMember
2070 Total non-derivative financial instruments Member azn:NonderivativeFinancialInstrumentsMember
2071 Bank overdrafts and other loans Member azn:BankOverdraftsAndOtherLoansMember
2072 Bonds Member azn:BondsNonDerivativeFinancialLiabilitiesMember
2073 Finance leases Member ifrs-full:LeaseLiabilitiesMember
2074 Trade and other payables Member azn:TradeAndOtherPayablesMember
2075 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
2076 Financial assets Member ifrs-full:FinancialAssetsMember
2077 Total derivative financial instruments Member azn:DerivativeFinancialInstrumentsMember
2078 Interest rate swaps Member ifrs-full:InterestRateSwapContractMember
2079 Cross currency swaps Member ifrs-full:CurrencySwapContractMember
2080 Undiscounted Cash Flows of Financial Liabilities Effects [Axis] Axis azn:UndiscountedCashFlowsOfFinancialLiabilitiesEffectsAxis
2081 Effects Of Undiscounted Cash Flows Of Financial Liabilities [Domain] Member azn:EffectsOfUndiscountedCashFlowsOfFinancialLiabilitiesDomain
2082 Amount before effects Member azn:AmountBeforeEffectsMember
2083 Retrospective application and retrospective restatement [axis] Axis ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis
2084 Currently stated [member] Member ifrs-full:RestatedMember
2085 Previously stated Member ifrs-full:PreviouslyStatedMember
2086 Continuing involvement in derecognised financial assets by type of instrument [axis] Axis ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfInstrumentAxis
2087 Types of instrument [member] Member ifrs-full:TypesOfInstrumentMember
2088 Put option Member ifrs-full:WrittenPutOptionsMember
2089 Maturity analysis of financial liabilities LineItems azn:DisclosureOfMaturityAnalysisForFinancialLiabilitiesLineItems
2090 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
2091 Short-term fixed income investments Concept (Monetary) As Of Debit azn:ShortTermFixedIncomeInvestments
2092 Fixed deposits Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
2093 Overdrafts Concept (Monetary) As Of Credit ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
2094 Committed bank facilities Concept (Monetary) As Of Credit azn:CommittedBankFacilities
2095 Increase in committed bank facilities Concept (Monetary) For Period Credit azn:IncreaseDecreaseInCommittedBanckFacilities
2096 Extension option (in years) Concept (xbrli:durationItemType) For Period azn:PeriodOfTimeForExtensionOption
2097 Debt instruments issued Concept (Monetary) As Of Credit ifrs-full:DebtSecurities
2098 Undrawn committed bank facilities Concept (Monetary) As Of Credit ifrs-full:UndrawnBorrowingFacilities
2099 Non-derivative financial instruments Concept (Monetary) As Of Credit ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
2100 Derivative financial instruments Concept (Monetary) As Of Debit azn:DerivativeFinancialAssetsUndiscountedCashFlows
2101 Financial instruments Concept (Monetary) As Of Credit azn:FinancialLiabilitiesUndiscountedCashFlows
2102 Derivative financial instruments Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
2103 Derivative financial instruments Concept (Monetary) As Of Debit ifrs-full:CurrentDerivativeFinancialAssets
2104 Derivative financial receivables Concept (Monetary) As Of Debit azn:DerivativeFinancialReceivables
2105 Derivative financial payables Concept (Monetary) As Of Credit azn:DerivativeFinancialPayables
2106 Effect of interest Concept (Monetary) As Of Debit azn:EffectOfInterest
2107 Effect of discounting, fair values and issue costs Concept (Monetary) As Of Debit azn:EffectOfDiscountingFairValuesAndIssueCosts
2108 Financial instruments after effects of interest and discounting, fair values and issue costs Concept (Monetary) As Of Credit azn:FinancialInstrumentsAfterAdjustments
2109 Contingent consideration Concept (Monetary) As Of Credit ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
2110 Potential payable Concept (Monetary) As Of Credit ifrs-full:AmountsPayableToTransfereeInRespectOfTransferredAssets
2111 42703 - Disclosure - Financial risk management objectives and policies - Market risk (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesMarketRiskDetails
2112 Disclosure of financial instruments by type of interest rate [table] Table

*

*

 ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable
2113 Types of interest rates [axis] Axis ifrs-full:TypesOfInterestRatesAxis
2114 Interest rate types [member] Member ifrs-full:InterestRateTypesMember
2115 Fixed rate Member ifrs-full:FixedInterestRateMember
2116 Floating rate Member ifrs-full:FloatingInterestRateMember
2117 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
2118 Financial liabilities Member ifrs-full:FinancialLiabilitiesMember
2119 Interest rate swaps Member ifrs-full:InterestRateSwapContractMember
2120 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
2121 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
2122 Bonds Maturing in 2023 Member azn:BondsMaturingIn2023Member
2123 Bonds Maturing in 2029 Member azn:BondsMaturingIn2029Member
2124 Bonds Maturing in 2048 Member azn:BondsMaturingIn2048Member
2125 Bonds Maturing in 2018 Member azn:BondsMaturingIn2018Member
2126 7% Guaranteed debentures Member azn:GuaranteedDebentures7PercentMember
2127 1.75% Callable bond Member azn:CallableBond1.75PercentMember
2128 Types of hedges [axis] Axis ifrs-full:TypesOfHedgesAxis
2129 Hedges [member] Member ifrs-full:TypesOfHedgesMember
2130 Instruments in a fair value hedge relationship Member ifrs-full:FairValueHedgesMember
2131 Instruments at fair value through profit or loss Member ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember
2132 Disclosure of financial instruments by interest rate LineItems ifrs-full:DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems
2133 Borrowings Concept (Monetary) As Of Credit ifrs-full:Borrowings
2134 Notional amount Concept (Monetary) As Of ifrs-full:NotionalAmount
2135 Interest rate on borrowings Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
2136 Current financial liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentFinancialLiabilities
2137 Non-current financial liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentFinancialLiabilities
2138 Total financial liabilities Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilities
2139 Short-term deposits, not classified as cash equivalents Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
2140 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
2141 Total financial assets Concept (Monetary) As Of Debit ifrs-full:FinancialAssets
2142 Current and non-current asset investments and other financial assets on which no interest is received Concept (Monetary) As Of Debit azn:OtherCurrentAndNonCurrentAssetsInvestmentsAndOtherFinancialAssetsNoInterestReceived
2143 42704 - Disclosure - Financial risk management objectives and policies - Foreign currency risk (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesForeignCurrencyRiskDetails
2144 Disclosure of nature and extent of risks arising from financial instruments [table] Table

*

*

 ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable
2145 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
2146 Risks [member] Member ifrs-full:TypesOfRisksMember
2147 Interest rates Member ifrs-full:InterestRateRiskMember
2148 Exchange rates Member ifrs-full:CurrencyRiskMember
2149 Ifrs Currency [Axis] Axis azn:IfrsCurrencyAxis
2150 Ifrs All Currencies [Domain] Member azn:IfrsAllCurrenciesDomain
2151 US Member azn:IfrsCurrencyUsMember
2152 All currencies except US Member azn:AllCurrenciesExceptUnitedStatesMember
2153 Pound sterling Member azn:IfrsCurrencyGbpMember
2154 Euro Member azn:IfrsCurrencyEurMember
2155 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
2156 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
2157 0.875% Non-callable bond Member azn:NonCallableBond0.875PercentMember
2158 Types of hedges [axis] Axis ifrs-full:TypesOfHedgesAxis
2159 Hedges [member] Member ifrs-full:TypesOfHedgesMember
2160 Instruments in a fair value hedge relationship Member ifrs-full:FairValueHedgesMember
2161 Foreign currency risk LineItems ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems
2162 Percentage of entity's revenue Concept (Percent) For Period ifrs-full:PercentageOfEntitysRevenue
2163 Percentage of interest-bearing loans and borrowings Concept (Percent) As Of azn:PercentageOfInterestBearingLoansAndBorrowings
2164 Number of hyper inflationary countries Concept (Decimal) As Of azn:NumberOfHyperInflationaryCountries
2165 Amount issued Concept (Monetary) As Of ifrs-full:NotionalAmount
2166 Borrowings Concept (Monetary) As Of Credit ifrs-full:Borrowings
2167 Borrowings, interest rate Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
2168 Cash Concept (Monetary) As Of Debit ifrs-full:Cash
2169 Exchange rate Concept (Decimal) As Of ifrs-full:ClosingForeignExchangeRate
2170 Increase in interest expense that would result from increased interest rate, per sensitivity analysis Concept (Monetary) As Of Debit azn:IncreaseDecreaseInAnnualNetInterestChargeDueToReasonablyPossibleIncreaseInRiskVariable
2171 Assumed strengthening of US currency Concept (Percent) As Of azn:PercentageIncreaseInStregtheningOfUsCurrency
2172 Assumed weakening of US currency Concept (Percent) As Of azn:PercentageDecreaseInWeakeningOfUsCurrency
2173 Changes in rates Concept (Percent) As Of azn:PercentageOfReasonablyPossibleChangesInRiskAssumption
2174 Assumed percentage increase Concept (Percent) As Of azn:PercentageOfReasonablyPossibleIncreaseInRiskAssumption
2175 Assumed percentage decrease Concept (Percent) As Of azn:PercentageOfReasonablyPossibleDecreaseInRiskAssumption
2176 Increase/(decrease) in fair value of financial instruments ($m) due to increase in risk component Concept (Monetary) As Of azn:IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseInDesignatedRiskComponent
2177 Increase/(decrease) in fair value of financial instruments ($m) due to decrease in risk component Concept (Monetary) As Of azn:IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleDecreaseInDesignatedRiskComponent
2178 Impact on profit: (loss)/gain ($m) due to increase in risk component Concept (Monetary) As Of azn:IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleIncreaseInDesignatedRiskComponent
2179 Impact on profit: (loss)/gain ($m) due to decrease in risk component Concept (Monetary) As Of azn:IncreaseDecreaseInProfitAndLossDueToReasonablyPossibleDecreaseInDesignatedRiskComponent
2180 Impact on equity: gain/(loss) ($m) due to increase in risk component Concept (Monetary) As Of azn:IncreaseDecreaseInEquityDueToReasonablyPossibleIncreaseInDesignatedRiskComponent
2181 Impact on equity: gain/(loss) ($m) due to decrease in risk component Concept (Monetary) As Of azn:IncreaseDecreaseInEquityDueToReasonablyPossibleDecreaseInDesignatedRiskComponent
2182 42705 - Disclosure - Financial risk management objectives and policies - Credit risk (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesCreditRiskDetails
2183 Disclosure of provision matrix [table] Table

*

*

 ifrs-full:DisclosureOfProvisionMatrixTable
2184 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
2185 Risks [member] Member ifrs-full:TypesOfRisksMember
2186 Counterparty credit risk Member ifrs-full:CreditRiskMember
2187 Method of assessment of expected credit losses [axis] Axis ifrs-full:MethodOfAssessmentOfExpectedCreditLossesAxis
2188 Method of assessment of expected credit losses [member] Member ifrs-full:MethodOfAssessmentOfExpectedCreditLossesMember
2189 Provisions for trade receivables Member ifrs-full:ExpectedCreditLossesCollectivelyAssessedMember
2190 Classes of financial instruments [axis] Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
2191 Financial instruments, class [member] Member ifrs-full:ClassesOfFinancialInstrumentsMember
2192 Trade receivables Member ifrs-full:TradeReceivablesMember
2193 Past due status [axis] Axis ifrs-full:PastDueStatusAxis
2194 Past due status [member] Member ifrs-full:PastDueStatusMember
2195 Not past due Member ifrs-full:CurrentMember
2196 Past due 0 - 90 days Member ifrs-full:NotLaterThanThreeMonthsMember
2197 Past due 90 - 180 days Member ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember
2198 Past due > 180 days Member ifrs-full:LaterThanSixMonthsMember
2199 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
2200 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
2201 US Member azn:IfrsCountryUsMember
2202 Ageing of trade receivables LineItems ifrs-full:DisclosureOfProvisionMatrixLineItems
2203 Payment profile period (in months) Concept (xbrli:durationItemType) For Period azn:PeriodOfTimeOfPaymentProfilesToDetermineLossAllowance
2204 Expected loss rate Concept (Percent) As Of ifrs-full:ExpectedCreditLossRate
2205 Financial assets Concept (Monetary) As Of Debit ifrs-full:FinancialAssets
2206 Loss allowance Concept (Monetary) As Of Credit ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
2207 Movements in provisions for trade receivables Abstract ifrs-full:ReconciliationOfChangesInAllowanceAccountForCreditLossesOfFinancialAssetsAbstract
2208 At 1 January Concept (Monetary) As Of Credit ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
2209 Income statement Concept (Monetary) For Period Credit azn:IncreaseDecreaseInAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets
2210 Amounts utilised, exchange and other movements Concept (Monetary) For Period Debit azn:UtilisationExchangedAndOtherMovementsAllowanceAccountForCreditLossesOfFinancialAssets
2211 At 31 December Concept (Monetary) As Of Credit ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
2212 Credit risk Abstract ifrs-full:DisclosureOfCreditRiskExposureAbstract
2213 Number of wholesaler Concept (Integer) As Of azn:NumberOfWholesaler
2214 Percentage of sales Concept (Percent) For Period ifrs-full:PercentageOfEntitysRevenue
2215 Number of fund managers for money market securities Concept (Integer) As Of azn:NumberOfExternalThirdPartyFundManagersMoneyMarketPortfolios
2216 Maximum percentage the Company's investments represent of each overall fund value Concept (Percent) As Of azn:PercentageOfEachOverallFundValue
2217 Third-party collateralised investments as a percentage of cash deposited Concept (Percent) For Period azn:CollateralisedInvestmentsPercentageOfValueOfCashDeposited
2218 Collateralised investments held by third-party custodian Concept (Monetary) As Of Debit azn:CollateralisedInvestmentsRelatedToCashDeposited
2219 Number of fund managers for fixed income securities Concept (Integer) As Of azn:NumberOfExternalThirdPartyFundManagersFixedIncomeSecurities
2220 Current assets Abstract ifrs-full:CurrentAssetsAbstract
2221 Cash at bank and in hand Concept (Monetary) As Of Debit ifrs-full:Cash
2222 Money market liquidity fund Concept (Monetary) As Of Debit azn:MoneyMarketLiquidityFund
2223 Collateralised repurchase agreements Concept (Monetary) As Of Debit azn:CollateralisedRepurchaseAgreements
2224 Bank collateral Concept (Monetary) As Of Credit azn:BankCollateral
2225 Other short-term equivalents Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
2226 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
2227 Fixed income securities at fair value through profit and loss Concept (Monetary) As Of Debit ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss
2228 Fixed income securities available for sale Concept (Monetary) As Of Debit ifrs-full:CurrentFinancialAssetsAvailableforsale
2229 Fixed deposits Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
2230 Total derivative financial instruments Concept (Monetary) As Of Debit azn:DerivativeFinancialAssetsLiabilitiesNet
2231 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
2232 Non-current assets Abstract ifrs-full:NoncurrentAssetsAbstract
2233 Equity securities at fair value through other comprehensive income Concept (Monetary) As Of Debit ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome
2234 Equity securities available for sale Concept (Monetary) As Of Debit ifrs-full:NoncurrentFinancialAssetsAvailableforsale
2235 Derivative financial instruments Concept (Monetary) As Of Debit ifrs-full:NoncurrentDerivativeFinancialAssets
2236 Total non-current assets Concept (Monetary) As Of Debit ifrs-full:NoncurrentAssets
2237 42706 - Disclosure - Financial risk management objectives and policies - Other financial assets (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureFinancialRiskManagementObjectivesAndPoliciesOtherFinancialAssetsDetails
2238 Implied Table Table

*

*

 implied:Table
2239 Disclosure Of financial risk management objectives and policies Abstract azn:DisclosureOfFinancialRiskManagementAbstract
2240 Cash collateral on financial derivatives Concept (Monetary) As Of Debit azn:CashCollateralOnDerivatives
2241 Cash collateral posted by the group Concept (Monetary) As Of Debit azn:CashCollateralOnDerivativesPostedByGroup
2242 42801 - Disclosure - Employee costs and share plans for employees, Employee numbers (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesEmployeeNumbersDetails
2243 Disclosure of geographical areas [table] Table

*

*

 ifrs-full:DisclosureOfGeographicalAreasTable
2244 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
2245 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
2246 UK Member azn:IfrsCountryGbMember
2247 Europe Member azn:IfrsEuropeMember
2248 The Americas Member azn:IfrsAmericasMember
2249 Asia, Africa And Australasia Member azn:AsiaAfricaAndAustralasiaMember
2250 Disclosure of geographical location LineItems ifrs-full:DisclosureOfGeographicalAreasLineItems
2251 Average number of employees Concept (Decimal) For Period ifrs-full:AverageNumberOfEmployees
2252 Number of employees Concept (Decimal) As Of ifrs-full:NumberOfEmployees
2253 42802 - Disclosure - Employee costs and share plans for employees, Employee costs (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesEmployeeCostsDetails
2254 Implied Table Table

*

*

 implied:Table
2255 Employee costs and share plans for employees Abstract azn:EmployeeCostsAndSharePlansForEmployeesAbstract
2256 Salaries Concept (Monetary) For Period Debit ifrs-full:WagesAndSalaries
2257 Social security costs Concept (Monetary) For Period Debit ifrs-full:SocialSecurityContributions
2258 Pension costs Concept (Monetary) For Period Debit azn:PostEmploymentBenefitExpense
2259 Other employment costs Concept (Monetary) For Period Debit ifrs-full:OtherEmployeeExpense
2260 Total employee benefits expense Concept (Monetary) For Period Debit ifrs-full:EmployeeBenefitsExpense
2261 Severance costs Concept (Monetary) For Period Debit ifrs-full:TerminationBenefitsExpense
2262 42803 - Disclosure - Employee costs and share plans for employees, Bonus plans (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesBonusPlansDetails
2263 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
2264 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2265 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2266 Bonus plans Member azn:BonusPlansMember
2267 AstraZeneca Deferred Bonus Plan Member azn:AstrazenecaDeferredBonusPlanMember
2268 AstraZeneca Sweden Bonus Plan Member azn:AstrazenecaSwedenBonusPlanMember
2269 AstraZeneca U.S. Bonus Plans Member azn:AstrazenecaU.s.BonusPlanMember
2270 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
2271 Bonus plans Abstract azn:BonusPlansAbstract
2272 Deferral period for bonus Concept (xbrli:durationItemType) For Period azn:DeferredBonusPlanDeferralPeriod
2273 Percentage of bonuses paid into fund investing Concept (Percent) For Period azn:PercentageOfBonusesPaidIntoFundInvesting
2274 Percentage of bonuses paid in cash Concept (Percent) For Period azn:PercentageOfBonusesPaidInCash
2275 Number of all-employee short-term or annual performance bonus plans Concept (Integer) For Period azn:NumberOfShortTermOrAnnualPerformanceBonusPlans
2276 Number of senior staff long-term incentive schemes Concept (Integer) For Period azn:NumberOfLongTermIncentiveSchemes
2277 Number of participants that may be eligible for awards granted Concept (Integer) For Period azn:NumberOfParticipantsEligibleForAwards
2278 42804 - Disclosure - Employee costs and share plans for employees, Share-based payments (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesShareBasedPaymentsDetails
2279 Implied Table Table

*

*

 implied:Table
2280 Employee costs and share plans for employees Abstract azn:EmployeeCostsAndSharePlansForEmployeesAbstract
2281 Share-based payments equity settled Concept (Monetary) For Period Debit ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
2282 42805 - Disclosure - Employee costs and share plans for employees, AstraZeneca UK All Employee Share Plan (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesAstrazenecaUkAllEmployeeSharePlanDetails
2283 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
2284 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2285 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2286 AstraZeneca UK All Employee Share Plan Member azn:AstrazenecaUkAllEmployeeSharePlanMember
2287 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
2288 Threshold for employee investment in ordinary shares of entity Concept (Monetary) For Period Credit azn:EmployeeSharePlanThresholdInvestment
2289 Investment period Concept (xbrli:durationItemType) For Period azn:EmployeeSharePlanInvestmentPeriod
2290 Number of shares awarded for every four shares purchased Concept (Shares) For Period azn:EmployeeSharePlanNumberOfSharesAwardedForEveryFourSharesPurchased
2291 42806 - Disclosure - Employee costs and share plans for employees, AstraZeneca 2014 Performance Share Plan (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesAstrazeneca2014PerformanceSharePlanDetails
2292 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
2293 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2294 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2295 AstraZeneca 2014 Performance Share Plan Member azn:Astrazeneca2014PerformanceSharePlanMember
2296 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
2297 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
2298 Director Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
2299 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
2300 Plan term Concept (xbrli:durationItemType) For Period azn:ShareBasedPlanPeriod
2301 Period of wait time until awards granted vest Concept (xbrli:durationItemType) For Period azn:InvestmentPlanPeriodOfWaitTimeForAwardVesting
2302 Number of shares awarded Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
2303 Weighted average fair value Concept (Monetary) As Of Credit ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
2304 Additional holding period that can be subject to achievement of performance conditions Concept (xbrli:durationItemType) For Period azn:PerformanceSharePlanAdditionalHoldingPeriodThatCanBeSubjectToAchievementOfPerformanceConditions
2305 42807 - Disclosure - Employee costs and share plans for employees, AstraZeneca Investment Plan (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesAstrazenecaInvestmentPlanDetails
2306 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
2307 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2308 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2309 AstraZeneca Investment Plan Member azn:AstrazenecaInvestmentPlanMember
2310 Range [axis] Axis ifrs-full:RangeAxis
2311 Ranges [member] Member ifrs-full:RangesMember
2312 Minimum Member ifrs-full:BottomOfRangeMember
2313 Maximum Member ifrs-full:TopOfRangeMember
2314 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
2315 Period of wait time until awards granted vest Concept (xbrli:durationItemType) For Period azn:InvestmentPlanPeriodOfWaitTimeForAwardVesting
2316 Number of shares awarded Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
2317 Weighted average fair value Concept (Monetary) As Of Credit ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
2318 Period of performance conditions Concept (xbrli:durationItemType) For Period azn:InvestmentPlanTermOfPerformanceConditions
2319 42808 - Disclosure - Employee costs and share plans for employees, AstraZeneca Global Restricted Stock Plan (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesAstrazenecaGlobalRestrictedStockPlanDetails
2320 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
2321 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2322 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2323 AstraZeneca Global Restricted Stock Plan Member azn:AstrazenecaGlobalRestrictedStockPlanMember
2324 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
2325 Number of shares awarded Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
2326 Weighted average fair value Concept (Monetary) As Of Credit ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
2327 42809 - Disclosure - Employee costs and share plans for employees, AstraZeneca Restricted Share Plan (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesAstrazenecaRestrictedSharePlanDetails
2328 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
2329 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2330 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2331 AstraZeneca Restricted Share Plan Member azn:AstrazenecaRestrictedSharePlanMember
2332 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
2333 Number of shares awarded Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
2334 Weighted average fair value Concept (Monetary) As Of Credit ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
2335 Number of times plan used to make awards in specified year Concept (Integer) For Period azn:RestrictedSharePlanNumberOfTimesUsedInSpecifiedYear
2336 Number of employees granted awards Concept (Decimal) As Of azn:RestrictedSharePlanNumberOfEmployeesGrantedAwards
2337 42810 - Disclosure - Employee costs and share plans for employees, AstraZeneca Extended Incentive Plan (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureEmployeeCostsAndSharePlansForEmployeesAstrazenecaExtendedIncentivePlanDetails
2338 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
2339 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
2340 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
2341 Astrazeneca Extended Incentive Plan Member azn:AstrazenecaExtendedIncentivePlanMember
2342 Share plans LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
2343 Number of shares awarded Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
2344 Weighted average fair value Concept (Monetary) As Of Credit ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
2345 42901 - Disclosure - Commitments and contingent liabilities (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails
2346 Implied Table Table

*

*

 implied:Table
2347 Legal Proceedings and Contingent Liabilities Abstract azn:IfrsCommitmentsAndContingenciesDisclosureAbstract
2348 Commitments Abstract ifrs-full:CapitalCommitmentsAbstract
2349 Contracts placed for future capital expenditure on property, plant and equipment and software development costs not provided for in these accounts Concept (Monetary) As Of Credit ifrs-full:ContractualCapitalCommitments
2350 42902 - Disclosure - Commitments and contingent liabilities, Research and development (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilitiesResearchAndDevelopmentDetails
2351 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
2352 Maturity [axis] Axis ifrs-full:MaturityAxis
2353 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
2354 Due within one year Member ifrs-full:NotLaterThanOneYearMember
2355 Years 1 and 2 Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
2356 Years 3 and 4 Member ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember
2357 Years 5 and greater Member azn:NotLaterThanFiveYearsAndGreaterThanFiveYearsMember
2358 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
2359 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
2360 Future potential research and development milestone payments Member azn:ContingentLiabilityFuturePotentialResearchAndDevelopmentMilestonePaymentsMember
2361 Future potential revenue milestone payments Member azn:ContingentLiabilityFuturePotentialRevenueMilestonePaymentsMember
2362 Commitments and contingent liabilities LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
2363 Effect of potential milestone payments Concept (Monetary) As Of ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
2364 42903 - Disclosure - Commitments and contingent liabilities, Environmental costs (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilitiesEnvironmentalCostsDetails
2365 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
2366 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
2367 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
2368 Zeneca, Inc. Member azn:ZenecaInc.Member
2369 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
2370 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
2371 Environmental costs and liabilities Member ifrs-full:ContingentLiabilityForDecommissioningRestorationAndRehabilitationCostsMember
2372 Classes of other provisions [axis] Axis ifrs-full:ClassesOfProvisionsAxis
2373 Other provisions [member] Member ifrs-full:OtherProvisionsMember
2374 Environmental Member ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember
2375 Range [axis] Axis ifrs-full:RangeAxis
2376 Ranges [member] Member ifrs-full:RangesMember
2377 Minimum Member ifrs-full:BottomOfRangeMember
2378 Maximum Member ifrs-full:TopOfRangeMember
2379 Commitments and contingent liabilities LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
2380 Number of sites likely to incur future environmental investigation or consequences Concept (Integer) As Of azn:NumberOfSitesPotentialEnvironmentalInvestigationOrConsequences
2381 Provisions Concept (Monetary) As Of Credit ifrs-full:OtherProvisions
2382 Estimated financial effect of contingent liabilities Concept (Monetary) As Of ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
2383 42904 - Disclosure - Commitments and contingent liabilities, Legal proceedings (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilitiesLegalProceedingsDetails
2384 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
2385 Classes of contingent liabilities [axis] Axis ifrs-full:ClassesOfContingentLiabilitiesAxis
2386 Contingent liabilities [member] Member ifrs-full:ContingentLiabilitiesMember
2387 Legal proceedings Member ifrs-full:LegalProceedingsContingentLiabilityMember
2388 Brilinta Member azn:BrilintaMember
2389 Patent Infringement Lawsuits U.S. District Court New Jersey Member azn:PatentInfringementLawsuitsU.s.DistrictCourtNewJerseyMember
2390 Nexium Member azn:NexiumMember
2391 Seroquel IR Member azn:SeroquelIrMember
2392 Aralez Litigation Member azn:AralezLitigationMember
2393 Apotex, Inc. Member azn:ApotexInc.Member
2394 Crestor Member azn:CrestorMember
2395 Nexium And Prilosec Member azn:NexiumAndPrilosecMember
2396 Onglyza Kombiglyze Member azn:OnglyzaKombiglyzeMember
2397 Symbicort Member azn:SymbicortMember
2398 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
2399 Products and services [member] Member ifrs-full:ProductsAndServicesMember
2400 Faslodex Member azn:FaslodexMember
2401 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
2402 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
2403 China Member azn:IfrsCountryCnMember
2404 Canada Member azn:IfrsCountryCaMember
2405 US Member azn:IfrsCountryUsMember
2406 Pennsylvania Member stpr:PA
2407 Commitments and contingent liabilities LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
2408 Number of patents invalidated Concept (Integer) For Period azn:NumberOfPatentsInvalidated
2409 Number of claims filed Concept (Integer) For Period azn:IfrsLossContingencyNewClaimsFiledNumber
2410 Number of patents where claims were filed Concept (Integer) For Period azn:NumberOfPatentsClaimsFiled
2411 Number of claims settled Concept (Integer) For Period azn:IfrsLossContingencyClaimsSettledNumber
2412 Number of class action lawsuits Concept (Integer) As Of azn:NumberOfClassActionLawsuits
2413 Number of class action lawsuits representing individuals in Canada Concept (Integer) As Of azn:NumberOfClassActionLawsuitsRepresentingIndividualsInCanada
2414 Amount award to AstraZeneca Concept (Monetary) For Period Debit azn:IfrsLitigationSettlementAmountAwardedFromOtherParty
2415 Number of Orange Book listed patents Concept (Integer) For Period azn:NumberOfOrangeBookListedPatentsIncludedInLegalProceedings
2416 Number of plaintiffs Concept (Integer) For Period azn:IfrsLossContingencyNumberOfPlaintiffs
2417 Amount Aralez claim they owe Concept (Monetary) As Of Debit azn:LossContingencyReceivableCounterpartyClaim
2418 Amount Company claims is due Concept (Monetary) As Of Debit azn:IfrsLossContingencyReceivable
2419 Number of pharmaceutical manufacturers in an US. Congressional inquiry Concept (Decimal) As Of azn:NumberOfCompaniesUsCongressionalInquiry
2420 42905 - Disclosure - Commitments and contingent liabilities, Tax (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureCommitmentsAndContingentLiabilitiesTaxDetails
2421 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
2422 Range [axis] Axis ifrs-full:RangeAxis
2423 Ranges [member] Member ifrs-full:RangesMember
2424 Minimum Member ifrs-full:BottomOfRangeMember
2425 Maximum Member ifrs-full:TopOfRangeMember
2426 Commitments and contingent liabilities LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
2427 Tax contingency related to transfer pricing audits included in tax accrual Concept (Monetary) As Of Credit azn:TaxContingencyTransferPricing
2428 Decrease in tax contingency related to transfer pricing Concept (Monetary) For Period Credit azn:IncreaseDecreaseTaxContingencyRelatedToTransferPricing
2429 Maximum amount of possible additional losses, transfer pricing Concept (Monetary) For Period Debit azn:TaxContingencyTransferPricingMaximumAdditionalLossesAboveAndBeyondAmountProvided
2430 Other tax contingencies included in tax accrual Concept (Monetary) As Of Credit azn:TaxContingencyOther
2431 Decrease in other tax contingencies included in tax accrual Concept (Monetary) For Period Credit azn:IncreaseDecreaseInTaxContingencyOther
2432 Maximum amount of possible additional losses, other tax contingencies Concept (Monetary) For Period Debit azn:TaxContingencyOtherTaxContingenciesAdditionalLossesAboveAndBeyondAmountProvided
2433 Anticipated number of years significant disputes may be resolved Concept (xbrli:durationItemType) For Period azn:NumberOfYearsToResolveSignificantTaxDisputes
2434 Accrued interest Concept (Monetary) For Period Credit azn:TaxContingenciesAccruedInterest
2435 43001 - Disclosure - Operating leases (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingLeasesDetails
2436 Implied Table Table

*

*

 implied:Table
2437 Operating leases Abstract ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeAbstract
2438 Operating leases Concept (Monetary) For Period Debit ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense
2439 43002 - Disclosure - Operating leases, Future minimum payments (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingLeasesFutureMinimumPaymentsDetails
2440 Disclosure of finance lease and operating lease by lessee [table] Table

*

*

 ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeTable
2441 Maturity [axis] Axis ifrs-full:MaturityAxis
2442 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
2443 Due within one year Member ifrs-full:NotLaterThanOneYearMember
2444 Later than one year and not later than five years Member ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember
2445 Later than five years Member ifrs-full:LaterThanFiveYearsMember
2446 Operating leases LineItems ifrs-full:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeLineItems
2447 Future minimum lease payments Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
2448 43003 - Disclosure - Operating leases - IFRS 16 (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureOperatingLeasesIfrs16Details
2449 Disclosure of initial application of standards or interpretations [table] Table

*

*

 ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable
2450 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
2451 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
2452 IFRS 16 Member ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember
2453 Retrospective application and retrospective restatement [axis] Axis ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis
2454 Currently stated [member] Member ifrs-full:RestatedMember
2455 Previously stated Member ifrs-full:PreviouslyStatedMember
2456 Application of new accounting standards LineItems ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems
2457 Operating leases Concept (Monetary) For Period Debit ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense
2458 Future minimum lease payments Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
2459 43101 - Disclosure - Statutory and other information, Audit fees (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureStatutoryAndOtherInformationAuditFeesDetails
2460 Disclosure of Statutory Information [Table] Table

*

*

 azn:DisclosureOfStatutoryInformationTable
2461 IFRS Statement Scenario [Axis] Axis azn:IfrsStatementScenarioAxis
2462 IFRS Scenario Unspecified [Domain] Member azn:IfrsScenarioUnspecifiedDomain
2463 Pricewaterhouse Coopers LLP Member azn:PricewaterhouseCoopersLlpMember
2464 Statutory information LineItems azn:StatutoryInformationLineItems
2465 Auditor's remuneration Abstract ifrs-full:AuditorsRemunerationAbstract
2466 Group audit fee Concept (Monetary) For Period Debit ifrs-full:AuditorsRemunerationForAuditServices
2467 The audit of subsidiaries pursuant to legislation Concept (Monetary) For Period Debit azn:AuditorsRemunerationAuditOfSubsidiariesPursuantToLegislation
2468 Attestation under s404 of Sarbanes-Oxley Act 2002 Concept (Monetary) For Period Debit azn:AuditRelatedAssuranceServicesInternalControlFees
2469 Audit-related assurance services Concept (Monetary) For Period Debit azn:AuditorsRemunerationAuditRelatedAssuranceServices
2470 Tax compliance services Concept (Monetary) For Period Debit ifrs-full:AuditorsRemunerationForTaxServices
2471 Other assurance services Concept (Monetary) For Period Debit ifrs-full:AuditorsRemunerationForOtherServices
2472 The audit of subsidiaries pension schemes Concept (Monetary) For Period Debit azn:AuditorsRemunerationAuditOfSubsidiariesPensionSchemes
2473 Total auditor's remuneration Concept (Monetary) For Period Debit ifrs-full:AuditorsRemuneration
2474 Fees related to 2017 group audit and audit of subsidiaries Concept (Monetary) For Period Credit azn:AuditorSRemunerationRelatedToPriorYear
2475 Related party transactions Abstract ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract
2476 Short-term employee benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
2477 Post-employment benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
2478 Share-based payments Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
2479 Total key management personnel compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
2480 43201 - Disclosure - Subsequent events (Details) Network

*

*

 http://www.astrazeneca.com/role/DisclosureSubsequentEventsDetails
2481 Disclosure of non-adjusting events after reporting period [table] Table

*

*

 ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable
2482 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
2483 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
2484 New Borrowing Member azn:NewBorrowingMember
2485 Sale of Rights and Participate Member azn:SaleOfRightsAndParticipateMember
2486 Categories of financial assets [axis] Axis ifrs-full:CategoriesOfFinancialAssetsAxis
2487 Financial assets, category [member] Member ifrs-full:FinancialAssetsCategoryMember
2488 Instruments at fair value through other comprehensive income Member ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember
2489 Sobi Member azn:SwedishOrphanBiovitrumAbMember
2490 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
2491 Products and services [member] Member ifrs-full:ProductsAndServicesMember
2492 Synagis and MEDI8897 Member azn:SynagisAndMedi8897Member
2493 Synagis Member azn:SynagisMember
2494 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
2495 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
2496 Bank Loan Due December 2019 Member azn:BankLoanDueDecember2019Member
2497 Subsequent events LineItems ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
2498 Number of manufacturing sites closed Concept (Integer) For Period azn:NumberOfManufacturingSitesClosed
2499 Impairment loss recognised in profit or loss, property, plant and equipment Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
2500 Inventory write-down Concept (Monetary) For Period ifrs-full:InventoryWritedown2011
2501 Maximum borrowing capacity Concept (Monetary) As Of Credit azn:IfrsLineOfCreditFacilityMaximumBorrowingCapacity
2502 Cash received Concept (Monetary) For Period Credit ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
2503 Fair value Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAtFairValue
2504 Effective percentage of ownership interest in equity investment accounted for as FVOCI Concept (Percent) For Period azn:ProportionOfOwnershipInterestInEquityInvestmentsAccountedForAsFvoci
2505 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
2506 43301 - Schedule - Group Subsidiaries and Holdings (Details) Network

*

*

 http://www.astrazeneca.com/role/ScheduleGroupSubsidiariesAndHoldingsDetails
2507 Disclosure of subsidiaries [table] Table

*

*

 ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesTable
2508 Subsidiaries [axis] Axis ifrs-full:SignificantInvestmentsInSubsidiariesAxis
2509 Entity's total for subsidiaries [member] Member ifrs-full:EntitysTotalForSubsidiariesMember
2510 Astrazeneca S.A. Argentina Member azn:AstrazenecaSaArgentinaMember
2511 AstraZeneca Holdings Pty Limited Member azn:AstrazenecaHoldingsPtyLimitedMember
2512 AstraZeneca PTY Limited Member azn:AstrazenecaPtyLimitedMember
2513 Pharmaceutical Manufacturing Company Pty Limited Member azn:PharmaceuticalManufacturingCompanyPtyLimitedMember
2514 Pharmaceutical Manufacturing Division Pty Limited Member azn:PharmaceuticalManufacturingDivisionPtyLimitedMember
2515 AstraZeneca Osterreich GmbH Member azn:AstrazenecaOsterreichGmbhMember
2516 AstraZeneca S.A. / N.V. Member azn:AstrazenecaS.a.N.v.Member
2517 AstraZeneca do Brasil Limitada Member azn:AstrazenecaDoBrasilLimitadaMember
2518 AstraZeneca Bulgaria EOOD Member azn:AstrazenecaBulgariaEoodMember
2519 AstraZeneca Canada Inc.1 Member azn:AstrazenecaCanadaIncMember
2520 AZ Reinsurance Limited Member azn:AzReinsuranceLimitedMember
2521 Astrazeneca S.A. Chile Member azn:AstrazenecaSaChileMember
2522 AstraZeneca Farmaceutica Chile Limitada Member azn:AstrazenecaFarmaceuticaChileLimitadaMember
2523 AstraZeneca Pharmaceuticals Co., Limited. Member azn:AstrazenecaPharmaceuticalsCo.Limited.Member
2524 AstraZeneca (Wuxi) Trading Co. Ltd Member azn:AstrazenecaWuxiTradingCo.LtdMember
2525 AstraZeneca Investment (China) Co. Ltd Member azn:AstrazenecaInvestmentChinaCo.LtdMember
2526 AstraZeneca Pharmaceutical (China)Co. Ltd Member azn:AstrazenecaPharmaceuticalChinaCo.LtdMember
2527 AstraZeneca Pharmaceuticals Technologies (Beijing) Co., Ltd. Member azn:AstrazenecaPharmaceuticalsTechnologiesBeijingCo.Ltd.Member
2528 AstraZeneca Colombia S.A.S. Member azn:AstrazenecaColombiaS.a.s.Member
2529 AstraZeneca CAMCAR Costa Rica, S.A. Member azn:AstrazenecaCamcarCostaRicaS.a.Member
2530 AstraZeneca d.o.o. Member azn:AstrazenecaD.o.o.Member
2531 AstraZeneca Czech Republic, s.r.o. Member azn:AstrazenecaCzechRepublicS.r.o.Member
2532 AstraZeneca A/S Member azn:AstrazenecaSMember
2533 AstraZeneca Egypt for Pharmaceutical Industries JSC Member azn:AstrazenecaEgyptForPharmaceuticalIndustriesJscMember
2534 AstraZeneca Egypt for Trading LLC Member azn:AstrazenecaEgyptForTradingLlcMember
2535 Drimex LLC Member azn:DrimexLlcMember
2536 AstraZeneca Eesti OU Member azn:AstrazenecaEestiOuMember
2537 AstraZeneca OY. Member azn:AstrazenecaOy.Member
2538 AstraZeneca S.A.S. Member azn:AstrazenecaS.a.s.Member
2539 AstraZeneca Finance S.A.S. Member azn:AstrazenecaFinanceS.a.s.Member
2540 AstraZeneca Holding France S.A.S. Member azn:AstrazenecaHoldingFranceS.a.s.Member
2541 AstraZeneca Dunkerque Production SCS Member azn:AstrazenecaDunkerqueProductionScsMember
2542 Astrazeneca Holding GmbH Member azn:AstrazenecaHoldingGmbhMember
2543 AstraZeneca GmbH Member azn:AstrazenecaGmbhMember
2544 Sofotec GmbH Member azn:SofotecGmbhMember
2545 Definiens AG Member azn:DefiniensAgMember
2546 AstraZeneca S.A. Greece Member azn:AstrazenecaSaGreeceMember
2547 AstraZeneca Hong Kong Limited Member azn:AstrazenecaHongKongLimitedMember
2548 AstraZeneca Kft Member azn:AstrazenecaKftMember
2549 Astrazeneca India Private Limited 3 Member azn:AstrazenecaIndiaPrivateLimitedMember
2550 AstraZeneca Pars Company Member azn:AstrazenecaParsCompanyMember
2551 AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company Member azn:AstrazenecaPharmaceuticalsIrelandDesignatedActivityCompanyMember
2552 AstraZeneca Israel Ltd Member azn:AstrazenecaIsraelLtdMember
2553 Simesa SpA Member azn:SimesaSpaMember
2554 AstraZeneca SpA Member azn:AstrazenecaSpaMember
2555 AstraZeneca K.K. Member azn:AstrazenecaK.k.Member
2556 AstraZeneca Pharmaceuticals Limited Member azn:AstrazenecaPharmaceuticalsLimitedMember
2557 AstraZeneca Latvija SIA Member azn:AstrazenecaLatvijaSiaMember
2558 AstraZeneca Lietuva UAB Member azn:AstrazenecaLietuvaUabMember
2559 AstraZeneca Luxembourg S.A. Member azn:AstrazenecaLuxembourgS.a.Member
2560 AstraZeneca Asia-Pacific Business Services Sdn Bhd Member azn:AstrazenecaAsiaPacificBusinessServicesSdnBhdMember
2561 AstraZeneca Sdn Bhd Member azn:AstrazenecaSdnBhdMember
2562 AstraZeneca, S.A. de C.V. Member azn:AstrazenecaS.a.DeC.v.Member
2563 AstraZeneca Health Care Division, S.A. de C.V. Member azn:AstrazenecaHealthCareDivisionS.a.DeC.v.Member
2564 AstraZeneca Maroc SARLAU Member azn:AstrazenecaMarocSarlauMember
2565 AstraZeneca B.V. Member azn:AstrazenecaB.v.Member
2566 AstraZeneca Continent B.V. Member azn:AstrazenecaContinentB.v.Member
2567 AstraZeneca Gamma B.V. Member azn:AstrazenecaGammaB.v.Member
2568 AstraZeneca Holdings B.V. Member azn:AstrazenecaHoldingsB.v.Member
2569 AstraZeneca Jota B.V. Member azn:AstrazenecaJotaB.v.Member
2570 AstraZeneca Rho B.V. Member azn:AstrazenecaRhoB.v.Member
2571 AstraZeneca Sigma B.V. Member azn:AstrazenecaSigmaB.v.Member
2572 Astrazeneca Treasury B. V. Member azn:AstrazenecaTreasuryBvMember
2573 AstraZeneca Zeta B.V. Member azn:AstrazenecaZetaB.v.Member
2574 MedImmune Pharma B.V. Member azn:MedimmunePharmaB.v.Member
2575 AstraZeneca Limited Member azn:AstrazenecaLimitedMember
2576 AstraZeneca Nigeria Limited Member azn:AstrazenecaNigeriaLimitedMember
2577 AstraZeneca AS Member azn:AstrazenecaAsMember
2578 Astrazeneca Pharmaceuticals Pakistan (Private) Limited 4 Member azn:AstrazenecaPharmaceuticalsPakistanPrivateLimitedMember
2579 AstraZeneca CAMCAR, S.A. Member azn:AstrazenecaCamcarS.a.Member
2580 AstraZeneca Peru S.A. Member azn:AstrazenecaPeruS.a.Member
2581 AstraZeneca Pharmaceuticals (Phils.) Inc. Member azn:AstrazenecaPharmaceuticalsPhils.Inc.Member
2582 AstraZeneca Pharma Poland Sp.z.o.o. Member azn:AstrazenecaPharmaPolandSp.z.o.o.Member
2583 Astra Alpha Produtos Farmaceuticos Lda Member azn:AstraAlphaProdutosFarmaceuticosLdaMember
2584 AstraZeneca Produtos Farmaceuticos Lda Member azn:AstrazenecaProdutosFarmaceuticosLdaMember
2585 Novastra Promocao e Comercio Farmaceutico Lda Member azn:NovastraPromocaoEComercioFarmaceuticoLdaMember
2586 Novastuart Produtos Farmaceuticos Lda Member azn:NovastuartProdutosFarmaceuticosLdaMember
2587 Stuart-Produtos Farmaceuticos Lda Member azn:StuartProdutosFarmaceuticosLdaMember
2588 Zeneca Epsilon - Produtos Farmaceuticos Lda Member azn:ZenecaEpsilonProdutosFarmaceuticosLdaMember
2589 Zenecapharma Produtos Farmaceuticos Lda Member azn:ZenecapharmaProdutosFarmaceuticosLdaMember
2590 IPR Pharmaceuticals, Inc. Member azn:IprPharmaceuticalsInc.Member
2591 AstraZeneca Pharma S.R.L. Member azn:AstrazenecaPharmaS.r.l.Member
2592 AstraZeneca Industries, LLC Member azn:AstrazenecaIndustriesLlcMember
2593 AstraZeneca Pharmaceuticals, LLC Member azn:AstrazenecaPharmaceuticalsLlcMember
2594 AstraZeneca Singapore Pte Limited Member azn:AstrazenecaSingaporePteLimitedMember
2595 AstraZeneca Pharmaceuticals (Pty) Limited Member azn:AstrazenecaPharmaceuticalsPtyLimitedMember
2596 AstraZeneca Korea Co. Ltd Member azn:AstrazenecaKoreaCo.LtdMember
2597 AstraZeneca Farmaceutica Spain S.A. Member azn:AstrazenecaFarmaceuticaSpainS.a.Member
2598 AstraZeneca Farmaceutica Holding Spain, S.A. Member azn:AstrazenecaFarmaceuticaHoldingSpainS.a.Member
2599 Laboratorio Beta, S.A. Member azn:LaboratorioBetaS.a.Member
2600 Laboratorio Lailan, S.A. Member azn:LaboratorioLailanS.a.Member
2601 Laboratorio Odin, S.A. Member azn:LaboratorioOdinS.a.Member
2602 Laboratorio Tau S.A. Member azn:LaboratorioTauS.a.Member
2603 Astra Export & Trading Aktiebolag Member azn:AstraExportTradingAktiebolagMember
2604 Astra Lakemedel Aktiebolag Member azn:AstraLakemedelAktiebolagMember
2605 AstraZeneca AB Member azn:AstrazenecaAbMember
2606 AstraZeneca Biotech AB Member azn:AstrazenecaBiotechAbMember
2607 AstraZeneca BioVentureHub AB Member azn:AstrazenecaBioventurehubAbMember
2608 Astrazeneca Holding Aktiebolag Member azn:AstrazenecaHoldingAktiebolagMember
2609 Astrazeneca International Holdings Aktiebolag Member azn:AstrazenecaInternationalHoldingsAktiebolagMember
2610 AstraZeneca Nordic AB Member azn:AstrazenecaNordicAbMember
2611 AstraZeneca Pharmaceuticals Aktiebolag Member azn:AstrazenecaPharmaceuticalsAktiebolagMember
2612 AstraZeneca Sodertalje 2 AB Member azn:AstrazenecaSodertalje2AbMember
2613 Stuart Pharma Aktiebolag Member azn:StuartPharmaAktiebolagMember
2614 Tika Lakemedel Aktiebolag Member azn:TikaLakemedelAktiebolagMember
2615 Aktiebolaget Hassle Member azn:AktiebolagetHassleMember
2616 Symbicom Aktiebolag Member azn:SymbicomAktiebolagMember
2617 Astra Tech International Aktiebolag Member azn:AstraTechInternationalAktiebolagMember
2618 AstraZeneca AG Member azn:AstrazenecaAgMember
2619 Spirogen Sarl Member azn:SpirogenSarlMember
2620 Astrazeneca Taiwan Limited Member azn:AstrazenecaTaiwanLimitedMember
2621 AstraZeneca (Thailand) Limited Member azn:AstrazenecaThailandLimitedMember
2622 AstraZeneca Tunisie SaRL Member azn:AstrazenecaTunisieSarlMember
2623 AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi Member azn:AstrazenecaIlacSanayiVeTicaretLimitedSirketiMember
2624 Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi Member azn:ZenecaIlacSanayiVeTicaretAnonimSirketiMember
2625 AstraZeneca Ukraina LLC Member azn:AstrazenecaUkrainaLlcMember
2626 AstraZeneca FZ-LLC Member azn:AstrazenecaFzLlcMember
2627 Ardea Biosciences Limited Member azn:ArdeaBiosciencesLimitedMember
2628 Arrow Therapeutics Limited Member azn:ArrowTherapeuticsLimitedMember
2629 Astra Pharmaceuticals Limited Member azn:AstraPharmaceuticalsLimitedMember
2630 Astrapharm Member azn:AstrapharmMember
2631 AstraZeneca China UK Limited Member azn:AstrazenecChinaUkLimitedMember
2632 AstraZeneca Death In Service Trustee Limited Member azn:AstrazenecaDeathInServiceTrusteeLimitedMember
2633 AstraZeneca Employee Share Trust Limited Member azn:AstrazenecaEmployeeShareTrustLimitedMember
2634 AstraZeneca Finance Limited Member azn:AstrazenecaFinanceLimitedMember
2635 Astrazeneca Intermediate Holdings Limited Member azn:AstrazenecaIntermediateHoldingsLimitedMember
2636 AstraZeneca Investments Limited Member azn:AstrazenecaInvestmentsLimitedMember
2637 AstraZeneca Japan Limited Member azn:AstrazenecaJapanLimitedMember
2638 AstraZeneca Nominees Limited Member azn:AstrazenecaNomineesLimitedMember
2639 AstraZeneca Quest Limited Member azn:AstrazenecaQuestLimitedMember
2640 AstraZeneca Share Trust Limited Member azn:AstrazenecaShareTrustLimitedMember
2641 AstraZeneca Sweden Investments Limited Member azn:AstrazenecaSwedenInvestmentsLimitedMember
2642 Astrazeneca Treasury Limited Member azn:AstrazenecaTreasuryLimitedMember
2643 AstraZeneca UK Limited Member azn:AstrazenecaUkLimitedMember
2644 Astrazeneca Us Investments Limited Member azn:AstrazenecaUsInvestmentsLimitedMember
2645 AZENCO2 Limited Member azn:AzencoTwoLimitedMember
2646 AZENCO4 Limited Member azn:AzencoFourLimitedMember
2647 Cambridge Antibody Technology Group Limited Member azn:CambridgeAntibodyTechnologyGroupLimitedMember
2648 KuDOS Horsham Limited Member azn:KudosHorshamLimitedMember
2649 KuDOS Pharmaceuticals Limited Member azn:KudosPharmaceuticalsLimitedMember
2650 Zenco (No 8) Limited Member azn:ZencoNo8LimitedMember
2651 Zeneca Finance (Netherlands) Company Member azn:ZenecaFinanceNetherlandsCompanyMember
2652 MedImmune Limited Member azn:MedimmuneLimitedMember
2653 MedImmune U.K. Limited Member azn:MedimmuneU.k.LimitedMember
2654 Amylin Pharmaceuticals LLC Member azn:AmylinPharmaceuticalsLlcMember
2655 AstraZeneca Collaboration Ventures LLC Member azn:AstrazenecaCollaborationVenturesLlcMember
2656 AstraZeneca Pharmaceuticals, LP Member azn:AstrazenecaPharmaceuticalsLpMember
2657 Atkemix Nine Inc. Member azn:AtkemixNineInc.Member
2658 Atkemix Ten Inc. Member azn:AtkemixTenInc.Member
2659 BMS Holdco Inc. Member azn:BmsHoldcoInc.Member
2660 Corpus Christi Holdings Inc. Member azn:CorpusChristiHoldingsInc.Member
2661 Omthera Pharmaceuticals, Inc. Member azn:OmtheraPharmaceuticalsInc.Member
2662 Stauffer Management Company, LLC Member azn:StaufferManagementCompanyLlcMember
2663 Zeneca Holdings Inc. Member azn:ZenecaHoldingsInc.Member
2664 Zeneca, Inc. Member azn:ZenecaInc.Member
2665 Zeneca Wilmington Inc Member azn:ZenecaWilmingtonIncMember
2666 ZS Pharma Inc. Member azn:ZsPharmaInc.Member
2667 Alphacore Pharma LLC Member azn:AlphacorePharmaLlcMember
2668 Amylin Ohio LLC Member azn:AmylinOhioLlcMember
2669 Ardea Biosciences, Inc. Member azn:ArdeaBiosciencesInc.Member
2670 AZ-Mont Insurance Company Member azn:AzMontInsuranceCompanyMember
2671 Definiens Inc. Member azn:DefiniensInc.Member
2672 MedImmune Biologics Inc. Member azn:MedimmuneBiologicsInc.Member
2673 MedImmune, LLC Member azn:MedimmuneLlcMember
2674 MedImmune Ventures, Inc. Member azn:MedimmuneVenturesInc.Member
2675 Optein, Inc. Member azn:OpteinInc.Member
2676 Pearl Therapeutics, Inc. Member azn:PearlTherapeuticsInc.Member
2677 AstraZeneca S.A. Uruguay Member azn:AstrazenecaSaUruguayMember
2678 AstraZeneca Venezuela S.A. Member azn:AstrazenecaVenezuelaS.a.Member
2679 Gotland Pharma S.A. Member azn:GotlandPharmaS.a.Member
2680 Astrazeneca Vietnam Company Limited Member azn:AstrazenecaVietnamCompanyLimitedMember
2681 SPA AstraZeneca Al Djazair Member azn:SpaAstrazenecaAlDjazairMember
2682 AstraZeneca Pharma India Limited Member azn:AstrazenecaPharmaIndiaLimitedMember
2683 P.T. AstraZeneca Indonesia Member azn:P.t.AstrazenecaIndonesiaMember
2684 Acerta Pharma B.V. Member azn:AcertaPharmaB.v.Member
2685 Aspire Therapeutics B.V. Member azn:AspireTherapeuticsB.v.Member
2686 Acerta Pharma LLC Member azn:AcertaPharmaLlcMember
2687 Subsidiaires LineItems ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
2688 Effective percentage of equity owned in subsidiaries Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestInSubsidiary
2689 43302 - Schedule - Group Subsidiaries and Holdings - Joint Venture (Details) Network

*

*

 http://www.astrazeneca.com/role/ScheduleGroupSubsidiariesAndHoldingsJointVentureDetails
2690 Disclosure of joint ventures [table] Table

*

*

 ifrs-full:DisclosureOfJointVenturesTable
2691 Joint ventures [axis] Axis ifrs-full:JointVenturesAxis
2692 Entity's total for joint ventures [member] Member ifrs-full:EntitysTotalForJointVenturesMember
2693 WuXi MedImmune Biopharmaceutical Co. Limited Member azn:WuxiMedimmuneBiopharmaceuticalCo.LimitedMember
2694 Archigen Biotech Limited Member azn:ArchigenBiotechLimitedMember
2695 Centus Biotherapeutics Limited Member azn:CentusBiotherapeuticsLimitedMember
2696 Montrose Chemical Corporation of California Member azn:MontroseChemicalCorporationOfCaliforniaMember
2697 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Member azn:DizalJiangsuPharmaceuticalCo.LtdMember
2698 Viela Bio Member azn:VielaBioIncMember
2699 Less than 100% Subsidiaries and Joint Ventures LineItems ifrs-full:DisclosureOfJointVenturesLineItems
2700 Effective percentage of equity owned in joint ventures Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestInJointVenture
2701 43303 - Schedule - Group Subsidiaries and Holdings - Associates and Equity Investments at FVOCI (Details) Network

*

*

 http://www.astrazeneca.com/role/ScheduleGroupSubsidiariesAndHoldingsAssociatesAndEquityInvestmentsAtFvociDetails
2702 Disclosure of associates [table] Table

*

*

 ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesTable
2703 Categories of financial assets [axis] Axis ifrs-full:CategoriesOfFinancialAssetsAxis
2704 Financial assets, category [member] Member ifrs-full:FinancialAssetsCategoryMember
2705 Instruments at fair value through other comprehensive income Member ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember
2706 Armaron Bio Ltd Member azn:ArmaronBioLtdMember
2707 C.C.Global Chemicals Company Member azn:C.c.globalChemicalsCompanyMember
2708 Adherium Limited Member azn:AdheriumLimitedMember
2709 Innate Pharma S.A. Member azn:InnatePharmaSMember
2710 ADC Therapeutics Sarl Member azn:AdcTherapeuticsSarlMember
2711 Circassia Pharmaceuticals PLC Member azn:CircassiaPharmaceuticalsPlcMember
2712 Datapharm Communications Limited Member azn:DatapharmCommunicationsLimitedMember
2713 Mereo Biopharma Group PLC Member azn:MereoBiopharmaGroupPlcMember
2714 Silence Therapeutics PLC Member azn:SilenceTherapeuticsPlcMember
2715 AbMed Corporation Member azn:AbmedCorporationMember
2716 Affinita Biotech Inc. Member azn:AffinitaBiotechInc.Member
2717 Albireo Pharma, Inc. Member azn:AlbireoPharmaInc.Member
2718 Arcutis Inc. Member azn:ArcutisIncMember
2719 Aristea Therapeutics, Inc. Member azn:AristeaTherapeuticsIncMember
2720 Biodesix Inc. Member azn:BiodesixInc.Member
2721 Biohaven Pharmaceutical Holding Company Ltd. Member azn:BiohavenPharmaceuticalHoldingCompanyLtd.Member
2722 BlinkBio Inc. Member azn:BlinkbioInc.Member
2723 Cerapedics Inc. Member azn:CerapedicsIncMember
2724 Corvidia Corporation Member azn:CorvidiaCorporationMember
2725 Elusys Therapeutics, Inc. Member azn:ElusysTherapeuticsIncMember
2726 Entasis Therapeutics Limited Member azn:EntasisTherapeuticsLimitedMember
2727 FibroGen, Inc. Member azn:FibrogenInc.Member
2728 G1 Therapeutics, Inc. Member azn:G1TherapeuticsInc.Member
2729 Hydra Biosciences Inc. Member azn:HydraBiosciencesInc.Member
2730 Millendo Therapeutics, Inc. Member azn:MillendoTherapeuticsIncMember
2731 Moderna Therapeutics Inc. Member azn:ModernaTherapeuticsIncMember
2732 Myotherix Inc Member azn:MyotherixIncMember
2733 Nano Precision Medical, Inc. Member azn:NanoPrecisionMedicalInc.Member
2734 PhaseBio Pharmaceuticals, Inc. Member azn:PhasebioPharmaceuticalsIncMember
2735 Rani Therapeutics, LLC Member azn:RaniTherapeuticsLlcMember
2736 Regulus Therapeutics Inc. Member azn:RegulusTherapeuticsInc.Member
2737 Rocket Pharmaceuticals Inc. Member azn:RocketPharmaceuticalsIncMember
2738 Associates [axis] Axis ifrs-full:SignificantInvestmentsInAssociatesAxis
2739 Entity's total for associates [member] Member ifrs-full:EntitysTotalForAssociatesMember
2740 Apollo Therapeutics LLP Member azn:ApolloTherapeuticsLlpMember
2741 Significant and associate holdings LineItems ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesLineItems
2742 Effective percentage of equity owned in associates Concept (Percent) For Period ifrs-full:ProportionOfOwnershipInterestInAssociate
2743 Effective percentage of ownership interest in equity investment accounted for as FVOCI Concept (Percent) For Period azn:ProportionOfOwnershipInterestInEquityInvestmentsAccountedForAsFvoci

*

*